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Abstract 
Myosins form a large family of actin-based motor proteins that are involved in 
different forms of cellular motility. Those include muscle contraction, intracellular 
transport, endo- and exocytosis and cell division and locomotion. Certain myosin isoforms 
are also involved in hearing and vision processes. So far, very little is known about the 
myosin class 9. Myosin 9 has been proposed to be involved in cell differentiation and 
morphology. Mammals express two class 9 myosins; myosin 9a is expressed in brain and 
its loss results in the formation of hydrocephalus, while myosin 9b appears to be involved 
in the directional movement of dendritic cells. On the structural level, myosin 9 contains a 
RhoGAP domain in its tail region, indicating it could link its mechanical activity along 
actin filaments to intracellular protein G signaling.  
So far, only myosin 9b orthologs have been investigated. Here, I used the 
baculovirus/insect cell system to express recombinant human myosin 9a constructs, 
optimized the purification procedure and examined the function of myosin 9a motor in 
vitro. Designed constructs contained the motor and neck domains of myosin 9a, fused to 
different N- and C-terminal tags to facilitate purification. I addressed the ATPase activity of 
myosin 9a (particularly the Minimal Motor Domain construct) in the absence and presence 
of F-actin by means of an NADH enzyme-linked assay. The mechanical activity of myosin 
9a was addressed by means of the gliding filament assay. The velocity of actin gliding over 
the lawn of surface-bound myosin 9a molecules was largely independent from the motor 
density on the surface of a flow cell.  
In summary, this work presents the first successful purification of recombinant 
human myosin 9a motor constructs and describes basic mechanochemical properties of 
human myosin 9a motor. The results presented in this work provide framework for further 
investigation of myosin 9a properties, including investigation of the regulatory role of the 
tail domain of myosin 9a.  
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Zusammenfassung 
Myosine bilden eine grosse Familie von Aktin-basierten Motorproteinen die an 
einer Vielzahl von Formen zellulärer Motilität beteiligt sind. Dies reicht von der 
Muskelkontraktion, intrazellulärem Membrantransport, Endo- und Exozytose, Zellteilung, 
Zellfortbewegung bis hin zu Prozessen beim Hör- und Sehvorgang. Über Myosine der 
Klasse 9 ist bisher sehr wenig bekannt. Myosin-9 soll an der Ausdifferenzierung von Zellen 
und an der Ausbildung der Zellmorphologie beteiligt sein. Der Verlust des im Säugergehirn 
exprimierten Myosin-9a führt zur Bildung eines Hydrocephalus, während Myosin-9b an der 
gerichteten Fortbewegung von dendritischen Zellen beteiligt zu sein scheint. Eine 
strukturelle Besonderheit von Myosin-9 ist eine RhoGAP-Domäne in der Schwanzregion. 
Dies eröffnet die interessante Möglichkeit, dass Myosine der Klasse 9 ihre mechanische 
Aktivität entlang von Aktin-Filamenten an intrazelluläres G-Protein Signalling koppeln 
können.   
In der Literatur wurden bisher Myosine der Klasse 9b untersucht. In der 
vorliegenden Arbeit habe ich ein Baculovirus-Insektenzell-System verwendet, um 
rekombinante Myosin-9a Konstrukte zu exprimieren und exprimiertes Myosin-9a erstmals 
in vitro funktionell zu charakterisieren. Es gelang, eine Reihe verschiedener Konstrukte 
bestehend aus der Motordomäne sowie der Calmodulin-bindenden Nackendomäne, als 
GFP-Fusionsprotein, sowie mit verschiedenen N-und C-terminalen Tags erfolgreich zu 
exprimieren, aufzureinigen und zu lagern. Die ATPase Aktivität der exprimierten Myosin-
9a Konstrukte (insbesondere das Konstrukts minimale Motordomäne) wurde mit Hilfe von 
NADH-enzyme-linked assays charakterisiert und die Myosin-typische Aktivierung der 
ATPase durch Aktin bestimmt. Die Untersuchung der mechanischen Aktivität des 
Motorproteins Myosin-9a erfolgte mit Hilfe von sogenannten Gleit-Filament assays. Die 
gemessene Gleitgeschwindigkeit der Aktin-Filamente, die über einen Rasen von 
Oberflächen-gebundenen Myosin-9 Motorproteinen fortbewegt wurden, war weitgehend 
unabhängig von der Motorprotein-Dichte auf der Oberfläche. Sie waren jedoch stark von 
der Art der Anheftung der Myosin-Motoren an die Oberfläche abhängig.  
Zusammenfassend konnte ich erstmals Konstrukte des Motorproteins Myosin-9a 
erfolgreich exprimieren, aufreinigen und funktionell hinsichtlich ATPase und mechanischer 
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Aktivität hin untersuchen. Basierend auf den Ergebnissen dieser Arbeit sollen in Zukunft 
Myosin-9a Konstrukte einschliesslich der regulatorischen Schwanzregion hergestellt und in 
vitro charakterisiert werden.    
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CHAPTER 1: INTRODUCTION 
 
 
 
 
1.1. Cytoskeletal motors actively navigate and organize complex cellular 
environments. 
The eukaryotic cell is a sophisticated factory composed of dense protein and 
membrane networks that divide it into multiple compartments and organelles, each of 
which is responsible for different tasks; for example, maintenance and replication of DNA 
in the nucleus, energy production in mitochondria, sorting of vesicles by the Golgi 
apparatus or matrix attachment by cellular protrusions during cell locomotion. All that is 
governed by concerted action of cellular workhorses - proteins that have evolved different 
structures and functions as adaptations to a specific cellular compartment.  
A single budding yeast cell contains on the order of up to 50 million different 
protein molecules (Ghaemmanghami et al., 2003) within 50μm3 cell volume (Woldringh et 
al., 1993). A single protein would diffuse from one end to the other of a single yeast cell on 
the subsecond timescale (Moran et al., 2010). However, when one considers human cells, 
the necessity of efficient means of transportation becomes more apparent. A HeLa cell has 
a diameter of ~20μm and a volume of up to 5,000μm3; it would take 5 - 20s for a protein to 
diffuse the full diameter of a single HeLa cell. Neurons are extremely long, with their axons 
extending up to 1m! It would take up to several hours for a protein to diffuse that distance, 
yet nervous signals are transported on a timescale of milliseconds.  
Subsecond reaction timescales of individual cells are essential for the development 
and maintenance of multicellular organisms. Therefore, an efficient organization of cellular 
space has to be maintained. Mechanisms ensuring proper localization of cellular 
machineries in a spatiotemporal manner are necessary. 
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Eukaryotic cells have evolved multiple mechanisms to ensure an efficient 
organization of the cell; spatiotemporal regulation of protein activity by signaling pathways, 
electrochemical gradients across membranes, dynamic cytoskeletal structures contributing 
to cell polarity and migration, and molecular cargo transporters that deliver molecular parts 
to specific compartments.  
Motor proteins associated with the cytoskeleton (kinesins, dyneins and myosins) 
function as anchors, tension generators and transporters, and, apart from cargo trafficking, 
are involved in spatial and temporal regulation of the cytoskeletal architecture. All motors 
utilize ATP as their energy source to perform above-mentioned functions. Kinesins and 
myosins share the highest structural similarity; in these motors the filament-binding site is 
localized opposite to the ATP site within a globular head. Dynein is composed of multiple 
units and its structure differs significantly from that of myosin and kinesin (Mallik and 
Gross, 2004).  
Dyneins and kinesins utilize microtubules as their cellular tracks, whereas myosins 
bind to actin. Both microtubules and actin are highly dynamic polymers and hydrolyze GTP 
and ATP, respectively, to polymerize. Because one end of the polymer grows faster than 
the other, both microtubules and actin filaments exhibit polarity. In the cell most actin 
filaments point towards the cell membrane with their fast growing end. Due to the polarity 
of the motor binding site on actin and tubulin, the associated molecular motors move 
directionally along their filament tracks. Most myosins move towards the fast-growing end 
of actin filaments. This ensures their translocation towards the cell membrane; a single 
well-established reverse-directed motor, myosin 6, is employed in endocytosis and 
transports vesicles from  the cell membrane to the cell center (Mallik and Gross, 2004).  
Why have so many different types and isoforms of the cytoskeleton-associated 
molecular motors evolved? All couple ATP hydrolysis to binding and dissociation from 
their respective cytoskeletal tracks, enabling them to tether to filaments and to move along 
them. Each isoform exhibits specific adaptations of its ATPase cycle to perform its 
mechanical function (Vale, 1999). How that mechanochemical coupling is translated into a 
particular function in the context of the whole cell is of particular interest.  
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1.2.  Structure of a muscle fibre and discovery of myosin. The sliding 
filament theory. 
The name ‘myosin’ was given by Kühne (1864) to a protein extracted at high salt 
from muscle. The protein formed threads in water, therefore clearly was not globular. In 
1939, Engelhardt and Lyubimova showed for the first time that those extracts exhibit an 
ATPase activity. This was followed by a demonstration that threads shorten in the presence 
of ATP. Simultaneously, time-dependent high salt treatment resulted in the separation of 
low- and high-viscosity fractions from the muscle. The high viscosity of the latter fraction, 
containing actin and myosin, was reduced upon addition of ATP in a high salt buffer. This 
was caused by the dissociation of the actomyosin complex; in a low salt buffer contraction 
was initiated by addition of ATP. The conclusive proof that the actomyosin interaction in 
the presence of ATP seen in extracts is the basic mechanism for muscle contraction was 
obtained with glycerol-extracted psoas muscle fibres. Upon addition of MgATP, fibres 
started contracting and generated tension comparable to that of living muscle (Szent-
Györgyi, 2004).  
Vertebrate muscles are composed of individual muscle fibers (or myofibers), each 
containing multiple nuclei and surrounded by the sarcolemma. Individual muscle fibers are 
composed of myofibrillar protein bundles. The contracting unit of striated skeletal muscle is 
the sarcomere (Figure 1.1). Actin and myosin are the main components of the contractile 
machine within the sarcomere, forming linear interdigitating arrays. Each sarcomere is 2 - 
3μm long, extending between two Z-lines. Myosin forms 1.6μm long thick filaments in the 
A-band, whereas actin forms 1μm long thin filaments, extending from the Z-line to the H-
zone. The H-zone is characterized by an empty space between the ends of thin filaments in 
the middle of the sarcomere. The I-band is the fraction of the thin filament in direct 
proximity to the Z-line with no overlapping thick filaments (Szent-Györgyi, 2004).  
Electron micrographs of sarcomeres (Figure 1.1) revealed details about the structure 
of the thick filament (Huxely, 1957). Muscle myosin forms bipolar filaments by means of 
rod association of individual molecules.  The globular heads point out from both ends of the 
thick filament, facing in opposite directions. The central region of the filament is not 
decorated with myosin heads and is formed only by myosin rods associated with one 
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another at low ionic strength. Globular myosin heads protruding from opposite ends of the 
filament connect to actin, forming crossbridges (Szent-Györgyi, 2004).  
Proteolytic digestion of isolated thick filaments provided an insight into the role of 
individual myosin domains, formation of the filaments, and their mechanical properties 
(Figure 1.1). A single muscle myosin molecule is a hexamer composed of two heavy chains 
and two pairs of associated light chains. The globular N-terminal head with the regulatory 
and essential light chains is termed S1 (subfragment-1). It functions as an isolated 
crossbridge as it is able to bind actin and hydrolyze ATP. Two S1’s are joined together by a 
short region of the rod and together they form a heavy meromyosin (HMM) molecule. The 
isolated region of the rod in HMM is called S2. The remaining portion of the rod, 
responsible for association of myosin molecules into filaments at physiological ionic 
strength is called light meromyosin (LMM). The whole rod region is mostly ɑ-helical, 
enabling dimerization of individual myosin heavy chains (Szent-Györgyi, 2004). 
 
 
 
 
 
  8 
Figure 1.1. Organization of skeletal muscle and structure of a muscle myosin. A: a 
schematic depiction of the organization of human skeletal muscle; muscle fibers are 
multinucleated muscle cells surrounded by the sarcolemma. They are composed of 
myofibrils which are bundles of protein filaments organized in repeating units - sarcomeres. 
Sarcomeres are contractile units of muscles and are composed of interdigitating thick and 
thin filaments - myosin and actin, respectively. B: an electron micrograph of a section 
through a single muscle fiber. Regularly organized sarcomeres are easily distinguishable. 
Magnification 25,000. C: an electron micrograph of a sarcomere; Z-lines represent 
sarcomere borders. The length of thick filaments is represented by the A-band with myosin 
heads interacting with actin filaments in dark regions. The I-band is where thin filaments do 
not overlap with thick filaments. The H-zone is devoid of actin filaments with only rods of 
thick filaments present. Magnification 50,000. D: a schematic depiction of proteolytic 
fragments of a muscle myosin. The N-terminal globular head is associated with a pair of 
light chains (LC) and together they form S1 (subfragment-1) which binds actin and 
hydrolyzes ATP. Two heads of individual heavy chains are dimerized by a short rod region 
called S2 (subfragment-2). S1 and S2 together form a heavy meromyosin (HMM) molecule 
comprising two heads, two pairs of light chains and a region of coiled-coil. The remaining 
part of the rod, responsible for association of myosin into filaments at physiological ionic 
strength is called light meromyosin (LMM). Figures adapted from Huxley, 1957, Szent-
Györgyi, 2004 and Batters et al., 2014.  
 
 
In 1954 two groups (A.F. Huxley and R. Niedergerke, and H.E. Huxley and J. 
Hanson) proposed models to explain how the skeletal muscle contracts. These models 
remain valid in many aspects until today. By means of high resolution microscopy and 
using two independent experimental systems (intact frog muscle and isolated glycerinated 
myofibrils), it was revealed that during muscle contraction the length of the A-band 
encompassing thick filaments of myosin in the sarcomere does not change. Instead, 
shortening of the H-zone and I-band was observed. That led to the conclusion that transient 
interactions between myosin heads on the thick filament and actin in the thin filament must 
cause translocation of the latter towards the center of the sarcomere (Szent-Györgyi, 2004). 
That model is known as the sliding filament theory. 
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Figure 1.2. The sliding filament theory. A: a schematic depiction of interdigitating 
thick and thin filaments within the sarcomere, sliding past one another in the presence of 
MgATP. The sarcomere on the top is relaxed, while the sarcomere at the bottom is fully 
contracted. During the course of contraction, the length of thick and thin filaments remains 
constant, but the degree to which they overlap increases. This results in shortening of the H-
zone and I-band and brings Z-lines closer together leading to shortening of the whole 
sarcomere. B: electron micrographs of sarcomeres contracted to different extents. In a 
stretched sarcomere, the degree of overlap between thin and thick filaments is the lowest 
and I-bands and H-zones are clearly visible. At full contraction, the ends of actin filaments 
in the center of the sarcomere are brought so close towards one another that the H-zone 
cannot be distinguished anymore. In a slightly contracted sarcomere, I-bands and the H-
zone are still seen but are much shorter than in a stretched sarcomere. Bars represent the 
length of the H-zone in each sarcomere. Magnification 35,000. Figures adapted from 
Huxley, 1957 and Szent-Györgyi, 2004. 
 
 
1.3. The myosin superfamily.  
Myosins are molecular motors that utilize chemical energy from ATP hydrolysis 
and convert it into mechanical work coupled to force generation and movement along actin 
filaments (Howard, 1997). The myosin heavy chain comprises three conserved domains: an 
N-terminal head domain that is the catalytic core of the molecule; a neck region consisting 
of one or more IQ motifs that bind light chains of the calmodulin family; a C-terminal tail 
domain that specifies the function of a myosin (Sellers, 2000).  
Myosins are evolutionarily conserved and present in all eukaryotic cells from 
protists to mammals. It has been suggested that all have evolved from one common 
ancestor myosin consisting of the catalytic head and neck regions. This might explain high 
sequence and structural similarities within these regions of known myosin heavy chains 
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studied to date, as opposed to their highly diverse tail structures (Thompson and Langford, 
2002). Therefore, the classification of myosins is usually based on the highly conserved 
head sequences. The most recent genomic analysis of 2,269 myosin sequences from 328 
eukaryotic species grouped myosins into 35 classes and 149 orphan myosins that could not 
be assigned to any of the groups (Figure 1.3), (Odronitz and Kollmar, 2007). According to 
this classification, the conventional myosin class 2 (Mhc in Figure 1.3) and unconventional 
myosin 1 comprise the biggest groups. There are at least 40 myosin genes in the human 
genome (Foth et al., 2006) encoding myosin heavy chains from at least 12 different classes 
(Berg et al., 2001).  
The identification of skeletal muscle myosin was followed by the purification of two 
myosins (myosin 1 and myosin 2) from Acanthamoeba castellani (Pollard and Korn, 1973a 
and b). Myosin 2 from Acanthamoeba revealed structural similarity to the muscle myosin in 
that it formed filaments at physiological ionic strength (Pollard et al., 1978). Therefore, 
those myosins were grouped into myosin class 2 and termed conventional myosins (Sellers, 
2000). Since then, conventional myosin 2 isoforms have been identified in smooth and 
cardiac muscles as well as non-muscle cells (Berg et al., 2001). All other myosin classes are 
called unconventional myosins. 
The plethora of myosin isoforms and their wide distribution among eukaryotic 
organisms suggests they can perform a variety of cellular functions and that they are 
important for sustaining life.  The functional and structural adaptation of conventional 
myosin to power muscle contraction was described above; conventional non-muscle myosin 
was shown to be involved in the constriction of the cytokinetic furrow during cell division 
(Glotzer, 2005) and in the formation of stress fibers (Hotulainen and Lappalainen, 2006). 
The unconventional myosins have been implicated in cell motility and polarity, vesicle 
transport, immune response, wound healing, signaling and actin reorganization (Cheney 
and Mooseker, 1995; Sellers, 2000). 
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Figure 1.3. The phylogenetic tree of the myosin superfamily. The tree shows the 
classification of myosin motor domains into 35 classes and 149 orphan myosins. The 
classification was based on a multiple alignment of 1,984 myosin head sequences. The 
scale bar corresponds to the number of amino acids within a sequence. Individual groups 
are color-coded. Figure adapted from Odronitz and Kollmar, 2007. 
 
1.4.  Atomic structure of myosin S1. 
Fast chicken skeletal muscle myosin S1, the first myosin to be crystallized, revealed 
many important features of the myosin structural organization (Rayment et al, 1993a). The 
globular N-terminal head is divided into two distinct parts by a large cleft (50kDa cleft) 
across the short axis of the head. The actin-binding site is formed by several elements of the 
cleft (pointing towards the actin filament), whereas the nucleotide-binding pocket is 
localized at the other end of the cleft. It is separated from the actin-binding site by 4 – 6nm. 
Therefore, it was proposed that the 50kDa cleft provides a communication route between 
the actin and the nucleotide sites. Such communication could be achieved by reciprocal 
  12 
closing of the actin- and nucleotide-binding pockets at both ends of the cleft (Rayment et 
al., 1993b). 
Historically, the myosin head can be divided into 25K, 50K and 20K subdomains, 
obtained by the proteolytic cleavage of surface exposed loop 1 (near the nucleotide pocket) 
and loop 2 (part of the actin interaction site), respectively, and corresponding to their 
respective molecular weights (Rayment et al, 1993a; Sweeney and Houdusse, 2010). 
Currently, more exact terms are used to describe structural rearrangements associated with 
individual domains: N-terminal (or 25K) subdomain, upper and lower 50K subdomain 
(U50K and L50K, respectively) and the converter. The converter functions as a hinge for 
the light chain binding domain (Sweeney and Houdusse 2010).  
The globular myosin head is composed of α-helices surrounding the 7-stranded 
central β-sheet formed mainly by the N-terminal and U50K fragments and localized near 
the nucleotide-binding site, on the border between subdomains. Structural rearrangements 
of individual subdomains during the ATPase cycle of myosin are facilitated by sequential 
distortion of the β-sheet. Therefore, it has been termed the transducer (Sweeney and 
Houdusse, 2010). 
Figure 1.4 shows the tertiary structure of nucleotide-free chicken myosin 5 with a 
truncated lever arm. The C-terminal part of S1 forms an extended α-helix (Fig. 1.4. light 
brown) anchored at the converter domain (Fig. 1.4. light blue) of the globular head and is 
stabilized by bound light chains. It is referred to as the lever arm throughout the text. 
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Figure 1.4. The tertiary structure of myosin S1. The figure shows nucleotide-free 
myosin 5 S1 (PDB #1oe9) including the head domain and a single IQ motif within the neck 
region, with a single light chain wrapped around it (light brown). Individual domains are 
color-coded as indicated. The N-terminal region (light gray) is located near the C-terminal 
lever arm (light brown). The majority of the globular head is divided into upper and lower 
50K domains (U50K – purple and L50K – pink) by a 50kDa cleft with the actin-binding 
site and the nucleotide pocket at opposite ends. Multiple α-helices surround the central β-
sheet transducer (green). A number of structural elements involved in the mechanochemical 
transduction are indicated: the SH1 helix – yellow, the relay helix – red and the converter – 
light blue. U50K and L50K of myosin 5 are connected by a ~5aa-long strut (light green, 
next to the actin binding site; Coureux et al., 2004). The primary actin interaction site of 
myosins, loop 2, could not be resolved and is shown as a dashed line between U50K and 
L50K. Borders of each domain where established by literature search and colors were 
adjusted with UCSF Chimera (Pettersen et al., 2004). 
  
The structural organization of the active site of myosin is conserved across the 
family of NTPases, including G-proteins and microtubule-dependent motors, such as 
kinesins (Smith and Rayment, 1996). The nucleotide-binding pocket is formed by P-loop 
flanked by switch 1 and switch 2 regions (Figure 1.5). NTPases are characterized by a P-
loop sequence of GXXXXGK(T/S) with myosins containing a conserved sequence 
GESG(A/S)GKT. In most myosins, switch 1 has a conserved sequence of NXNSSRFG, 
whereas switch 2 is characterized by the DIXGFE sequence, where X can by any amino 
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acid (Smith and Rayment, 1996; Saski and Sutoh, 1998; Sellers, 2000). Multiple 
interactions between the active site elements are pivotal for stabilization of specific 
conformations of the nucleotide binding pocket associated with the presence or absence of a 
nucleotide. (Trivedi et al., 2012; Coureux et al., 2003). 
 
 
Figure 1.5. The nucleotide-binding site of myosin. The figure is based on the 
myosin 5 structure with an ATP analogue bound in the active site (PDB # 1w7j). ATP and a 
magnesium ion are indicated. Small red spheres are solvent molecules. Individual elements 
of the active site: P-loop, switch 1 and switch 2 are color-coded pink, green and blue, 
respectively.  
 
1.5.  Actin structure. 
Vertebrates express three isoforms of actin: α-actin, present in skeletal, cardiac and 
smooth muscles, and β- and γ-actin, present in both muscle and non-muscle cells 
(Dominguez and Holmes, 2011). In cells, actin exists in a dynamic equilibrium between 
globular, monomeric G-actin and polymerized, fibrous F-actin. A single G-actin molecule 
is composed of two major domains, divided into two subdomains each (Kabsch et al., 
1990). For the rest of the chapter the term ‘subdomains’ will be referred to as ‘domains’, in 
agreement with the literature (Oda et al., 2009; Fujii et al., 2010; Dominguez and Holmes, 
2011).  
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G-actin is an ATPase with the nucleotide-binding pocket enclosed by all four 
domains of the monomer. MgATP binds to domains 3 and 4, whereas domains 1 and 2 form 
a hydrophobic groove for binding protein partners, including neighbouring actin monomers 
in the filament (Oda et al., 2009; Dominguez and Holmes, 2011). The crystal structure of a 
single G-actin molecule with bound ATP and a cryo-EM reconstruction of an actin filament 
(F-actin) are presented in Figure 1.6. As shown by the X-ray diffraction of aligned actin 
fibers (Oda et al., 2009) and cryoelectron microscopy (Fujii et al., 2010), actin filaments are 
composed of two F-actin protofilaments, wrapped around each other to form a right-handed 
helix with a helical repeat every 36nm (Trinick et al., 1986). 
 
 
Figure 1.6. The structural organization of G- and F-actin. A: a crystal structure of a 
G-actin molecule with bound nucleotide. Two major domains are colored sea green and 
pink. ATP is coordinated by Ca2+ (green sphere). D-loop (involved in interactions with 
several binding partners and adjacent actin molecules) is depicted in dark red and Gln137, 
essential for ATP hydrolysis, is shown in blue. D-loop is ordered in this structure as it is 
adapted from the DNase I:actin complex structure (Kabsch et al., 1985; PDB #1atn). 
Individual (sub)domains (SD) are indicated. Note the deep cleft forming the nucleotide 
binding pocket. The structure was modified with UCSF Chimera. B: an atomic model of F-
actin fitted into a cryo-EM density map with individual monomeric actin molecules 
embedded in the filament colored. Domains 1 - 4 in the green subunit are indicated. Figure 
adapted from Galkin et al., 2010.  
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1.6. The actin binding site of myosin and models of actomyosin interface. 
Myosin binds actin either weakly or strongly depending on the presence or absence 
of ATP. Transition from the weak to strong interaction is essential for force generation and 
movement. The initial collision complex involving weak, mainly electrostatic interactions, 
is thought to isomerize to a strong (rigor) complex which involves major subdomain 
rearrangements accompanied by conformational changes in the active site and the release of 
hydrolysis products. Strong binding is thought to be achieved upon closure of the 50kDa 
cleft, rotation of the U50K subdomain towards the actin helix and increase in the contact 
area between actin and myosin (Lorenz and Holmes, 2010; Behrmann et al., 2012). Cleft 
closure seems to involve a conformational change in the strut that would bring the upper 
and lower subdomains in close proximity, allowing their interaction. Apart from the strut, 
multiple residues on the inner surface of the U50K and L50K might participate in 
maintaining closed cleft in the absence of a nucleotide. Sequence differences between 
different myosins might contribute to the extent of cleft closure and suggest structural 
adaptations to a biochemical function (Coureux et al., 2004).  
When incubated with F-actin in the absence of the nucleotide, myosin S1 molecules 
bind the filament in the strong (rigor) conformation, producing ‘decorated actin’ (Figure 
1.7) with all myosin heads binding in the same direction (Moore et al., 1970).  
 
Figure 1.7. ‘Decorated actin’. Myosin S1 molecules were incubated with F-actin 
and negatively stained images were acquired by EM. Magnification 180,000x. Figure 
adapted from Moore et al., 1970).  
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The crystal structure of nucleotide-free myosin 5 (Coureux et al., 2003) exhibits 
closed 50kDa cleft. Indeed, fitting of the crystal structure onto cryo-electron density maps 
of myosin 2-decorated F-actin revealed no major rearrangements of the tertiary structure of 
myosin 5 were necessary to achieve a good fit (Holmes et al., 2003; Holmes et al., 2004). 
Therefore, the nucleotide-free myosin 5 crystal structure provides a good explanation for 
how the rigor binding can occur. Even though other myosins in the apo (nucleotide-free) 
form exhibit open or only partially closed 50kDa cleft in detached states, cryo-EM maps of 
their complexes with actin suggest the cleft closes upon formation of the rigor state 
(Volkmann et al., 2000; Volkmann et al., 2003).  
Fitting of the crystal structures of different myosin isoforms in different nucleotide 
states to cryo-EM maps of actomyosin complexes reveals that myosin surface loops that are 
disordered in crystal structures of detached myosins become ordered and clearly visible in 
cryo-EM densities. This suggests surface loops become stabilized and participate in 
interactions with actin filament (Volkmann et al., 2000; Volkmann et al., 2003; Lorenz and 
Holmes, 2010). 
Multiple regions and surface loops near the apex of the myosin 50kDa cleft, as well 
as actin side chains, are thought to participate in the contact formation between actin and 
myosin (Lorenz and Holmes, 2010). Due to the lack of a co-crystal structure of myosin 
complexed with actin, the most detailed description of the myosin elements participating in 
direct interactions with actin in the rigor state comes from the subnanometer resolution 
(7.7Å) cryo-EM reconstructions of F-actin decorated with Dictyostelium MyoE in the 
presence of tropomyosin (Behrmann et al., 2012) (Figure 1.8). The initial contact area is 
formed by regions of the L50K subdomain of the myosin head and loop 2 between the 
U50K and L50K fragments, and is speculated to be mainly non-stereospecific in nature. 
Secondary contacts between actin and myosin are developed by surface loops of the U50K 
domain and include bond formation with actin side chains as well as stabilizing interactions 
with other myosin loops on the actin binding interface of myosin (Lorenz and Holmes, 
2010, Gyimesi et al., 2008). Secondary contacts seem to be mainly hydrophobic. The U50K 
subdomain forms contacts with actin only in the rigor complex, whereas the L50K 
subdomain mediates both weak and strong interactions (Várkuti et al., 2012). In rigor, 
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myosin interacts with two actin monomers in the same F-actin strand, forming a contact 
surface of ~1800 Å (Lorenz and Holmes, 2010; Behrmann et al., 2012).  
 
Figure 1.8. The actomyosin interface. The side and top views of the actomyosin 
contact surface of Dictyostelium MyoE. Regions on the myosin head involved in the 
interaction are highlighted and labeled: loop 2 (547-561aa), helix HW (563-577aa), loop 3 
(422-501aa), loop 4 (278-298aa), CM loop (322-342aa) and helix-loop-helix motif (445-
481aa). Regions highlighted in orange and blue are part of the L50K and U50K domains of 
myosin, respectively. Residue numbering corresponds to Dictyostelium discoideum MyoE. 
Scale bar 1nm. Figure adapted from Behrmann et al., 2012.  
 
Models of the actomyosin surface are based on the fitting of myosin S1 crystal 
structures onto electron density maps of electron micrographs of myosin-decorated F-actin. 
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Since there is no crystal structure of any actomyosin complex available to date, one must 
keep in mind that EM reconstructions usually involve adjustments of the tertiary structure 
of the motor domain in solution to fit the electron density maps and thus serve only as 
models of an actomyosin interaction. Thus, docking of crystal structures onto density maps 
has to be accompanied by biochemical studies and single molecule mechanical experiments 
to unravel the molecular basis of weak-to-strong transition necessary for understanding the 
basis of force production by myosins (Veigel and Schmidt, 2011).  
 
1.7. The structural basis of the relationship between the actin- and 
nucleotide-binding sites. 
The mechanism of the mechanochemical coupling in myosins arises from structural 
rearrangements of individual subdomains of the myosin head associated with different 
nucleotide states. According to current models, introduction of ATP induces conformational 
changes of the active site elements that are communicated to the actin-binding site through 
the 50kDa cleft. Via this communication route, binding of ATP and formation of the rigor 
complex of myosin on actin are mutually exclusive; i.e., binding and hydrolysis of ATP 
require closing of the active site pocket which causes weakening of the affinity for actin 
and eventually dissociation of the actomyosin complex, whereas binding to actin induces 
conformational changes that result in the opening of the nucleotide-binding site and 
acceleration of product release. The central element in the reciprocal coordination of 
structural changes at the nucleotide- and actin-binding interface is the transducer. Coupled 
distortion of the β-strands links conformational changes of the active site to movement of 
subdomains. On the other hand, position of the lever arm appears to be directly coupled to 
the position of switch 2 during hydrolysis of ATP and to be communicated from the active 
site via relay loop and converter (Coureux et al, 2004; Holmes et al, 2004).  
In the rigor state, the lever arm is in the ‘down’ position and all subdomains are 
tightly coupled. The U50K subdomain is moved towards an actin filament by means of the 
transducer distortion, resulting in closing of the 50kDa cleft on actin. This is associated 
with exclusion of water molecules from the cleft and involves formation of specific 
interactions between the L50K and U50K subdomains. Rotation of the U50K subdomain 
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towards the actin surface enables formation of secondary actin-binding interface essential 
for the achievement of the rigor state. Low nucleotide affinity in the rigor conformation 
stems from the specific active site conformation, whereby individual elements interact with 
one another in a way that hinders coordination of MgATP (Coureux et al., 2003; Coureux et 
al., 2004).  
Upon binding of ATP (post-rigor), untwisting of the transducer occurs. It is 
associated with change in the position of switch 1 which enables coordination of Mg2+ and 
β- and γ-phosphates, as well as U50K moving away from actin surface, opening of the 
actin-binding cleft and dissociation of the actomyosin complex. This also causes closing of 
switch 2 on the γ-phosphate, necessary for ATP hydrolysis to occur and transition into the 
pre-powerstroke (transition) state. This is associated with the rotation of the L50K 
subdomain that applies strain on the relay helix (Holmes et al, 2004). To accommodate that 
strain, the relay forms a kink that results in a ~60o rotation of the converter domain. This 
situates the lever arm in the up or ‘primed’ position. The transition state is regarded as the 
beginning of the powerstroke or a force-generating cycle of myosin.  
It was proposed that after ATP hydrolysis myosin binds to actin in a step-wise 
manner, where each step is associated with an increase in the affinity for actin and a 
decrease in the affinity for the nucleotide in the myosin active site. The initial weak 
interactions are followed by a conformational change in the transducer (Geeves and 
Holmes, 2005). This introduces an intramolecular strain that could be released through 
straightening of the relay loop (Holmes et al, 2004). At this point, the converter domain 
would rotate back and the lever arm would undergo a swing to its rigor-like position, a 
phenomenon called a power stroke. This might be concomitant with the γ-phosphate release 
probably through a ‘back door’ mechanism (Yount et al, 1995). Simultaneously, distortion 
of the transducer would result in the movement of the U50K domain and closure of the 
actin cleft, separation of switch 1 and P-loop and destabilization of the myosin-nucleotide 
complex. Described model provides an explanation for how can actin act as a nucleotide 
exchange factor of myosin; upon strong binding to actin, a conformational rearrangement of 
the active site elements could disrupt high affinity coordination of Mg2+ (necessary for 
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maintenance of cleaved γ- phosphate) and nucleotide (Coureux et al, 2003).  
 
1.8. The kinetic cycle of a myosin crossbridge. 
The overall mechanism of the actomyosin ATPase cycle is conserved within the 
myosin superfamily. That is, the order of the kinetic pathway as well as kinetic 
intermediates are the same for all myosin motors. Yet, rates and equilibrium constants of 
individual steps within the cycle differ between isoforms and represent adaptations of 
different superfamily members to perform diverse mechanical and physiological functions. 
Thus, revealing the transition rates and population lifetimes of particular steps in the 
pathway is important for understanding biochemical adaptations of individual myosin 
isoforms to perform specific physiological tasks (De La Cruz and Ostap, 2004; Geeves et 
al., 2005; De La Cruz and Ostap, 2009).  
The basis of the current view on the biochemical cycle of the myosin cross bridge is 
provided by initial measurements of (Lymn & Taylor, 1971) performed with rabbit muscle 
HMM. The Lymn and Taylor cycle explains how enzymatic events related to ATP binding 
and hydrolysis correspond to mechanical steps of the cross bridge. The kinetic cycle of 
Lymn and Taylor consists of 4 steps: i) a rapid dissociation of the actomyosin complex 
following ATP binding, ii) hydrolysis of ATP to ADP.Pi on free myosin in solution, iii) 
interaction of actin with the myosin-ADP.Pi complex, iv) product release from actomyosin. 
That data complements the mechanical cross bridge cycle where the dissociation of myosin 
from actin is followed by structural changes in myosin associated with the transition to the 
pre-power stroke conformation, subsequent recombination of myosin and actin and product 
release concomitant with the power stroke. The kinetic cycle of the mechanical cross-bridge 
is presented in Figure 1.9. 
Furthermore, Lymn and Taylor’s measurements show that i) the rate constant of 
ATP hydrolysis by HMM alone and actin-HMM complex is similar, ii) ATP binding causes 
a rapid dissociation of the actomyosin complex with the rate constant at least 10x faster 
than ATP hydrolysis and iii) actin accelerates product release as compared to the rate of 
HMM alone (Lymn and Taylor,1971).  
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Figure 1.9. Lymn and Taylor kinetic pathway of the mechanical crossbridge. The 
rigor actomyosin complex (AM) dissociates upon ATP binding (M.ATP). Free myosin 
hydrolyzes ATP to ADP.Pi (M.ADP.Pi) concomitant with the rotation of the lever arm to 
the UP position (recovery stroke). The pre-power stroke state (M.ADP.Pi) recombines with 
actin (AM.ADP.Pi) and myosin undergoes a power stroke associated with product release 
resulting in formation of the rigor (AM complex). M - myosin, AM - actomyosin.  
 
The Lymn and Taylor cycle implies a direct coupling between individual kinetic and 
mechanical steps of myosin on actin. Additionally, an indirect coupling model (3G model) 
proposed by Geeves et al. (1984) suggests that each step in the kinetic cycle (namely 
actomyosin complex formation, ATP binding and the release of hydrolysis products) is 
associated with at least two-step mechanical event. This model implies that force generation 
by crossbridges in the sarcomere occurs as a result of changes in the affinities between actin 
and myosin in a nucleotide-dependent manner. When binding to actin, myosin initially 
forms a weak collision complex with the thin filament, followed by an isomerization to a 
strong-binding complex. This change in the affinity between the two steps does not have to 
be accompanied by a large structural change of myosin S1, and can only constitute of small 
changes in the actomyosin interface. This is in contrast to the direct coupling model that 
suggests that force generation is the direct result of the conformational change in the 
myosin. After the rigor complex formation, an initial collision complex of actomyosin with 
ATP is formed, followed by an isomerization step associated with rapid dissociation of 
myosin from actin. The release of hydrolysis products from myosin occurs in a detached 
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state. If the isomerization to the strong actin-binding complex causes a structural change 
which results in force generation on actin, then product release would be associated with a 
reversal of that change (Bagshaw et al., 1974). The 3G model implies that such structural 
change would occur in a detached state of myosin, thus causing no negative force-
generating event on actin (Geeves et al., 1984). The most widely accepted scheme of the 
actomyosin ATPase cycle is presented below:  
 
Figure 1.10. Model of the kinetic cycle of myosin S1. The top row represents actin-
associated states and bottom row – actin-detached states. The major ATPase pathaway is 
highlighted in bold. Figure adapted from Liu et al., 2005.  
 
1.9. The mechanism of the myosin ATPase activation by actin. 
It has been proposed that actin and nucleotide binding are reciprocal, namely that 
binding of ATP to myosin causes dissociation of the actomyosin complex, whereas a 
recombination with actin accelerates product release (Conibear et al., 2003). Therefore, the 
recombination of myosin with actin following ATP hydrolysis and the transition from weak 
to strong actin binding is thought to be the basis for the activation of the intrinsic myosin 
ATPase by actin and results in the generation of force and motion on an actin filament.  
The acceleration of the γ-phosphate release after hydrolysis is the first step of the 
isomerization to the strong actin-binding state. In order to achieve strong binding, the U50K 
domain would need to rotate towards the actin filament and L50K domain. Since switch 1 is 
structurally a part of the U50K domain, rotation of the latter would remove switch 1 from 
the active site. This would result in the opening of the nucleotide-binding pocket and 
destruction of bonds with the hydrolyzed nucleotide resulting in product release (Conibear 
et al., 2003; Holmes et al., 2003; Onishi et al., 2006).   
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By contributing ionic or hydrophobic interactions, which affect weak and strong 
actomyosin binding, different regions on the myosin surface influence the maximal ATPase 
rate (Vmax) and apparent dissociation constant of myosin from actin in the presence of ATP 
(Km). The overall charge of the primary actin interaction site of myosin, loop 2, modulates 
actin affinity (Bobkov et al., 1996; Murphy and Spudich, 2000; Joel et al., 2001). The 
lysine cluster at the end of loop 2 (which contains 2-4 lysine residues, depending on the 
myosin isoform) seems important for the transition from the weak to strong actin binding. 
This was demonstrated by the inhibition of the sliding velocity and the maximal ATPase 
activation by actin in mutants lacking the C-terminal lysines cluster in loop 2 (Joel et al., 
2001). Furthermore, the cardiomyopathy (CM) loop of the U50K domain, which creates 
secondary stereospecific contacts with actin in the strong binding state, contains a cluster of 
hydrophobic residues with solvent-exposed side chains for actin interaction (Sasaki et al., 
1999, Onishi et al., 2006). In agreement with its function in strong actin binding, necessary 
for product release, mutations in the CM loop led to the decreased actin-activated ATPase 
(Sasaki et al., 1999; Onishi et al., 2006). Furthermore, a conserved Arg right upstream of 
the CM loop corresponding to Arg397 in Dictyostelium discoideum myosin 2 is also 
essential for actin-activated ATPase (Sasaki et al., 1999). In human β-cardiac myosin, 
mutation of that residue to Gln causes familial hypertrophic myopathy (Geisterfer et al., 
1990). It was proposed that residue is involved in the stabilization of a specific loop 2 
conformation (Lorenz and Holmes, 2010). Therefore such severe phenotype caused by a 
single mutation is related to decreased actin affinity in mutants with substituted Arg at this 
position (Sweeney et al., 1994; Fujita et al., 1997). Also within the CM loop, a TEDS site 
(corresponding to Asp403 in D. discoideum myo2), containing one of the indicated 
residues, has been characterized (Kollmar et al., 2002). Myosins with Asp or Glu at this 
position are constitutively active, whereas Thr or Ser provides means of regulating the 
intrinsic ATPase activity by phosphorylation (Sasaki et al., 1999, Kollmar et al., 2002). 
Loop 3 of the L50K domain of myosin also contains a cluster of hydrophobic residues 
which contribute to strong actin binding and thus are necessary for actin-activated ATPase 
and accelerated γ-phosphate release from the nucleotide pocket (Kojima et al., 2001, Onishi 
et al., 2006).  
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Finally, a recently characterized activation loop located in the relay helix has been 
suggested to improve the efficiency of successful power strokes, i.e. performed in actin-
attached, rather than actin-detached, state (Várkuti et al., 2012). That loop consists of a few 
amino acids with a conserved positive charge (usually Lys or Arg) at a position 
corresponding to Arg520 in Dictyostelium discoideum myosin 2. Following ATP binding, 
switch 2 closes on the nucleotide, leading to a change in the conformation of the lever arm 
into an UP position concomitant with ATP hydrolysis and transition into the beginning of 
the power stroke state. By means of the interaction of the activation loop with actin, that 
specific conformation of the lever arm is stabilized, therefore directing the catabolic fluxes 
towards successful force generation on actin and directly coupling hydrolysis product 
release to force production. Such mechanism might be essential for robust muscle 
contraction (Várkuti et al., 2012).  
 
1.10. Generation of force and movement by a single crossbridge.  
The sliding filament theory described in section 1.1. explains the mechanism behind 
the shortening of sarcomeres and muscle contraction. Myosin molecules (crossbridges) in 
thick filaments cyclically interact with actin in interdigitating thin filaments driving sliding 
of the two past each other. A few models have been proposed regarding the interaction and 
performance of individual crossbridges in the muscle sarcomere. 
 
1.10.1. The thermal ratchet model (AF Huxley’s 1957 model). 
Binding of myosin to actin is dependent on the position of myosin in relation to the 
available binding site on actin. The myosin motor contains a flexible element that becomes 
extended as it undergoes thermal fluctuations in search for the next binding site. Extension 
of that element introduces strain into the motor domain. Binding of myosin to actin can 
occur only when strain is introduced into the spring element of the molecule, thus 
facilitating binding of extended molecules that would drive contraction, as opposed to 
molecules with a contracted elastic element. Strain produces force on actin filament and 
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drives contractile motion. Shortening of the elastic element during an actin-attached state 
results in strain relief. This is followed by the release of myosin from actin.  
 
Figure 1.11. The thermal ratchet model based on Huxley, 1957. The myosin 
molecule contains an elastic spring element that undergoes thermal fluctuations along the 
filament lattice. In the presence of strain myosin attaches to actin, applying force and 
driving motion. Motor detaches from actin under strain release. Figure adapted from 
Howard, 2009. 
 
Given a moderate rate of attachment, dependent on the relative position of myosin 
and actin, the rate of detachment of myosin from actin is low during force production and 
high at the end of it. During an isometric muscle contraction, the detachment rate of myosin 
crossbridges is slow. However, during active muscle shortening, the detachment rate will 
increase due to continuous change in the position of available binding sites on actin. This 
accounts for increased cycle rates and energy consumption during contraction. Furthermore, 
myosin will interact with any given actin binding site only for a limited period of time with 
the interaction time decreasing with the increasing shortening velocity. Therefore, the 
number of crossbridges bound to actin will decrease with higher shortening velocity, 
eventually leading to a decrease in muscle tension. At high shortening velocities, a number 
of crosbridges will exhibit a negative displacement on actin, causing a drag force. The 
number of positively (exerting force in the direction of movement) and negatively (exerting 
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drag) displaced crossbridges will reach an equilibrium at the maximum unloaded shortening 
velocity, resulting in the net force of muscle contraction equal 0.  
 
1.10.2. The power stroke model (AF Huxley and Simmons 1971 model). 
In the power stroke model, the strain in the myosin motor domain that results in 
force generation and motion along the actin filament lattice comes from a relatively large 
conformational change in the motor domain (Figure 1.12) (Howard, 2009). Such 
conformational change would occur as myosin rebinds actin following ATP hydrolysis, and 
would involve a rowing-like motion, the power stroke, that would bring about the 
displacement of the thin filament relative to the myosin crossbridge in the thick filament. 
The power stroke would occur concomitantly with ATP hydrolysis products release.  
That model, also referred to as a swinging crossbridge model, did not provide a 
clear explanation as to what part of the molecule is the subject of the conformational 
change that leads to force generation and results in muscle contraction. The first crystal 
structure of myosin S1 (Rayment et al., 1993a) led the authors to hypothesize that the 
globular myosin head might bind actin in a relatively fixed orientation, allowing the C-
terminal extended α-helical neck to rotate around the anchor point, behaving like a lever. In 
that sense large changes in the position of the neck would be the result of small changes in 
the motor domain. The rotation of the neck domain was proposed to be the basis of force 
generation and movement (Rayment et al., 1993b). This model is now known as the 
swinging lever arm model. 
Following the hypothesis that the lever arm multiplies small conformational changes 
in the myosin motor domain into large scale mechanical steps on actin, an in vitro motility 
assay for quantitative measurements of myosin movement was developed to test the 
predictions. The first quantification of myosin movement rates along actin was made by 
using Nitella cells that contain well-organized, polarized actin cables. Application of 
skeletal myosin HMM covalently linked to fluorescent beads onto exposed actin cables in 
the presence of ATP resulted in robust and directional movement over long distances. It 
required ATP and enzymatically-active myosin molecules, confirming that the observed 
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motility was the result of the mechanochemical coupling in myosin molecules. The rate of 
movement was determined from the change in the position of fluorescent beads along an 
actin path during the timecourse of the experiment (Sheetz and Spudich, 1983). An 
improved version of the assay, that is routinely used nowadays, involved fully reconstituted 
actin-myosin system composed of isolated components (Kron and Spudich, 1986). Myosin 
molecules are fixed to a glass surface of an experimental chamber and covered with 
fluorescent phalloidin-stabilized actin filaments. Filaments move over long distances over 
the myosin-coated surface in the presence of ATP. The most important features of that 
assay include reproducibility and ease of preparation and enable testing different buffer 
conditions and myosin isoforms (Kron and Spudich, 1986; Harada et al., 1987). The 
velocity was not dependent on the species origin of actin (Kron and Spudich, 1986).  
 
Figure 1.12. The power stroke model based on Huxley and Simmons, 1971. The 
myosin motor domain contains a spring-like element that undergoes a conformational 
change following binding to actin. This conformational change in the motor domain 
introduces strain into the molecule and causes generation of force on an actin filament. 
Strain relief occurs as the elastic element in the motor domain returns to its original position 
and is concomitant with actin displacement. This is followed by detachment of myosin from 
actin and recovery. Figure adapted from Howard, 2009.  
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1.10.3. Single molecule mechanics with optical tweezers. 
The development of the in vitro motility assays enabled the investigation of 
mechanical properties of molecular motors working as an ensamble. However, similar to 
the situation in muscle, individual motor molecules deposited on the surface of the flow 
chamber do not have their kinetic cycles synchronized. That means that in any given 
population of motors in the direct viccinity of the filament, only a certain fraction will 
interact with the filament and produce force at any given timepoint. Furthermore, it still was 
unknown how a single motor would move on the filament. Would it exhibit periods of 
activity interspersed with unproductive periods? Or would it move in uniformly distributed 
discrete steps? How many ATP molecules are hydrolyzed per single step of myosin on the 
filament? Therefore, in order to reveal the action of individual motors in the muscle, one 
has to study them under conditions ensuring interaction of only a single motor with actin at 
a time.  
This has been achieved by employing an optical trapping setting. First experiments 
with cytoskeletal motors in the optical trap were performed with kinesin (Svoboda et al., 
1993). Individual kinesin molecules were attached to silica beads and deposited on 
microtubules attached to the coverslip surface. The bead was held in the laser trap and its 
position was detected throughout the experiment. In the presence of ATP kinesin exhibited 
robust movement along the microtubule lattice, causing displacement of the bead from the 
centre of the trap. Per single encounter with microtubule, kinesin would take multiple steps 
before detaching. Each step caused the bead displacement of 8nm, suggesting it spans a 
distance of one dimer in a protofilament. By changing the laser power, the load imposed on 
the bead could be adjusted. Individual step sizes were independent from the load applied, 
showing that kinesin can sustain low pN-range forces when travelling along microtubule. 
Furthermore, decreasing the ATP concentration caused slower velocity of kinesin on 
microtubule, without affecting the step size. This confirms the hypothesis that a single step 
happens per one ATP hydrolysis cycle (Svoboda et al., 1993).  
A firm filament attachment to the coverslip surface might hinder unobstructed 
movement of the motor that follows a helical, instead of a linear, path along the filament. 
Thus, the assay geometry was improved to allow the filament to be unconstrained during 
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the experiment. An actin filament was suspended between two polystyrene beads trapped 
by laser above the coverslip surface. Myosin was deposited on silica beads firmy attached 
to the coverslip. Low myosin densities were used to ensure that observed interaction events 
include a single crossbridge. By bringing the actin filament in the proximity of the myosin-
coated platform bead, the interaction was initiated. The position and Brownian motion of 
one of the beads was monitored. Upon the actomyosin interaction, the Brownian noise 
decreased due to an increase in the stiffness of the system. The displacement and force 
produced by myosin on actin was related to the change in the position of one of the beads in 
a trap (Finer et al., 1994). The schematic depiction of that assay geometry is shown in Fig. 
1.13.  
 
Figure 1.13. A three-bead optical trapping assay corresponding to Finer et al., 1994. 
Polystyrene beads (black) were trapped in a two-beam optical trapping laser. Actin filament 
ends were attached to solution-suspended beads coated with inactivated myosin molecules. 
Silica beads (gray) were attached to the coverslip surface and coated with myosin motors. 
The actin filament was brought close to the myosin platform, allowing an interaction 
between the motor and the filament.  
 
The assay was used to directly measure the displacement and force produced by 
single-headed muscle myosin S1 molecules (Molloy et al., 1995). The attachment lifetime 
of individual actomyosin complexes was dependent on ATP at low ATP concentrations. 
This indicates that a single attachment is terminated by a new ATP molecule binding to 
myosin, and thus a single ATPase cycle is coupled to an individual step of myosin on actin. 
Furthermore, comparison of S1 and HMM molecules revealed that the displacement and 
forces produced were similar for both constructs. This suggests that in a dimeric muscle 
myosin 2 the heads are independent from each other and that a single crossbridge is enough 
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to generate force and movement in muscle (Molloy et al., 1995). This is in agreement with 
the lack of coordination of chemomechanical cycles of individual myosins in thick 
filaments in sarcomeres.  
 
1.10.4. Load-dependence of muscle contraction. 
In order to maintain efficient energy use, the shortening velocity of the sarcomere is 
high at low loads enabling rapid tension generation and muscle contraction. However, when 
high load is applied, at extended contraction duration, the shortening velocity is slower 
(Huxley and Simmons, 1971). From the molecular point of view this means that the muscle 
metabolism, and ultimately the kinetics of individual corssbridges, is strain-dependent.  
Analysis of single interaction events of smooth muscle myosin S1 with actin 
revealed that the overall attachment lifetimes are dependent on the amplitude and direction 
of an applied load (Veigel et al., 2003). Similar to other myosin isoforms described below, 
smooth muscle S1 produced a working stroke in two phases contributing to different 
extents to the overall stroke. It was proposed the two conformational changes between two 
phases are associated with subsequent Pi and ADP release. Thus, the lifetimes of the first 
and second phase correspond to the amount of time spent in the ADP-bound and 
nucleotide-free forms, respectively. This is in agreement with the structural data that shows 
different conformations of the smooth muscle myosin lever in the presence and absence of 
ADP (Whittaker et al., 1995; Gopllub et al., 1996). In contrast to the first phase, the 
duration of the second phase was ATP concentration-dependent, suggesting the working 
stroke is terminated when new ATP molecule binds to myosin. The duration of the first 
phase was extended when the load applied in the direction of movement was increased. 
This suggests that the force-generating biochemical state of myosin (ADP-bound) might be 
dependent on the applied strain and thus control the interaction lifetime of crossbridges 
with the thin filament in muscle (Veigel et al., 2003). Indeed, in an unloaded muscle 
undergoing the maximal shortening velocity of contraction only 1% of all heads interact 
with actin and that number might increase up to 80% under an isometric force (Bagshaw et 
al., 1993). Therefore, the amount of myosin heads attached to thin filaments at a given time 
point acts as a mechanism to oppose an external load. 
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1.11. The lever arm hypothesis. 
The power stroke model described above has been gradually updated to a swinging 
lever arm model, whereby the bulk part of myosin (i.e. the globular head) binds actin in a 
relatively fixed geometry and only the C-terminal part of S1 (i.e. the neck region) changes 
its orientation relative to actin. It was proposed that the small conformational changes in the 
active site of the motor are amplified into large swinging motion of the neck region. 
Because of that, the neck region is referred to as the lever arm (Holmes, 1995). 
In order to visualize the change in the conformation of the neck region, actin was 
decorated with myosin S1 in the presence and absence of ADP, and imaged by cryoelectron 
microscopy. Initial experiments with skeletal muscle myosin S1 did not show any 
difference in the position of the lever arm. Experiments performed with brush border 
myosin 1 (BBM1) S1 and smooth muscle myosin S1 showed that the neck region changes 
its angle relative to actin upon ADP release. Based on image analysis, it was suggested that 
the end of the lever arm of BBMI and smooth muscle S1 would swing by ~7.2nm and 
~3.2nm, respectively. That difference between the two myosins was attributed to a different 
amount of light chains bound to their lever arms (3 for BBM1 and 2 for smooth muscle 
myosin). Since the power stroke is the force-generating step in the myosin ATPase, it 
would only make sense if it occurred when myosin is strongly attached to actin. Thus, the 
electron micorscopy data provided direct evidence that ADP release acts at least as a part of 
the power stroke, which occurs during strongly-bound states of myosin on actin. 
Furthermore, it was concluded that the neck region converts small molecular changes at the 
active site into a large mechanical change, resulting in movement. Because of this, the light 
chain binding domain was termed the lever arm (Jontes et al., 1995; Whittaker et al., 1995). 
It was further confirmed that such angular change in the position of the neck domain occurs 
in a contracting muscle. By fluorescently labeling of regulatory light chains in isolated 
skeletal muscle fibers, tilting of the neck regions of myosin heads was observed by 
fluorescence polarization. This way individual power strokes of myosins within the thick 
filament of the sarcomere were observed (Irving et al., 1995). 
Finally, the rotation of the neck region between the nucleotide-free state (that adopts 
a conformation of a rigor form of myosin) and the transition state (ADP.Pi state, thought to 
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represent the beginning of the power stroke) was shown in the crystal structure of 
Dictyostelium myosin 2 with bound ADP.Vanadate (a transition state analog) (Smith and 
Rayment, 1996). When compared to the nucleotide-free structure of chicken skeletal S1 
(Rayment et al., 1993a), the lever arm swung by ~12nm in the transition state Dictyostelium 
myosin 2 structure (Figure 1.14). It is possible such conformational change could occur in 
an actin-bound state. 
 
Figure 1.14. Structures of actin-bound myosin in the transition and rigor states. 
Reconstructions of the actomyosin complex in the transition (left) and rigor (right) states 
based on Dictyostelium myosin 2 with ADP.Vanadate and nucleotide-free chicken skeletal 
S1, respectively. The structures represent the beginning (left) and end (right) of the power 
stroke. The position of the lever arm in the Dictyostelium structure was restored from 
chicken skeletal S1 coordinates based on the position of the converter in that structure.  
 
If the lever arm undergoes a dynamic large conformational change in association 
with the ATPase cycle, then the velocity of myosin should be proportional to the amplitude 
of the rotation of the lever, and therefore to the lever arm length. In combination with 
protein engineering strategies and recombinant protein expression, the in vitro gliding 
filament assay was used to prove the sliding velocity of myosin is linearly-dependent on the 
length of the neck domain (Figure 1.15; Uyeda et al., 1996). The lever arm of Dictyostelium 
myosin 2 was gradually shortened by a single light chain-binding site at a time or was 
extended by one additional motif. The sliding velocity was directly proportional to the 
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length of the neck domain with a y-intercept corresponding to the position of the fulcrum 
point in the motor domain, which serves as a pivot point over which the swinging of the 
lever occurs (an SH1-SH2 helix). A construct containing only the first IQ motif exhibited 
half the velocity of actin movement of the wild type, whereas one with an additional IQ 
motif added downstream of the wild type lever arm translocated actin 0.25 times faster than 
the wild type (Uyeda et al., 2002). In line with that, chimeric myosin constructs containing 
α-actinin repeats in place of IQ motifs functioned as artificial lever arms, resulting in faster 
sliding velocities in myosins containing more repeats (Anson et al., 1996; Ruff et al., 2001; 
Warshaw et al.,2000). 
 
Figure 1.15. The sliding velocity of myosin is linearly dependent on the length of 
its lever arm. Dictyostelium myosin 2 containing 0, 1, 2 (wild type) or 3 light-chain binding 
motifs in the neck region translocated actin filaments in the in vitro motility assay with the 
sliding velocity proportional to the length of the lever of the construct used. The y intercept 
corresponds to the position of the fulcrum in the motor domain over which rotation of the 
lever arm occurs. Figure adapted from Uyeda et al., 1996. 
 
1.12. The mechanochemical coupling in myosin motors. 
How does the conformational change of the lever arm occur? How is force produced 
by myosin bound to actin? How is it coupled to steps in the myosin ATPase cycle? Which 
stage of the hydrolysis product release process is associated with force generation? Does 
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movement and force production occur simultaneously with actin binding after ATP 
hydrolysis?  
A three-bead optical trapping assay was used to directly observe and measure 
isolated mechanical events of single-headed myosin 1 isoforms on actin (Veigel et al., 
1999). Slower kinetics of myosin 1 (longer actomyosin interactions and slower hydrolysis 
products release, as compared to fast skeletal muscle myosin; Jontes et al., 1997) enabled 
better spatiotemporal resolution of the experiment. Individual actomyosin interactions were 
analyzed following ensemble averaging that involved synchronization of the beginning and 
end points of single displacements and reduction of the background noise. Both myosin 
isoforms underwent a two-phase working stroke on actin. The first phase was larger than 
the second phase and occured with a slight delay following actin binding. The second phase 
was linearly dependent on ATP concentration, suggesting the event is terminated with a 
new ATP molecule binding to the motor domain. Therefore, the force-generating power 
stroke occurs in two phases probably related to sequential hydrolysis products release, and 
is associated with the hydrolysis of a single ATP molecule (Veigel et al., 1999).  
Finally, an improvement in the spatiotemporal resolution of optical tweezers 
enabled a direct observation and measurement of the power stroke of the fast rat non-
muscle myosin 2B (Capitanio et al., 2006). The power stroke of myosin 2B occurred in two 
phases, proposed to correspond to Pi release and ADP release, respectively. Again, the first 
phase was larger than the second phase and occurred rapidly after binding actin. The 
detachment rate of myosin 2B from actin was dependent on the rate of ATP binding, 
indicating that ADP release occurs faster than ATP binding. This has been suggested to be 
the basis for the robust shortening velocity of conventional myosins in muscles (Capitanio 
et al., 2006).  
A unidirectional two-phase power stroke which occurs with a delay after actin 
binding was also exhibited by recombinant single-headed myosin 5 S1 and intact dimeric 
myosin 5 (Veigel et al., 2002), myosin 6 (Lister et al., 2004) and myosin 10 (Takagi et al., 
2014). Similar to (Veigel et al., 1999), the displacement produced in the first phase is larger 
than that produced in the second phase. It was proposed that the first phase of the working 
stroke is related to Pi release, wherease the second phase is associated with ADP release 
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and leads to the formation of a rigor state. The lifetime of the second phase is ATP-
dependent, with a higher rate constant at higher ATP concentration (Veigel et al., 2002; 
Lister et al., 2004). The dependence of the rate constant of the second phase on ATP 
concentration is in agreement with solution kinetic experiments which show that ADP 
release is a rate-limiting step for both myosin 5 and myosin 6 (De La Cruz et al., 1999; De 
La Cruz et al., 2001).  
The dependence of the stroke amplitude on the length of the lever arm was directly 
presented by using the combination of recombinant protein techniques and optical trapping 
assays. Single- and double-headed mutant myosin 2 and myosin 5 isoforms engineered to 
encompass a different number of the light-chain binding motifs in their neck regions (Ruff 
et al., 2001; Purcell et al., 2002), or with artificial neck domains composed of α-actinin 
repeats (Ruff et al., 2001) were used to measure the size of the power stroke (termed step 
size) in three-bead laser trap assays. Step sizes were obtained from the change in the mean 
displacement of the bead in one of the traps during binding of myosin to actin. The stroke 
size was directly correlated to the length of the myosin lever arm of both dimeric and 
monomeric myosins, regardless of whether it contained IQ motifs or α-actinin repeats. 
Kinetic properties of monomeric constructs were not affected by the length or composition 
of the lever arm.  
The data described above suggests that all myosin isoforms share common 
mechanism of force production. The bound myosin state exists in two mechanical 
conformations associated with subsequent events in the ATPase cycle. The swinging of the 
lever arm is associated with nucleotide release. The amplitude of the stroke depends on the 
length of the lever arm and attachment lifetimes and detachment rates of myosin from actin 
represent differences in rate constants of the kinetic cycle of a given myosin isoform.  
 
1.13. Processivity and duty ratio. 
Processivity is defined as the ability of a molecular motor to take multiple steps 
upon its encounter with the cytoskeletal track. That means that processive myosins will 
undergo multiple ATPase cycles when associated with the filament and move longer 
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distances than a single step driven by a single ATPase cycle. In contrast, non-processive 
myosin motors perform only a single step on the filament before detaching from it (De La 
Cruz et al., 1999; Mehta et al., 1999, Higuchi and Endow, 2002). Processivity of a myosin 
motor can be easily assessed by in vitro motility assays, where the density of motors on the 
surface is gradually decreased until only a single motor interacts with a single actin 
filament; processive myosin will support translocation of the filament even at such low 
densities, whereas at least two non-processive motors are necessary for sliding of actin 
filaments, therefore releasing actin at lower densities (De La Cruz et al., 1999). 
 Duty ratio defines the fraction of the total ATPase cycle that myosin spends strongly 
bound to actin. Duty ratio and processivity are closely related, in that processive motors 
exhibit high duty ratios, i.e. spend most of their ATPase cycle in a strongly-bound actin 
state, whereas non-processive myosins are low duty ratio motors. Duty ratio is governed by 
the rate-limiting step of the ATPase cycle; for low duty ratio motors, Pi release, and 
therefore the entrance to the strong actin binding state, is the slowest step of the kinetic 
cycle, whereas high duty ratio myosins spend most of their cycle with ADP bound in the 
nucleotide-binding pocket (De La Cruz et al., 1999).  
Duty ratio and processivity are important features governing an intrinsic 
physiological function of different myosin motors. Skeletal muscle myosin 2 is a non-
processive motor and exhibits low duty ratio (Figure 1.16A), namely it spends most of its 
catalytic cycle in a weak actin-binding form. This ensures short-lived interactions with 
actin, consisting of a single power stroke per single encounter with the filament (Uyeda et 
al., 1991; De La Cruz and Ostap, 2004). Yet, the structural organization of thick filaments 
results in efficient muscle contraction. Despite working as an ensemble, there is no 
synchronization of the kinetic cycles of the heads in the thick filament and all heads are at 
different stages of the ATPase cycle at any given time point. By performing only a single 
power stroke upon interaction with actin in thin filaments of the sarcomere, individual 
myosin heads do not cause the drag on other myosin heads associated with actin. Those 
rapid interactions enable individual heads to perform as much work as possible, resulting in 
an efficient pulling of the filaments towards the center of the sarcomere and robust 
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contraction by means of many myosin heads asynchronously undergoing power strokes on 
the thin filament (Bagshaw et al., 1993).  
On the other hand, mammalian myosin 5a is a processive, high duty ratio motor 
(Figure 1.16B) involved in the transportation of cellular cargo along actin (Reck-Petterson 
et al., 2000; Vale, 2003). Myosin 5a exhibits high affinity for ADP and spends most of its 
ATPase cycle with ADP present in the nucleotide-binding pocket (De La Cruz et al., 1999). 
How the occupancy of the strongly-bound actin state through the majority of its catalytic 
cycle contributes to the motility of myosin 5 will be discussed below.  
 
 Figure 1.16. Full ATPase cycle of skeletal muscle myosin 2 (A) and mammalian 
single-headed myosin 5 (B) presented as a pie chart. The overall ATPase cycle (360o) is 
divided into sectors corresponding to the time of the cycle each myosin spends in a given 
state. Skeletal myosin 2 and single-headed myosin 5 stay strongly attached to actin for 1% 
and 67% of the total cycle time, respectively. Figure adapted from De La Cruz et al., 1999.  
 
1.14. The hand-over-hand mechanism of processivity of dimeric molecular 
        motors. 
Processive dimeric molecular motors, such as kinesin 1, myosin 5 and myosin 6 
(myosin 6 is a conditional dimer), move on their respective cytoskeletal tracks for hundreds 
to thousands of nanometers, taking multiple steps per one diffusional encounter before they 
detach from the filament (Toprak et al., 2009; Mehta et al., 1999; Rock et al., 2001). 
Thanks to the ability to move long distances in crowded intracellular environments, those 
motors are efficient cargo transporters (Hammer and Sellers, 2012; Ross et al., 2008). How 
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is the processivity achieved? What is the molecular mechanism of the processive movement 
of cytoskeletal motors? What is the kinetic and mechanical tuning of processive molecular 
motors and how is it different from non-processive molecular motors? 
The most widely accepted model for processive motility is the hand-over-hand 
model. In that model, starting from a point when both heads of a motor are bound to the 
filament – one in front of the other, the two heads of a dimeric processive molecular motor 
switch positions of the leading head. When the first leading head is strongly attached to the 
filament, the second head can bind ATP, release the filament and search for the next 
binding site in the direction of movement. Once that head rebinds to the filament, it 
becomes the new leading head. The motor undergoes multiple such cycles with two heads 
binding to successive binding sites in an alternating manner, resulting in multiple steps on 
the filament and long-range transport (Yildiz and Selvin, 2005).  
The first evidence for the processivity within the myosin superfamily comes from 
studies on a tissue-purified myosin 5 motor (Mehta et al., 1999). Similar to conventional 
myosin, myosin 5 is composed of two heavy chains dimerized by a coiled-coil in the tail 
region (Cheney et al., 1993). Processivity implies that an individual molecular motor is 
enough to drive the translocation of the filament (Howard et al., 1989). By applying the in 
vitro motility assay, authors investigated the landing rate, velocity and the distance of actin 
filament gliding over the surface coated with the decreasing amount of the motor, to the 
point where only a single motor molecule is predicted to interact with a single filament. The 
landing rate exhibited the first-power dependence on the surface density of myosin 5, the 
fraction of filaments moving longer distances than their length increased by 1 with the 
increasing motor density, and the velocity of actin filament movement was independent 
from the density of the motor on the surface of the flow cell (Mehta et al., 1999). Thus, 
myosin 5 exhibits properties expected for a processive motor. An optical trapping assay was 
used to directly prove that a single myosin 5 molecule can undergo multiple steps on actin 
before dissociation. The detected bead underwent several position changes, associated with 
steps of myosin on actin, separated by dwell periods, resulting in a staircase-like signal of 
the position of the bead before it returned to its mean position upon the dissociation of 
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myosin from actin (Figure 1.17). The change in the bead position between dwell periods, 
equal to the step size of myosin 5, was ~36nm (Mehta et al., 1999).   
 
Figure 1.17. Processive runs of myosin 5 on actin. A three-bead optical trapping 
assay was used as described above. Individual interactions of myosin 5 with actin were 
observed by detecting the position of one of the trapped beads over time. Upon a single 
encounter with actin, myosin 5 underwent several steps (arrowheads) before detaching 
(arrows) and returning to its mean position (noise on the level corresponding to 0nm 
displacement). Figure adapted from Mehta et al., 1999. 
 
After the direct demonstration of the processivity of myosin 5, the evidence for the 
hand-over-hand movement along actin came from one nanometer-resolution fluorescent 
studies (Yildiz et al., 2003). The centre of mass of a dimeric myosin 5 molecule moves 
~37nm during each mechanical step. In a molecule moving in a hand-over-hand manner 
this means that while exchanging its position as the lead head, the binding sites for each 
individual head are ~72nm apart. Myosin 5 molecules were fluorescently labeled on the 
neck domain by exchanging light chains for fluorescent calmodulin. The reaction was 
carried out under conditions that ensured only a single calmodulin light chain was 
exchanged, resulting in myosin 5 molecules labeled with a single fluorescent dye at 
different positions within the neck domain. Myosin 5 molecules moving in the presence of 
ATP on surface-immobilized actin filaments were observed and three populations of steps 
of 74, 52 or 23nm were measured. Since the neck of myosin 5 contains 6 IQ motifs for the 
light chain binding, the three step size populations might arise from the different location of 
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the fluorescent calmodulin on the neck. Assuming that the distance between the dye and the 
centre of mass of myosin 5 (in the plane parallel to the filament) equals x, and that the 
centre of mass takes ~37nm steps, then each measured step size is equal to 37±2x nm. Thus, 
for the observed ~74nm steps the dye was attached next to the head domain, and for 23nm 
steps – next to the centre of mass (Yildiz et al., 2003). A schematic drawing of the hand-
over-hand motility of myosin 5 is depicted in Figure 1.18. 
Such processive motility imposes one important constraint on the mechanochemical 
activity of the two heads in a double-headed motor: at least one head has to remain in an 
actin-bound form during movement, as simultaneous ATP binding to both heads would 
result in the whole molecule diffusing away from the filament before completion of the run. 
This implies that in a processive motor both heads regulate each other’s ATPase cycles to 
ensure spatiotemporal coordination of their mechanical performance. Transient kinetic 
analysis of recombinant single-headed myosin S1 revealed that the rate-limiting step of the 
ATPase cycle of myosin 5 is ADP release (De La Cruz et al., 1999). Single molecule 
optical trapping experiments confirmed that at saturating ATP concentrations and low load 
ADP release is the rate-limiting step of the catalytic cycle, with all other steps within the 
cycle occurring at much faster rates (Rief et al., 2000). This suggests tight 
mechanochemical coupling, whereby both the catalytic and mechanical cycles are regulated 
by the same rate-limiting step. Furthermore, the rate of ADP release from myosin 5 S1 is 
load-dependent (Veigel et al., 2005). Closer analysis of individual interactions of myosin 5 
S1 with actin revealed that the lifetimes of ADP-bound myosin decreased when an external 
load was applied in the direction of movement and increased when the load was applied in 
the opposite direction. It was proposed that in a native molecule each head imposes load on 
the second head as the cycle progresses. That load would introduce an intramolecular strain 
and result in the coordination of ADP release rates of each head. When both heads are 
bound to actin, the lead head would experience a negative load (opposite to the direction of 
movement) and the trail head would experience a positive load (in the direction of 
movement). As a result, the ADP release from the lead head would be slowed down and 
accelerated in the trail head. Faster ADP release from the trail head would enable it to 
rapidly bind and hydrolyse a new ATP molecule. The lead head would still remain in the 
ADP-bound state and progress through its power stroke, throwing the detached trail head 
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forward. As the trail head becomes the new lead head, it rebinds to actin and imposes a 
positive load on the new trail head. The new trail head could then release ADP and undergo 
a new catalytic cycle. The ability of two heads in processive molecular motors to coordinate 
their ATPase cycles has been termed the gaited gate and suggested to be a mechanism 
responsible for increasing the processivity of a molecular motor (Veigel et al., 2002; Veigel 
et al., 2005).  
 
Figure 1.18. A hand-over-hand model of motility of myosin 5. During the 
processive hand-over-hand movement myosin 5 takes multiple steps, with the centre of 
mass moving ~37nm (blue dashed lines) and both heads switching positions of the lead 
head. This implies that two consecutive binding sites for each head are ~74nm apart. By 
attaching a single fluorescent dye on the neck of myosin 5, a hand-over-hand motility was 
directly demonstrated. As the first leading head (orange, top) undergoes a power stroke, but 
remains attached to the same actin monomer, the dye on the neck (black dot) will move 37-
2x nm (green dashed line), where x is the distance between the centre of mass and the 
position of the dye. Simultaneously, the first trail head (blue, top) will bind to its next 
binding site, 74nm away in the direction of movement, and become the new lead head 
(blue, middle). The new trail head (orange, middle) will now swing 74nm to its next 
binding site. With the concomitant power stroke of the lead head, the centre of mass will 
change its position, and the dye will appear to be displaced by 37+2x nm (purple dashed 
line).  
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1.15. Myosin 9.  
Firstly characterized in rat, members of the myosin class 9 are widely distributed in 
invertebrates (with the exception of Drosophila), which contain a single myosin 9 gene, and 
vertebrates which express two myosin 9 isoforms (Bement et al., 1994; Reinhard et al., 
1995, Liao et al., 2010). Myr 5 and myr 7 from rat (the 5th and 7th unconventional myosins 
from rat) are human orthologs of myosin 9b and myosin 9a, respectively (Chieregatti et al., 
1998; Abouhamed et al., 2009). Myo9b is mainly expressed in various immune cells, 
including dendritic cells and macrophages (McMichael et al., 2014; Xu et al., 2014), and 
intestinal epithelium (Bement et al., 1994), whereas myo9a is found in the ependymal 
epithelium of the brain ventrical system (Abouhamed et al., 2009).  
Myosin 9 members are implicated in the differentiation and morphology of cells. 
Myo9a-deficient mice develop hydrocephalus (Abouhamed et al., 2009), whereas knockout 
of myo9b results in impaired directed migration of dendritic cells (DCs) both in vitro and in 
vivo and abolishes T cell activation by DCs, suggesting myo9b plays an important role in 
the development of primary immune response (Xu et al., 2014). Closer analysis revealed 
that epithelial cells lacking myosin 9 are irregularly shaped and display reduced maturation 
(Abouhamed et al., 2009, McMichael, 2014). Cell boundaries in the ependymal epithelium 
of brain ventrices of myo9a-/- mice lost linearity (Figure 1.19), suggesting they experienced 
an unequal tension along the plane of the epithelial sheet. This was caused by lower levels 
of occludin localization in tight junctions, resulting in an impaired cell-cell contact 
formation. Additionally, a great reduction in the number of multiciliated cells was 
observed, explaining improper flow of the cerebrospinal fluid (CSF) in brain ventrices 
resulting in hydrocephalus (Abouhamed et al., 2009). In line with disrupted cell-cell 
junctions, myosin 9 knockdown in 16HBE cell line (human bronchial epithelium) abolished 
collective cell migration in cell culture (Omelchenko and Hall, 2012).  
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Figure 1.19. Changes in the ependymal cell shape and epithelium distortion upon 
loss of myosin 9a in the ventral caudal 3rd ventricle and the aqueduct of the ventrical system 
of the mouse brain. Coronal sections of P0.5 myo9a-/- (A) and WT (B) mice were 
immunostained with anti-E-cadherin (green; adherens junctions marker) and anti-acetylated 
tubulin (red; cilia marker) and DAPI (DNA marker). In myo9a-/- the ependymal epithelial 
layer is distorted and the number of multiciliated cells isreduced, as compared to WT mice. 
C and D is a close-up view of A and B, respectively, stained for E-cadherin, showing 
distortion of the ependymal cell layer. P3.5 myo9a-/- (E) and WT (F) mice sagittal sections 
stained for β-catenin (adherens junction marker) showing irregular cell shape in the 
ependymal cell layer in myo9a-/- mice as compared to WT. G: linearity index of 
ependymal epithelium of myo9a-deficient (-/-) and WT (+/+) mice. The linearity index is 
defined as the ratio of the junctional length to the distance between vertices and is 
significantly increased in myo9a-/- mice. Sagittal sections of aqueducts from the P3.5 
myo9a-/- (H) and WT (I) mice were immunostained for β-catenin (green) and S-100 (red; 
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marker of mature ependymal cells) showing distortion and stenosis of the ependymal layer 
in the aqueduct of myo9a-/- mice. J and K: a close-up view of the selected area from H and 
I, respectively, stained for β-catenin. L – O: coronal sections of the ventral caudal 3rd 
ventricle of myo9a-/- and WT (myo9a+/+) mice showing disruption of cellular junctions in 
myo9a-deficient mice. Figure adapted from Abouhamed et al., 2009. 
 
On the structural level, myosin 9 members exhibit several unique features; a large 
(100-150 aa) N-terminal extension upstream of the motor domain adopts a Ras-binding fold 
but lacks conserved residues necessary for Ras binding and therefore its function remains 
unknown (Kalhammer et al., 1997); loop 2 insert of ~150aa with a putative calmodulin 
binding site that might regulate motor properties by means of interacting with actin (Bähler, 
2000; Liao et al., 2010); a RhoGAP domain in the tail that inhibits Rho-signalling by 
stimulating GTP hydrolysis by Rho GTPases both in vitro and in vivo (Müller et al., 1997; 
Chieregatti et al., 1998; Post et al., 1998, Omelchenko and Hall, 2012).  
The presence of the RhoGAP domain in the tail of myosin 9 members poses an 
intriguing hypothesis that myosin 9 functions as a motorized signaling molecule in the cell, 
coupling its mechanical and signalling properties to spatiotemporally regulate Rho GTPases 
(Bähler, 2000; van den Boom, 2007). Rho GTPases are known effectors of the cytoskeletal 
architecture, including formation of stress fibers and focal adhesions (Narumiya, 1996;  
Ridley, 1996; Hall, 1998). Indeed, disruption of cell-cell contacts during collective cell 
migration was assigned to abolished formation of actin fingers - stress fiber-like actin 
protrusions that overlap with a neighbouring cell in the first phase of contact formation. 
That phenotype was caused by an inhibition of Rho signalling by overexpression of myosin 
9a in 16HBE culture (Omelchenko and Hall, 2012; Omelchenko, 2012).  
Evidence for the mechanical activity of myosin 9 in vitro, indicating it could 
spatiotemporally deliver RhoGAP domain to the sites of high Rho signalling, comes from 
biochemical studies of recombinant nematode myosin 9 (Liu et al., 2010), and native and 
recombinant human and rat myosin 9b constructs (Post et al., 1998; Inoue et al., 2002; 
Nalavadi et al.; 2005; Nishikawa et al., 2006). There is no data available on the mechanical 
or kinetic properties of myosin 9a orthologs. Available data suggests myosin 9 is a single-
headed processive motor (Inoue et al., 2002; Post et al., 2002; Liao et al., 2010; Elfrink et 
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al., 2014). It is intriguing given that the processivity of a single-headed myosin motor 
cannot be explained by a hand-over-hand mechanism widely accepted for well-
characterized processive motors like myosin 5 or myosin 6 (Yildiz et al., 2003; Yildiz et al., 
2004a). It has been suggested that class 9-specific loop 2 insert might tether myosin 9 head 
to actin while enabling enough flexibility for a diffusive search of the next binding site. 
Loop 2 insert is well suited for such function given that loop 2 is the primary actin 
interaction site of myosin and the long insert behaves like an ectopic spring (Inoue et al., 
2002; Struchholz et al., 2009; Elfrink et al., 2014). During myosin 9 motility, loop 2 insert 
would tether the head to the actin filament, allowing for dissociation of the head upon ATP 
binding and preventing releasing the filament. Following binding of the head to the 
subsequent actin site, the insert would release the filament and go back to its original 
position near the actin-binding cleft of myosin head (Figure 1.20; Nishikawa et al., 2006).  
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Figure 1.20. An inchworm-like model of processive motility of myosin 9 along 
actin. ATP binds to the active site of myosin bound to actin in rigor (A). That causes release 
of the head from the filament; simultaneously, the head is tetherted to the filament by a 
flexible loop-2 insert preventing full detachment of the myosin (B). ATP is hydrolyzed and 
the head diffuses along the filament lattice and attaches to the next actin-binding site (C). 
Following ATP hydrolysis and recombination of myosin with actin, γ-phosphate is released 
from the nucleotide-binding pocket, the head isomerizes to strong actin binding, loop-2 
insert releases the filament and returns to its original position (D).  
 
1.16. Significance and project objectives. 
As opposed to conventional myosins which work in large assemblies to generate 
contraction, and dimeric myosins that pick up cargo and distribute it to specific cellular 
compartments, myosin 9 has been suggested to function as a monomeric processive motor 
involved in signaling events controlling cell morphology. It was proposed that myosin 9 
contains a built-in cargo in the form of a RhoGAP domain, and transports it to the sites of 
action by means of its enzymatic activity (Bähler, 2000). At destination sites, the RhoGAP 
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domain of myosin 9 could be involved in downregulation of RhoGTPases, known effectors 
of the cytoskeletal architecture (Abouhamed et al., 2009; Hall, 1998).  This poses a strict 
requirement on the spatiotemporal control of the intracellular localization of myosin 9 
which could be regulated by its mechanochemical properties. Therefore, it is of interest 
how myosin 9 members couple their motor and signaling activities to efficiently regulate 
signaling pathways. 
At present, there is no evidence that myosin 9a isoform is a mechanically and 
enzymatically active motor. Despite the sequence similarity with other myosin 9 isoforms 
which have been shown to display motor properties both in vitro and in vivo (Liao et al., 
2010; van den Boom, 2007; Nalavadi et al., 2005; Post et al., 2002; Post et al., 1998), low 
tissue expression levels of myosin 9a as well as difficulties in obtaining a recombinant 
protein have hindered investigations of that particular member of the myosin superfamily. 
Before one tries to understand the relationship between the mechanochemical and signaling 
properties of myosin 9a, it is essential to examine if this myosin functions as a catalytically 
active mechanical motor.  
The specific goals of the project include: 
- a heterologous expression and purification of a recombinant active myosin 9a 
- an investigation of its native structure 
- an examination of its actin-binding properties 
- an investigation of its catalytic activity 
- an investigation of its mechanical activity 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
 
 
2.1. Buffer and media recipes 
 
Western blot buffer 
Ingredient Final concentration Mass or volume/1L 
Trizma®Base 25mM 3.03g 
Glycine 192mM 14g 
Methanol 20% 200ml (shortly before the run) 
 
ACEX buffer 
Ingredient Final concentration Mass or volume/2.5L 
Tris-HCl pH 8.0 2mM 2.5ml (2M stock) 
ATP 0.2mM 5ml (0.1M stock) 
CaCl2 0.2mM 0.5ml (1M stock) 
DTT 1mM 2.5ml (1M stock) 
 
Myosin Lysis Buffer 
Ingredient Final concentration Mass or volume/1L 
KH2PO4 pH 6.8 90mM 90ml (1M stock) 
K2HPO4 60mM 60ml (1M stock) 
KCl 300mM 100ml (3Mstock) 
DTT 1mM 1ml (1M stock) 
Protease inhibitors  1 tablet/100ml 
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HisLow 
Ingredient Final concentration Mass or volume/1L 
Tris-HCl pH 7.5 50mM 50ml (1M stock) 
Imidazole 40mM 2.7g 
NaCl 500mM 200ml (2.5Mstock) 
DTT 1mM 1ml (1M stock) 
 
HisHigh 
Ingredient Final concentration Mass or volume/1L 
Tris-HCl pH 7.5 50mM 50ml (1M stock) 
Imidazole 400mM 27.2g 
NaCl 500mM 200ml (2.5Mstock) 
DTT 1mM 1ml (1M stock) 
 
Myosin Extraction Buffer (2x concentrated) 
Ingredient Final concentration Mass or volume/1L 
MOPS pH 7.2-7.4 20mM 4.2g 
NaCl 1M 58.44g or 400ml (2.5M stock) 
MgCl2 10mM 10ml (1M stock) 
EGTA 2mM 4ml (0.5M stock) 
NaN3 (for storage) 3mM 0.195g 
 
For preparation of 1x Myosin Extraction Buffer add: 
Ingredient Final concentration Mass or volume/0.2L 
ATP 3mM 6ml (0.1M stock) 
DTT 1mM 200µl 
Protease inhibitors  1 tablet 
Recheck pH 
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Myosin HMM buffer (2x concentrated) 
Ingredient Final concentration Mass or volume/1L 
MOPS pH 7.2-7.4 20mM 4.2g 
EGTA 0.2mM 0.4ml (0.5M stock) 
NaN3 (for storage of concentrated stock) 3mM 0.195g 
 
For preparation of 1x HMM add: 
Ingredient Final concentration Mass or volume/50ml 
NaCl 100/250/500mM 2ml/5ml/10ml (2.5M stock) 
DTT 1mM 50µl 
Recheck pH 
 
Motility buffer (5x concentrated MB) 
Ingredient Final concentration Mass or volume/50ml 
MOPS pH 7.2-7.4 50mM 0.52g 
KCl 125mM 2.1ml (3M stock) 
EGTA 5mM 0.5ml (0.5M stock) 
MgCl2 5mM 0.25ml (1M stock) 
 
For preparation of 1x MB add: 
Ingredient Final concentration 
DTT 10mM 
BSA (for MB-BSA) 1mg/ml 
ATP (for MB +) 1mM 
CaM (for MB +) 2µM 
 
General Actin buffer (10x concentrated) 
Ingredient Final concentration Mass or volume/50ml 
Tris-HCl pH 8.0 50mM 2.5ml (1M stock) 
CaCl2 2mM 0.1ml (1M stock) 
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 10x Polymerization Salts 
Ingredient Final concentration Mass or volume/10ml 
KCl 500mM 1.7ml (3M stock) 
MgCl2 20mM 0.2ml (1M stock) 
 
For polymerization of small volumes of actin mix: 
Ingredient Final concentration 
10x General Actin Buffer  1x 
10x Polymerization Salts 1x 
ATP 1mM 
DTT 1mM 
 
Actin polymerization buffer 
Ingredient Final concentration Mass or volume/1L 
MOPS pH 7.2 25mM 5.23g 
MgCl2 2mM 2ml (1M stock) 
DTT 1mM 1ml (1M stock) 
EGTA 1mM 2ml (0.5M stock) 
KCl 50mM 16.7ml (3M stock) 
NaN3 3mM 0.195g 
 
Gel filtration buffer 
Ingredient Final concentration Mass or volume/1L 
MOPS pH 7.2-7.4 10mM 2.1g 
NaCl 150mM/500mM 60ml/200ml (2.5M stock) 
EGTA/CaCl2 0.1mM/0.2mM 0.2ml/0.2ml (0.5M/1M stocks) 
DTT 1mM 1ml (1M stock) 
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ATPase buffer 
Ingredient Final concentration Mass or volume/0.5L 
MOPS pH 7.2-7.4 10mM 1.05g 
KCl 50mM 4.2ml (3M stock) 
EGTA 0.1mM 0.2ml (0.5M stock) 
MgCl2 1mM 0.5ml (1M stock) 
DTT 1mM 0.5ml (1M stock) 
CaM 5µM  
 
TG buffer (5x concentrated) 
Ingredient Final concentration (1x) Mass or volume/5L 
Trizma®Base pH 8.3 25mM 469.2g 
Glycine 250mM 75.7g 
SDS 0.1% 250ml (10% stock) 
 
PBS (10x concentrated) 
Ingredient Final concentration Mass or volume/1L 
NaCl 1.3 7M 80.06g 
KCl 27mM 2.01g 
Na2HPO4 pH 7.2 100mM 14.2g 
KH2PO4 18mM 2.45g 
 
2x YT medium 
Ingredient  Mass or volume/5L 
Tris-HCl pH 7.0  ~30ml 
Tryptone  80g 
Yeast extract  50g 
NaCl  25g 
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 LB medium 
Ingredient  Mass or volume/1L 
Tryptone  10g 
Yeast extract  5g 
NaCl  10g 
Adjust pH to 7.0 
 
 B2B medium 
B2B medium agar plates consist of 500ml LB medium supplemented with: 
Ingredient Final concentration Mass or volume/0.5L 
X-Gal 50µg/ml 1.25ml (20mg/ml stock) 
IPTG 40µg/ml 84µl (1M stock) 
Gentamycin 7µg/ml 70µl (50mg/ml stock) 
Kanamycin 50µg/ml 1ml (25mg/ml stock) 
Tetracyclin 10µg/ml 0.5ml (10mg/ml stock) 
Agar 1.5% 7.5g 
B2B liquid medium has the same recipe, except that there is no IPTG, X-Gal or Agar. 
 
2.2. Oligonucleotides 
 All oligonucleotides have been purchased from Sigma-Aldrich or Eurofins MWG 
Operon following manufacturer’s recommendations. 
Name Sequence (5’ –  3’) 
GFPfwd AGGATCCATGGTGAGCAAGGGCG 
GFPrev AAAAGCGGCCGCGGACTTGTACAGCTCGTCC 
9aFLpFBNAfwd AGGATCCATGAATATAAATGATGGAGG 
9aFLpFBNArev AAAAGCGGCCGCGACCATAAATTCATTATTTCC 
9afwd AAAAGCGGCCGCAATGAATATAAATGATGGAGG 
MMD9afwd AGGATCCATGGATGATTTATGTAG TTTACCTGATTTG 
1019rev TTCTAGATTACACCTCTTGGTGAAGCAGATC 
1162rev ATCTAGATTATTTTAAAGCTTTAAATCTTTGTCTTGC 
1019revFLAG TTCTAGACTACTTGTCATCGTCATCCTTGTAATCCACCTCTTGGTGA
AGCAGATC 
1162revFLAG TTCTAGACTACTTGTCATCGTCATCCTTGTAATCTGATTTTAAAGCT
TTAAATCTTTG 
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MMD9arev AAAAGCGGCCGCCACCTCTTGGTGAAGCAGATCTTG 
MMD9a-S1rev AAAAGCGGCCGCTTTTAAAGCTTTAAATCTTTGTC 
AviTag-fwd P-GGCCGCAGGTGGCGGTCTGAACGACATCTTCGAGGCTCAGAAA 
ATCGAATGGCACGAAGC 
AviTag-rev P-GGCCGCTTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGT 
TCAGACCGCCACCTGC 
EXTfwd AAGGATCCATGAATATAAATGATGGAGG 
EXTrev AAAAGCGGCCGCTTAATCAAAGTCTTTCTGTTGAGGC 
LOOP2fwd AAAGTCGACATGGCTGGAAAAGTAAAATATGGG 
LOOP2rev AAAAAGCTTTCAAGCATTAGAGCGAATGCATTTTAC 
RFPfwd TTTTTTGGATCCATGGCCTCCTCCGAGGACG 
RFPrev TTTTTTGGATCCGGCGCCGGTGGAGTGGCG 
CC1fwd AGGATCCATGAGCCAGAGTGGTGTGGACTTGCAGG 
CC1rev AAAGTCGACGCTCTACTCTTTGCTTTGACTGATAGGAAG 
CC2fwd AGGATCCATGCCAGGTCCATCGTCTCCTGTTGTAG 
CC2rev AAAGTCGACGCTCTGAGCTATCAGCAGTCCCAATGG 
pUC-M13F CCCAGTCACGACGTTGTAAAACG 
pUC-M13R AGCGGATAACAATTTCACACAGG 
 
 Constructs were sequenced at NHLBI core facility or by GATC Biotech and 
sequences were analyzed by SerialCloner 2.1 or MacVector.   
 
2.3. Experimental procedures 
2.3.1. Sequence analysis 
 Initial domain analysis of myosin 9a was performed with SMART (Simple Modular 
Architecture Research Tool) algorithm and was enriched by manual analysis and literature 
searches. The calmodulin-binding site search was performed using Calmodulin Target 
Database as a reference for CaM target sequences. Sequence alignments were performed 
using COBALT (Constraint-based Multiple Alignment Tool) software. Analysis of the 
sequence for the presence of putative coiled-coil domains was performed with Paircoil2 
(McDonnell et al., 2006).  
  56 
2.3.2. DNA amplification, restriction, ligation and transformation to E. coli 
DH5α 
A gene encoding full length human myosin 9a was chemically synthesized by 
GenScript (Piscataway, NJ, USA). The gene was cloned between XbaI and BamHI sites in 
the pUC57 vector and was used as a template for generation of all myosin 9a constructs 
used in this work. 
GFP-9a-Head and GFP-9a-S1 were generated by amplification of the first 1019 or 
1162 aa of myosin 9a, respectively, using 9afwd and 1019rev or 1162rev and introduced 
between NotI and XbaI restriction sites into pFastBac HT®B (Invitrogen). GFP was linked 
N-terminally to the motor domain by amplification with GFPfwd and GFPrev and ligation 
into BamHI and NotI sites. Both GFP and myosin 9a fragments were introduced in frame 
with the N-terminal 6x His-tag present in the vector. To add a FLAG-tag, primers were 
designed that contained a sequence complement to the last ~20 bases of the myosin 9a 
construct, followed by the sequence encoding the FLAG tag (DYKDDDK) upstream of the 
stop codon and XbaI site. Those were used together with an appropriate forward primer in 
PCR to ass the C-terminal FLAG-tag. PCR products flanked with BamHI and XbaI sites 
were ligated into pFastBac HT®B.  
The Minimal Motor Domain constructs were amplified with MMD9afwd and 
MMD9arev and MMD9a-S1rev and introduced between BamHI and NotI sites in frame 
with a C-terminal FLAG-tag in customized pFBNA vector (kind gift of Dr. Attila Nagy, 
NHLBI, NIH). Introduction of an Avi-tag between the end of myosin 9a sequence and the 
FLAG-tag was achieved by digestion of 9aMMD and 9aMMD-S1 with NotI and ligation 
with chemically synthesized Avi-tag oligonucleotides carrying free phosphate groups at the 
3’ end.  
The full length human myosin 9a gene was amplified with 9aFLpFBNAfwd and 
9aFLpFBNArev primers and introduced between BamHI and NotI sites into the pFBNA 
vector in frame with the C-terminal FLAG tag. 
The putative coiled-coil fragments from myosin 9a tail were amplified with the 
indicated primers and introduced into the pET28a vector (Novagen). These were introduced 
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in frame with a C-terminal CFP in a customized pET28a vector. All constructs contain an 
N-terminal His-tag.  
PCR amplifications were carried out in Mastercycler Personal (Eppendorf) or 
C1000 Touch™ Thermal Cycler (Bio-Rad). 50µl reactions were carried out using the 
Phusion® High-Fidelity PCR Kit (ThermoScientific) and included 10 µl 5x HF Buffer, 1 µl 
10 mM dNTPs, 2.5 µl 10 µM both primers, 0.5 µl Phusion Hot Start DNA Polymerase and 
50-100 ng DNA template. Reactions were programmed as follows:  
1. 980C 1min 
2. 980C 20sec 
3. 700C 15sec 
4. Ramp to 610C, 0.50C/sec 
5. 720C 1-3min 
6. 720C 5min 
7. 40C ∞ 
Steps 2-5 were repeated 30x. Duration of the elongation step (5.) was adjusted 
accordingly to the size of an amplified fragment following manufacturer’s specifications 
(30 sec/kbp). PCR products were analyzed by DNA electrophoresis to confirm the 
amplification of a DNA fragment of expected size and purified by the QIAquick PCR 
purification kit (QIAGEN) or the PureLink® PCR purification kit (Invitrogen) following 
manufacturer’s guidelines.  
DNA restriction was performed using the appropriate enzymes purchased from 
NewEngland BioLabs and according to specifications. In general, 40 µl reactions included 
1x NEBuffer, 1x BSA (if required), 30 µl DNA, 2 µl of each enzyme (or 1 µl each 
enzyme/1 µg DNA) and were incubated for 3-4 h at 370C. The whole volume was mixed 
with 10 µl DNA loading dye and 10 µl SYBR Green (ThermoScientific) and digested 
products were separated by DNA electrophoresis. Digested constructs were purified by 
cutting them out of agarose gels and purifying them following instructions in the 
PureLink® Gel Extraction kit (Invitrogen) or the QIAquick Gel Extraction kit (QIAGEN).  
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Concentrations of gel-extracted DNA constructs were measured on BioPhotometer 
plus (Eppendorf) and ligations were performed using a 3:1 ratio of insert to vector in 10µl 
reactions including 2 µl Rapid Ligation buffer and 1 µl T4 DNA polymerase from the 
Rapid Ligation Kit (ThermoScientific).  
Whole ligation reaction volumes were used to transform 100 µl E.coli DH5α cells, 
following a standard heat-shock protocol (2 min on ice; 30 sec in 420C; 5 min on ice). 200 
µl of LB media was added to transformed cells and samples transformed with pET28 
plasmids (carrying the kanamycin resistance gene) were shaken for 1 h 370C, 200 rpm. 150 
µl or 70 µl of cell suspensions were plated on LB agar plates containing either 50 µg/ml 
ampicillin (for pFBNA and pFastBac plasmids) or 25 µg/ml kanamycin (for pET plasmids). 
Following an overnight incubation at 370C, single colonies were inoculated into 3 ml of 
liquid LB media containing the appropriate antibiotic. After overnight growth at 200 rpm, 
370C, plasmid DNA was purified with the PureLink® Quick Plasmid Miniprep kit 
(Invitrogen) or the QIAprep Spin Miniprep kit (QIAGEN).  
Isolated plasmids were subject to restriction analysis to confirm successful ligation 
into vectors. In 10 µl reactions supplemented with NEBuffer, 5 µl of purified DNA was cut 
with 0.5 µl of the appropriate enzymes for 1 h at 370C. DNA electrophoresis was performed 
to confirm the presence of the desired insert in the vector. Those samples that contained 
products of expected sizes were subject to sequencing to confirm the correct generation of 
the desired constructs.  
 
2.3.3. Transformation and expression of proteins in E.coli BL21 cells 
 1 µl of plasmid containing myosin 9a tail fragments with the C-terminal CFP or a 
plasmid containing Xenopus calmodulin (CaM) incorporated in frame with the N-terminal 
His-tag, were used to transform 50 µl chemically competent One Shot® BL21 (DE3) E. 
coli cells (Invitrogen) following a standard heat-shock protocol. Cells were treated as 
described above for DH5α cells and single colonies from overnight agar plates were used to 
inoculate liquid starter cultures in 2x YT supplemented with 25 µg/ml kanamycin. 500 ml 
of media supplemented with kanamycin was inoculated with 50 ml of overnight starter 
  59 
cultures. Cells were grown to OD600 = 0.6 and expression was induced with 1 mM IPTG for 
5 h at 370C. Cell pellets were collected by 10 min centrifugation at 4000 rpm, 40C in the 
JLA-10.500 rotor (Beckman Coulter). Cell pellets from 1 L cultures were resuspended in 40 
ml of the His-Low buffer with 1mM DTT and protease inhibitors cocktail and stored at -
800C until use. 
 
 2.3.4. His-tag affinity purification of bacterially-expressed proteins 
 Pellets from 1L cultures were thawed in a water bath at 250C. Following sonication 
on ice for 5 min with 1 sec on/off bursts at 50% power (Bandelin HD 2070 sonicator) the 
soluble fraction was recovered by centrifugation at 20000 rpm, 40C, 20 min in the JA25.50 
rotor (Beckman Coulter) and loaded automatically on the 5 ml His-Trap FF column (GE 
Healthcare) equilibrated with the His-low buffer on ÄKTA Purifier FPLC (GE Healthcare). 
The column was thoroughly washed with His-low until the A280 reached the baseline. The 
protein was eluted with His-high in a step-wise manner (Batters et al., 2012). Flow rates 
and pressure limits were set according to specifications to 1 ml/min and 0.5 MPa, 
respectively. Eluate fractions corresponding to peaks in the A280 signal were analyzed by 
SDS-PAGE. Pure fractions were pooled together and concentrated if necessary. Proteins 
were extensively dialyzed into 1x PBS + 1 mM DTT overnight, snap-frozen in liquid N2 
and stored at -800C until use. Figure 2.1 shows a representative SDS-PAGE gel from the 
purification of CaM.  
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 Figure 2.1. A representative SDS-PAGE gel of exogenous calmodulin purified from 
BL21 E.coli cells by means of His-tag affinity chromatography. MW – molecular weight. 
Expected MW of exogenous CaM: ~21 kDa. Lanes correspond to subsequent elution 
fractions. 
 
 2.3.5. Generation of recombinant bacmids 
 1 µl of pFastBac or pFBNA plasmids with incorporated myosin 9a fragments were 
used to transform 10 µl competent MAX Efficiency® DH10Bac™ E.coli cells (Invitrogen); 
cells were kept on ice for 30 min, followed by 45 sec at 420C and incubation on ice for 2 
min. Cells were rescued in 90 µl S.O.C. media. Following a 4 h incubation at 200 rpm, 
370C, 100 µl of 1:10 and 1:100 cell dilutions were plated on B2B agar plates, containing 
tetracyclin, kanamycin, gentamycin, X-gal and IPTG as specified above. Plates were 
incubated at 370C for 48 h and white colonies were picked to inoculate 3 ml of B2B media 
supplemented with the antibiotics. Simultaneously, the same colonies were restreaked on 
B2B plates and incubated for 48 h at 370C to confirm the formation of white colonies.  
 Cells were grown in liquid B2B media overnight at 200 rpm, 370C and collected by 
centrifugation at 4000 rpm, 10 min. DNA was extracted with the PureLink® HiPure 
plasmid miniprep kit (Invitrogen) following manufacturer’s guidelines. Alternatively, 
bacmids were purified by an isopropanol extraction; after the resuspension of cells, lysis 
and neutralization with commonly available DNA miniprep kit buffers, ~800 µl supernatant 
was rescued by centrifugation, mixed with an equal volume of isopropanol and incubated 
for 20 min at -200C. DNA was pelleted by centrifugation in a tabletop centrifuge at max. 
speed, 20 min, 40C and after removal of the supernatant, washed with 0.5 ml of 70% 
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ethanol. DNA was recentrifuged and air-dried. Bacmids were resuspended in 40 µl of 
endonuclease-free water and stored in -200C until use. Since freeze-thaw cycles might 
hinder transfection efficiency, it is better to aliquot bacmid DNA before freezing. 
 Isopropanol extraction yields ~1000x higher DNA concentrations, yet cell 
transfections with DNA prepared in that way were not always successful. I attribute this to 
the fact that the isopropanol extraction results in the purification of both bacmid and 
chromosomal DNA and thus during transfection there might not be enough bacmid DNA to 
generate the virus. Bacmid extraction with a commercial miniprep kit yielded extremely 
low concentrations (~1 ng/µl), yet all transfections performed with those samples resulted 
in the successful generation of viruses.  
 Finally, the presence of desired constructs in isolated bacmids was confirmed by 
PCR with pUC-M13F and pUC-M13R primers following previously described 
specifications, with 4 min extension time. 
 
 2.3.6. Generation and amplification of a recombinant baculovirus 
 SF9 or SF21 cells were maintained in Grace’s medium (Invitrogen) supplemented 
with 10% FBS (heat-inactivated), 1% Pluronic® F-68 (Invitrogen) and 1µg/ml normocin 
(Invivogen),  or in SF900 II Serum Free Medium (Invitrogen) as suspension cultures at 
270C, 140 rpm.  
 Viruses were generated and amplified according to manufacturer’s guidelines. 0.6 x 
106 cells were plated per well in 2 ml of medium in 6-well plates. After 15 min at RT, if 
kept in a serum-containing medium, media in wells was exchanged to Unsupplemented 
Grace’s medium (Invitrogen). 100 µl of unsupplemented medium with 8 µl of Cellfectin® 
II reagent (Invitrogen) and 100 µl of unsupplemented medium with 12 µl of bacmid 
(prepared in separate tubes) were combined and incubated for 30 min at RT. The mix was 
added dropwise to the cell-containing wells and after 5-7 h incubation, the media was 
exchanged to remove free Cellfectin reagent and DNA and plates were incubated at 270C 
for ~1 week. Viruses were collected by centrifugation at 8000 rpm, 15 min. This was the P0 
virus stock. 
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 The virus titer was increased by subsequent virus amplification in increasing culture 
volumes to P3. 1.2*106 cells/ml in 25 ml or 250 ml were infected with 250 µl or 2.5 ml of 
the preceding virus stock, respectively, and grown for 72 h, 140 rpm, 270C. After 72 h, cell 
viability should be as low as 30-50% as calculated for 1:1 cell suspention:Trypan Blue 
(Bio-Rad) mix in the TC20™ Automated Cell Counter (Bio-Rad). Viruses were collected 
by centrifugation at 8000 rpm, 15 min, 40C and stored long-term at 40C.             
                          
 2.3.7. Expression and purification of myosin 9a motors from insect cells 
 500 ml cultures of SF9 or SF21 cells at 1.2*106 cells/ml were co-infected with 15 
ml of a myosin 9a baculovirus (P3 stock) and 10 or 15 ml of CaM baculovirus (P4 stock), 
for constructs without and with the lever arm, respectively. Proteins were expressed for 48 
h at 270C, 140 rpm and pellets collected by centrifugation at 8000 rpm, 15 min, 40C were 
frozen and stored at -800C until use.  
 Protein was purified based on a modified procedure from Wang et al., 2000. Pellets 
from 1000 ml cultures were resuspended in 80 ml of the Myosin Extraction Buffer and 
sonicated for 5 min with 1 sec on/off bursts at 40% power (Bandelin HD 2070 sonicator). 
Cell slurry was rotated in the presence of ATP for 1 h, 40C to facilitate dissociation of 
myosin 9a from actin. Cell debris was removed by centrifugation at 20000 rpm, 20 min, 
40C in the JA25.50 rotor (Beckman Coulter). The supernatant was combined with 0.9 ml of 
the Anti-FLAG M2 Affinity Gel (#A2220, Sigma Aldrich) prepared following 
manufacturer’s instructions and nutated for 45-60 min at 40C. Resin with bound protein was 
rescued by centrifugation at 1600 x g, 6 min, 40C, resuspended in 10 ml of the Myosin 
Extraction Buffer and poured into a disposable 10 ml Poly-Prep® Chromatography column 
(Bio-Rad). Following settling of the resin, it was washed twice with 10 ml of the Myosin 
Extraction Buffer and twice with 10 ml of 100 mM NaCl Myosin HMM buffer. Protein was 
eluted with 4 ml of 0.1 mg/ml FLAG® peptide (#F3290, Sigma Aldrich) in 100 mM NaCl 
HMM buffer and immediately loaded on 0.2-0.3 ml of the Q Sepharose Fast Flow (#17-
0510-10, GE Healthcare), equilibrated with 100 mM NaCl HMM buffer. Protein was eluted 
in 0.4 ml fractions of 250 mM and 500 mM NaCl HMM buffer. Protein yield, purity and 
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coelution of calmodulin light chain were confirmed by SDS-PAGE. Proteins were dialyzed 
overnight into 100 mM NaCl HMM or used directly after elution. 
 Before experiments, proteins were centrifuged at 160000 x g, 20 min, 40C, in the 
TLA-120 rotor (Beckman Coulter) to remove aggregates (Liao et al., 2010). Concentration 
was measured following the Christian-Warburg method that corrects protein concentration 
for the amount of the nucleic acid present in the sample. Absorbance at 260 nm and 280 nm 
was collected by Biophotometer plus (Eppendorf). Protein was used fresh within 2 days. 
 
2.3.8. Dynamic Light Scattering 
 0.1 mg/ml myosin 9a in filtered 100 mM NaCl HMM buffer was used to measure 
the time-dependent stability of the preparations. Intensity of refracted light was used to 
obtain hydrodynamic radii of molecular species present in the samples using the Zetasizer 
µV (Malvern) with automatically adjusted settings. Measurements were performed 3x for 
each time point with each measurement lasting 1 min. 
 
2.3.9. Stoichiometry of calmodulin binding to myosin 9a heavy chain and the 
effect of Ca2+ on CaM binding by myosin 9a 
 Xenopus calmodulin was expressed in E.coli BL21 cells and purified to 
homogeneity by His-tag affinity purification. Increasing amounts of CaM (0.05 – 1 µM) as 
well as known amounts of 9aMMD or 9aMMD-S1 (~0.5 µM) were separated by SDS-
PAGE and gels were silver-stained (ThermoScientific). The staining intensity of the 
calmodulin standards was quantified by analysis of the gels in Image Lab (Bio-Rad) and 
plotted against calmodulin concentration generating a calibration curve. The amount of 
calmodulin in each myosin sample was also quantified by band densitometry and fitted to 
the calibration curve, giving the amount of CaM light chain in each myosin sample. The 
molar ratio of CaM to the myosin heavy chain was calculated providing the binding 
stoichiometry of calmodulin to myosin. Experiments were performed for three independent 
myosin preparations. The protocol was adapted from Köhler et al., 2005. 
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 [Ca2+]-dependent dissociation of calmodulin from 9aMMD was addressed by 
incubating equal amounts of myosin (~1 µM) preparation with increasing concentration of 
free CaCl2 (0 – 1 mM free Ca2+) for 30 min at RT (Trybus et al., 2007). 10 µM phalloidin-
stabilized F-actin was added and the rigor complex was allowed to form for 20 min at RT. 
Samples containing myosin-actin mixtures as well as a negative control containing a 
mixture of exogenous calmodulin and actin were centrifuged at 80000 rpm, 20 min, 40C in 
the TLA.100 rotor (Beckman Coulter). Supernatants were combined with the SDS-loading 
dye and pellets were resuspended in equal volumes of 1x SDS-loading dye. Equal volumes 
of supernatant and pellets were separated by SDS-PAGE and stained with Commassie Blue. 
The intensity of CaM light chain in each pellet was assessed by band densitometry using 
ImageLab and normalized to CaM intensity in the absence of CaCl2. 
 
 2.3.10. Steady-state ATPase assay 
 The actin-activated MgATPase activity of myosin 9a was assayed with an NADH-
coupled assay at ~220C using Varian Cary 50 spectrometer (De La Cruz and Ostap, 2009). 
1 mM PEP (#P7127, SigmaAldrich), 0.2 mM NADH (#N8129, SigmaAldrich), at least 18 
U/ml lactate dehydrogenase and 12 U/ml puryvate kinase (#P0294, SigmaAldrich) in the 
ATPase buffer were mixed with 2 mM ATP and varying phalloidin-stabilized F-actin 
concentrations. Reactions were started by adding 0.1-0.2 mM myosin 9a and the decrease in 
the absorbance at 340 nm was followed for ~10 min. The MgATPase rate (1/s) at each actin 
concentration was calculated from the slope of A340, final myosin concentration in the 
reaction and NADH extinction coefficient Ɛ = 6220 M-1cm-1, according to equation 1: 
𝑅𝑅𝑅𝑅 (1/𝑠) =  𝛥𝛥340 ([𝑚𝑚𝑚𝑠𝑚𝑚] ∗ 𝜀)�  
 The ATPase rate of F-actin alone was substracted from actomyosin rates. 
Modifications of the assay included increased salt concentration, supplementing the buffer 
with 2 µM exogenous calmodulin and/or 100 µM free Ca2+. Measurements were repeated 
with 3 different myosin preparations for each actin concentration and data was fitted to the 
Michaelis-Menten equation: 
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𝑉 = 𝑉0 + (𝑉𝑚𝑅𝑉 ∗ [𝑅𝑎𝑅𝑚𝑚] 𝐾𝑅𝑎𝑅𝑚𝑚 + [𝑅𝑎𝑅𝑚𝑚]� ) 
where V is the rate at a given actin concentration, V0 is the basal ATPase activity in the 
absence of actin, Vmax is the maximum actin-activated ATPase rate, Kactin is the actin 
concentration at which myosin exhibits half maximal ATPase activity (apparent Km for 
actin) and [actin] is the actin concentration used. Values of Vmax and Kactin were obtained by 
fitting the data in SigmaPlot 12.0.nnnnnnnn 
 
2.3.11. Myosin 9a biotinylation 
9aMMD-Avi and 9aMMD-S1-Avi were expressed and handled as described above. 
Pellets were thawed on ice, resuspended in the Myosin Extraction Buffer and sonicated. 
Proteins were biotinylated by supplementing the cell slurry with 2 mM ATP, 4 mM D-
biotin (#B4501, SigmaAldrich) and 1 µM BirA ligase and rotated 1 h, 40C (Li and Sousa, 
2012). Purification was performed as before and successful biotinylation was confirmed by 
western blot. 
 
 2.3.12. Gliding filament assay 
 Methods for the gliding filament assay were adapted from Rock et al., 2000 and 
Sellers, 2001. 
1 µM G-actin in the General Actin Buffer was briefly sonicated in a water bath for 
15 sec and polymerized by adding 2 mM ATP and 1x Polymerization Salts for 30 min at 
RT. Actin was fluorescently labelled with 1 µM TMR-phalloidin (#P1951, SigmaAldrich) 
for 30 min at RT or overnight at 40C. Actin stock prepared in this way is stable for weeks.  
 Two pieces of a double-sided Scotch tape, separated by ~2 mm, were attached to a 
glass slide. A 24x40 mm coverslip (BRAND) was attached on top, creating a flow cell with 
~10 µl volume.  
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For a nonspecific protein immobilization on the surface, coverslips were covered 
with 2% nitrocellulose in amyl acetate and allowed to dry before attaching to a glass slide 
with a nitrocellulose-covered surface facing the flow cell area. 0.2 mg/ml (unless indicated 
otherwise) of myosin 9a in 1x MB- was introduced into the flow cell and incubated for 4 
min. Unbound myosin was washed out with double 1x MB- wash and 1 mg/ml BSA in 1x 
MB-BSA was incubated in the flow cell for 4 min. 20 nM TMR-actin in 1x MB-BSA was 
allowed to attach to myosin for 3 min and unbound actin was removed by thorough 
washing. Motility was initiated by flushing in 1x MB+ (containing 2 mM ATP, 20 mM 
DTT, 0.02 mg/ml catalase, 0.1 mg/ml glucose oxidase, 3 mg/ml glucose). Where stated, the 
motility buffer was supplemented with exogenous calmodulin and/or CaCl2.  
To achieve robust translocation of actin filaments by myosin 9a, a specific surface 
immobilization of the motor was required. The coverslip surface was covered with 1mg/ml 
biotinylated-BSA for 4 min, followed by 4 min incubation with 1 mg/ml streptavidin 
(#S4762 SigmaAldrich) in 1x MB-. Unbound streptavidin was removed from the flow cell 
and biotinylated myosin 9a was incubated for 4 min, followed by adding 20nM TMR-actin 
as before. Motility was initiated by addition of ATP. 
Frames were collected every 3 sec for 10 min in epifluorescence using Eclipse Ti 
microscope (Nikon), 60x 1.49 NA ApoTIRF objective (Nikon) and Andor CCD camera. 
Recordings were analyzed by GMimPro (Mashanov and Molloy, 2007) using 5-frame 
averaging and velocities were determined by tracking moving actin filaments for at least 7 
consecutive frames. At least three independent myosin preparations were used to 
investigate the mechanical properties of myosin 9a. 
 
2.3.13. Steady-state actin binding affinity of myosin 9a 
0.8-1 µM 9aMMD in 30 µl of 100 mM NaCl HMM was incubated with increasing 
actin concentrations (0 – 15 µM) of phalloidin-stabilized F-actin in the presence and 
absence of 2 mM MgATP or MgADP (Nalavadi et al., 2005). To deplete the solution of the 
nucleotides, 1 U/ml apyrase and 5mM EDTA were supplemented. Samples were incubated 
~30 min on ice and ultracentrifuged 80,000 rpm, 20 min, 40C in the TLA.100 rotor. The 
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supernatant was combined with 1x final SDS loading dye and pellets were resuspended in 
equal volume of 1x SDS loading dye. Equal volumes of supernatant and pellet were 
separated by SDS-PAGE and gel densitometry was used to determine fractions of bound 
myosin at each actin concentration.  
In the presence of a nucleotide, myosin 9a would pellet itself in the absence of actin. 
To correct the amounts of myosin bound to actin in the presence of nucleotides for the 
amount of myosin pelleted in the absence of actin, equation 3 was used (Guzik-Lendrum, 
2013): 
𝑃𝑎𝑚𝑃𝑃 = (𝑃𝑃𝑚𝑎𝑚𝑃𝑃 − 𝑃𝑅𝑃𝑚𝑚𝑅) (100 − 𝑃𝑅𝑃𝑚𝑚𝑅)�  
where Pcorr –  amount of myosin bound to actin corrected for myosin pelleted in the absence 
of actin, Puncorr –  uncorrected fraction of bound myosin, Palone –  amount of myosin pelleted 
in the absence of actin.   
 The fraction of myosin bound at each actin concentration was plotted against actin 
concentration and fitted to a quadratic equation using SigmaPlot 12.0 providing values of 
dissociation constants (Kd) for F-actin in each nucleotide state. 
  All experiments were performed at least 3 times with different myosin 
preparations and final Kd values are presented as Kd ± S.D. 
 
 2.3.14. Native molecular weight calculations 
 100 µl of pure 9aMMD or a mix of protein standards was loaded on a Superdex 200 
Increase GL 10/300 (GE Healthcare), equilibrated with the Gel Filtration buffer containing 
150 or 500 mM salt and supplemented with 0.1 mM EGTA. Runs were controlled with an 
ÄKTA purifier system (GE Healthcare) with 0.5 ml/min flow rate and 3 MPa pressure 
limit. The absorbance at 280 nm was monitored and the identity of peak eluate fractions 
was analyzed by SDS-PAGE. The partition coefficient (Kav) was obtained from equation 4 
(below) and related to the natural logarithm of Stokes radius (lnRs). The elution volume 
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(Ve) and the void volume (V0) were obtained from the A280 trace, whereas the total column 
volume (Vc) was calculated from the equation for a volume of a cylinder, taking into 
account column dimensions provided by the manufacturer. 
𝐾𝑅𝐾 =  (𝑉𝑅 − 𝑉0) (𝑉𝑎 − 𝑉0)�  
 4-20% sucrose gradients were formed in an appropriate Gel Filtration Buffer by 
incubation of 4% sucrose solution on top of 20% sucrose solution in the Polyallomer Quick 
Seal centrifuge bottles (Beckman Coulter) at ~450 for 1-2 h at 40C. 100 µl of purified 
9aMMD or a solution containing protein standards were layered on top of 6 ml gradients. 
Samples were centrifuged for 18 h at 38,000 rpm in the SW Ti 60 Beckman Coulter rotor. 
Following centrifugation, ~300 µl fractions were collected from the bottom of the tube by 
dripping and separated by SDS-PAGE.  
 Protein markers included 4 mg/ml BSA (NewEngland BioLabs), 5 mg/ml 
ovalbumin, 4 mg/ml RNase A and 3 mg/ml aldolase (GE Healthcare). 
 Native molecular weight was calculated according to equation 5 (below) with 
sedimentation coefficient (s20,ω) obtained from a calibration curve of protein markers 
separated on a sucrose density gradient, Rs obtained from the gel filtration, Avogadro’s 
number N = 6.02 x 1023, viscosity coefficient η = 1 x 10-2 g s-1cm-1, solution density ρ = 1 g 
cm-3 and partial specific volume ʋ = 0.72 cm3g-1. 
𝑀𝑀 =  𝑆20,𝜔 ∗ 𝑁 ∗ 6 ∗ 𝜋 ∗ 𝜂 ∗ 𝑅𝑠 1 − 𝜐 ∗ 𝜌�  
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The method was adapted from Lister et al., 2004 and Batters et al., 2012 and 
references therein. 
  
 2.3.15. Actin preparation and polymerization 
Acetone dried powder was prepared from rabbit skeletal muscle (Spudich and Watt, 
1971). 6 g was stirred in 120 ml of ACEX for 30 min, 40C. The solution was filtered 
through 4 layers of prewet cheesecloth and the resulting pellet was stirred in an additional 
80 ml of ACEX. Resulting supernatants were combined and spun at 20000 rpm in the JA 
25.50 rotor for 15 min, 40C. The soluble fraction was transferred to a beaker and, whilst 
stirring, brought to a final concentration of 5 mM Tris-HCl, pH 8.0, 50 mM KCl, 2 mM 
MgCl2 and 1 mM ATP and stirred for 2 h, 40C. To remove tropomyosin, the solution was 
adjusted to 800 mM KCl and pH 8.3-8.5 and centrifuged at 70000 rpm, 40 min, 40C in the 
Ti 70 rotor (Beckman Coulter). Pellets were softened in the ACEX buffer followed by 
homogenization on ice for 30 min. The resulting solution was dialyzed overnight in the 
remaining ACEX buffer. The following day, the solution was recentrifuged at 13000 rpm, 
15 min, 40C and concentrated if necessary. Concentration was measured as in equation 6: [𝛥] =  𝛥290 − 𝛥310 0.62�  
where [A] is the actin concentration, A290 and A310 are absorbance values at 290 and 310 
nm, respectively, and 0.62 is the extinction coefficient of actin. A representative SDS-
PAGE gel from the purification of actin is shown in Figure 2.2. 
 Actin polymerization was performed by dialysis of larger G-actin volumes in Slyde-
A-Lyzer 10 MWCO cassettes (Pierce) in 1 L of the Actin Polymerization buffer overnight 
at 40C. Following dialysis, F-actin was stabilized with equimolar phalloidin (#P2141, 
SigmaAldrich) dissolved in 100% ethanol or used fresh (without phalloidin-stabilization) 
within 1 week.  
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Figure 2.2. A representative SDS-PAGE gel from the purification of actin. MW – 
molecular weight. Expected MW of G-actin: ~42 kDa.Lanes 1-3 correspond to subsequent 
steps in the purification procedure.  
2.3.16. Western blots 
 Proteins were separated by SDS-PAGE and transferred to a nitrocellulose 
membrane in the western blot buffer for 1 h, 100 V. Membranes were blocked for 30-60 
min at RT, with 3% skimmed milk in PBS + 0.1% Tween-20, followed by incubation with 
the appropriate antibody for 1 h at RT or overnight at 40C. 1:10000 Streptavidin Poly-HRP 
or 1:2000 mouse monoclonal ANTI-FLAG® M2-Peroxidase (HRP) antibody dilutions in 
3% skimmed milk were used. Membranes were washed with PBST 3 x 15 min at RT. The 
signal was developed for 2 min at RT, with Clarity Western ECL Substrate and collected 
using ChemiDoc XRS+. 
 
 2.3.17. Calculation of the ionic strength and free calcium concentration 
 Ionic strength was calculated from equation 7.  
𝐼 =  1 2� �𝑎𝑚 ∗ 𝑧𝑚2𝑛
𝑖=0
 
,where I – ionic strength, ci – molar concentration of ion i, zi – charge of ion i.  
 Free calcium concentration was calculated with Maxchelator. 
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CHAPTER 3: CLONING, EXPRESSION, PURIFICATION 
AND HYDRODYNAMIC PROPERTIES OF MYOSIN 9A 
 
 
 
 
3.1. The primary structure of human myosin 9a 
Human myosin 9a consists of 2548aa and a single heavy chain has the molecular 
weight of 292.7kDa. An initial domain analysis of human myosin 9a using the SMART 
algorithm (http://smart.embl-heidelberg.de) indicates the presence of a Ras-association 
domain followed by a myosin motor domain, a neck region with 5 IQ motifs and a tail 
domain with a RhoGAP domain and segmented coiled-coil regions. Closer look at the 
sequence, including sequence alignments and literature search, provided an additional 
insight into the structural organization of human myosin 9a: i) the Ras-association domain 
lacks conserved residues essential for mediating interactions with Ras and thus its function 
remains unknown (Kalhammer et al., 1997), ii) loop 2 is extended as compared to other 
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myosin classes and contains a putative CaM-binding motif, similar to other myosin 9 
isoforms (Struchholz et al., 2009; Liao et al., 2010; Elfrink et al., 2014), iii) following the 
motor domain, the neck region contains 6 IQ motifs (as opposed to initial SMART analysis 
which indicated only 5 IQ motifs in the neck region), separated by 4-18 aa, iv) active site 
elements are conserved in sequence with other myosin family members, v) a PBD region is 
present at the C-terminal end of the myosin 9a tail and mediates interactions with PDZ-
containing proteins (Handa et al., 2013), vi) PairCoil2 analysis (McDonnell et al., 2006) of 
the human myosin 9a sequence revealed two putative coiled-coil regions between 1500-
1532 and 2314-2359aa of the tail. A schematic overview of myosin 9a is presented in 
Figure 3.1.  
 
 
 Figure 3.1. A schematic representation of the domain architecture of human myosin 
9a based on available reports and sequence alignments. A motor domain, a neck region 
(6IQ) and a tail domain are indicated. Positions of an N-terminal extension (1-148 aa) and 
loop 2 insert (684-892 aa) are depicted. Note there is a total number of 7 putative 
calmodulin-binding sites: 1 in the loop 2 insert (not depicted) and 6 in the neck region. CC - 
coiled-coil, RhoGAP – Rho GTPase-activating protein, PBD: PDZ-binding domain, C1: 
protein-protein and protein-phospholipids interaction domain.  
 
3.2. Description of primary sequence of developed human myosin 9a 
constructs 
A schematic overview of myosin 9a genetic constructs developed for this study is 
presented in Figure 3.2. Genetic constructs encoding the motor domain for expression in the 
baculovirus/insect cell system are presented in Figure 3.2A. GFP-9a-S1 and GFP-9a-Head 
consist of the first 1162 and 1019aa of human myosin 9a, respectively. Those constructs 
encompass the full head, including the N-terminal extension, the loop 2 insert and an actin- 
and ATP-binding sites as well as the whole converter region. Additionally, GFP-9a-S1 
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includes the full neck region with 6 IQ motifs for light chain binding. An N-terminal GFP-
tag was added to facilitate purification. The whole construct was introduced in frame with 
an N-terminal His-tag to facilitate affinity capture of the protein. As described below, 
IMAC affinity chromatography resulted in low protein yields and unsatisfactory purity. To 
further improve the homogeneity of my preparations, a FLAG-tag was fused to the C-
terminus of the myosin fragments. Once the expression and purification of motor 
truncations was optimized, I attempted to express and purify the full length protein. 
However, further optimization is necessary to obtain recombinant full length myo9a.  
The function of the N-terminal extension of myosin 9a is unknown and currently it 
is impossible to assess its impact on the functioning of the motor. In order to investigate the 
properties of the myosin 9a motor per se, I developed constructs truncated after the N-
terminal extension, encompassing a minimal motor domain with the lever arm (9aMMD-
S1; 149-1162aa) and without it (9aMMD; 149-1019aa). The minimal motor domain 
encompasses structural elements that enable a full catalytic activity. Based on sequence 
alignments with Dd myosin 2 whose minimal motor domain starts with E89 (personal 
communication with Dr. JR Sellers, NIH), the minimal motor of human myosin 9a begins 
with D149. 9aMMD and 9aMMD-S1 were cloned in frame with the C-terminal FLAG-tag 
to aid purification. Furthermore, to facilitate specific immobilization of the protein on the 
surface of a flow chamber for the in vitro gliding filament assay (described in Chapter 3), a 
biotin-binding site, an Avi-tag, was introduced between the C-terminus of a myosin 9a 
fragment and the FLAG-tag. All constructs were designed to maintain C-terminal tags in 
frame for proper translation. Alignment of the primary head and neck sequences of human 
myosin 9a and Dd myosin 2 heavy chains is presented in Figure 3.3 with the most 
conserved regions highlighted to facilitate reader’s understanding of the functional elements 
present in individual myosin 9a motor constructs developed for this study. 
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 Figure 3.2. A summary of myosin 9a genetic constructs developed for this study. 
Domain organization and names of each construct are indicated. Numbers of strategic 
amino acids within human myosin 9a sequence are depicted. A: constructs designed for the 
expression in insect cells, B: constructs expressed in bacteria. Tags of each construct and 
their localization in relation to myosin 9a fragments are indicated. GFP and CFP: Green and 
Cyan Fluorescent Protein, MMD: Minimal Motor Domain, CC: coiled-coil, S1: 
Subfragment-1, ins: loop-2 insert, ext: N-terminal extension, N-terminal gray – motor 
domain, brown – neck domain, C-terminal gray – tail domain.  
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To study the propensity of myo9a to dimerize, smaller tail fragments encompassing 
the putative coiled-coil sequences were cloned with a C-terminal fluorescent tag and an N-
terminal His-tag (Figure 3.2B) and expressed in the E.coli host. 
 
Figure 3.3. Alignment of the primary heavy chain sequences of the head and neck 
domains of human myosin 9a (HsMyo9a; UniProt: B2RTY4) and slime mold myosin 2 
(DdMyo2; UniProt: P08799). Functional domains are highlighted and the beginning of the 
minimal motor domain and neck regions is indicated in black. 
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3.3. Generation of recombinant baculoviruses with a Bac-to-Bac system and 
initial purification trials 
The tail domain of myosin is not essential for its activity. Therefore, initial attempts 
to purify myosin 9a focused on shorter constructs, GFP-9a-S1 and GFP-9a-Head with an N-
terminal His6-tag. That construct contains all structural elements necessary for a 
mechanochemical activity. It was established previously that a GFP fusion to a myosin (at 
either end of the protein) does not affect its activity (Wang et al., 2003). The GFP-tag 
served as a visual marker for protein expression, solubility and binding to the resin. A His-
tag provides means for a cost-effective, quick and automated protein purification procedure 
by means of protein capture on a nickel column. The recombinant baculoviruses were 
generated with the Bac-to-Bac system (Life Technologies) as described below. 
Cloning of GFP-9a-S1 and GFP-9a-Head was done in parallel and is presented in 
Figure 3.4. A chemically-synthesized gene encoding the full length human myosin 9a was 
used as a template for an amplification of the desired myosin 9a fragments. GFP was 
amplified using templates available in the lab. PCR products were cloned into the 
pFastBac™HTB vector, following procedures described in Chapter 2. The expression 
cassette contains the polyhedrin promoter for high levels of protein expression, an N-
terminal His-tag followed by a protease cleavage site and a Multiple Cloning Site (MCS). 
Transposition sites (Tn7R and Tn7L) flank the expression cassette and are essential for a 
site-specific transposition of the gene of interest into a baculovirus shuttle vector (bacmid). 
A schematic drawing of the pFastBac vector with introduced myosin 9a constructs along 
with a PCR amplification of individual elements and the restriction analysis of manipulated 
vectors is presented in Figure 3.4. 
The pFastBac plasmids with correctly introduced GFP-9a-Head and GFP-9a-S1 
were used to transform E.coli DH10Bac cells. That strain contains a bacmid vector with an 
attTn7 target site for a transposition of the gene of interest and a gene encoding a lacZ 
protein. A helper plasmid encodes proteins necessary for the transposition to occur. A 
successful transposition disrupts the lacZ gene, thus enabling a blue/white screening of 
colonies grown on plates supplemented with IPTG and X-gal. The bacmid DNA was 
isolated from white colonies (as those had the lacZ gene disrupted) and was subjected to 
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PCR to confirm a successful introduction of the gene of interest to the bacmid. Bacmid is 
large in size (~135kbp) and thus the PCR analysis was a method of choice at this stage. The 
PCR analysis was performed with a pair of primers annealing to the vector backbone, so 
that a resulting PCR product of ~2300bp + the size of the insert was expected to appear on 
the gel if the transposition occurred. GFP-9a-Head and GFP-9a-S1 have 3795 and 4224bp, 
respectively. PCR analysis revealed ~6100 and ~6525bp products (Figure 3.5C), 
confirming a successful introduction of genes into the bacmids.  
 
Figure 3.4. Cloning of GFP-9a-S1 and GFP-9a-Head. A: a schematic picture of the 
pFastBac™HTB vector with an ampicillin resistance gene (AmpR), transposition sites 
(Tn7) and a Multiple Cloning Site (MCS) depicted. A close-up view on the MCS presents 
an expression cassette containing a polyhedrin promoter (pPolh), a His6-tag, a TEV 
protease site, a myo9a construct and a poly(A) signal. GFP and myo9a fragments were 
introduced between BamHI, NotI and XbaI sites within the MCS. (*) indicates the stop 
codon at the end of a myo9a fragment sequence. B: a gel electrophoresis of the PCR 
products confirmed successful amplification of GFP and myo9a fragments with expected 
sizes (GFP: 738bp, 9a-Head: 3057bp and 9a-S1: 3486bp). The pFastBac vector and PCR 
fragments were digested with indicated restriction enzymes. Following ligation and 
transformation to E.coli DH5α, plasmid DNA was purified. Ligation of GFP and myo9a 
fragments was done separately. C: a restriction analysis of the pFastBac plasmids. 
Following digestion of small amounts of extracted DNA with BamHI, NotI and XbaI, 
samples were analyzed by gel electrophoresis, revealing three products as expected: a 
vector backbone (~4.9kb), myosin 9a fragments (~3kb for 9a-Head and ~3.5kb for 9a-S1) 
and a GFP (738bp). Finally, plasmids were sequenced to confirm a correct reading frame.   
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Figure 3.5. Generation of recombinant bacmids encoding GFP-9a-Head and GFP-
9a-S1. A: a schematic drawing of a transposition of the gene of interest to a bacmid. E.coli 
DH10Bac cells were transformed with a donor pFastBac plasmid containing a gene of 
interest (in this case GFP-9a-Head or GFP-9a-S1) in the expression cassette flanked with 
transposition sites. The target bacmid vector contains an attTn7 for a site-specific 
transposition from the donor plasmid. Recombination with the target bacmid occurs with a 
help of transposase encoded by the helper plasmid. Cells were plated on agar plates 
supplemented with kanamycin, tetracylin and gentamycin selection markers and IPTG and 
X-gal. Transposition disrupts the lacZ gene, resulting in an inhibition of X-gal cleavage and 
hinders the development of blue color during 48h plate growth. Bacmid DNA was 
subjected to a PCR analysis with primers flanking the transposition region. B: A 
representative DNA electrophoresis gel showing products of the bacmid PCR analysis. 
Successful transposition was confirmed by the presence of ~6.1kb and ~6.5kb bands for 
GFP-9a-Head and GFP-9a-S1 corresponding to the size of the donor plasmid and inserts. 
Bands of correct sizes on gels are indicated with asterisk. Note that due to a large size of the 
bacmid (~135kb), primers might anneal nonspecifically to other sequences within the 
bacmid, resulting in nonspecific PCR products represented by lower size bands on the gels.  
 
 Spodoptera frugiperda cells, SF9 or SF21 cells, were plated in 6-well plates and 
infected with recombinant bacmid DNA as described in the Methods section. P0 viruses 
were collected after ~10 days and scaled up to generate a high-titer stock. After 
amplification of the virus to a P3 stock, whole-cell lysates were analyzed by SDS-PAGE to 
assess protein expression (Figure 3.6A). As compared to a negative control (non-infected 
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cells), cells infected with GFP-9a-Head and GFP-9a-S1 baculoviruses express proteins of 
expected molecular weights (~165kDa for GFP-9a-S1 and ~130kDa for GFP-9a-Head).  
P3 viruses were used to infect larger volume cultures. 500ml cultures were 
coinfected with equal volumes of GFP-9a-S1 or GFP-9a-Head and calmodulin (CaM) virus 
and protein was expressed for 72h at 270C, 140rpm. Pellets were resuspended in the Myosin 
Lysis Buffer (phosphate buffer) and sonicated to release the protein from cells. The soluble 
fraction was loaded on a 5ml HisTrap FF™ (GE Healthcare) column equilibrated with the 
His-low buffer on ÄKTA Purifier (GE Healthcare). Column was washed and protein was 
eluted with the His-high buffer using a step gradient protocol (Batters et al., 2012). GFP-9a-
S1 and GFP-9a-Head bound and eluted from the column between 50-100 mM imidazole, 
but the protein yield wasn’t satisfactory and many contaminants were present in the sample, 
rendering it unsuitable for subsequent biochemical analysis (Figure 3.6B-C).  
 
Figure 3.6. Expression and purification of GFP-9a-Head and GFP-9a-S1. A: protein 
expression was assessed by SDS-PAGE of cell pellets from the P3 virus stock. As 
compared to non-infected cells (control), cells infected with GFP-9a-Head and GFP-9a-S1 
viruses expressed proteins of expected molecular weights (~130kDa and ~165kDa, 
respectively). 500ml SF21 cultures were coinfected with equal volumes of high-titer P3 
stocks of recombinant myosin 9a and calmodulin baculoviruses and proteins were 
expressed for 72h at 270C, 140rpm. Cells were collected and following disruption of the 
cell membrane, the soluble fraction was loaded onto a His-trap affinity chromatography 
column using an automated FPLC system. The column was washed to remove 
nonspecifically bound proteins and myosin was eluted with an increasing imidazole 
concentration. Elution fractions were analyzed by SDS-PAGE. Protein bands with sizes 
corresponding to those of GFP-9a-Head (B) and GFP-9a-S1 (C) were found in the eluted 
samples, along with multiple contaminants. Low yield and purity rendered the protein 
unsuitable for subsequent biochemical analysis.  
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 Judged by the visual inspection of cell pellets, high amounts of the protein remained 
in the insoluble fraction. That might indicate that myosin 9 aggregates during expression. In 
order to improve the amount of protein in the supernatant, I used Sarkosyl detergent to 
extract the myosin from cells. That detergent disrupts protein aggregates (Frankel et al., 
1991). Following sonication as described above, cell debris was collected and resuspended 
in a Sarkosyl buffer (1% Sarkosyl, 20mM TriEthanolAmine). After 30min nutation, the 
soluble fraction was applied to a 5ml HisTrap FF™ column and processed as before with a 
step-wise dilution of Sarkosyl with each wash of the column. The Sarkosyl extraction 
significantly improved the protein yield in the supernatant and a highly pure myosin 
fraction was obtained by means of the IMAC purification (Figure 3.7). Nonetheless, the 
Sarkosyl-extracted myosin 9a was rendered inactive as tested by the in vitro motility assay 
and an ATPase assay.  
 
Figure 3.7. Extraction of GFP-9a-S1 by Sarkosyl yielded more protein in the 
soluble fraction and improved the purity of the protein after affinity chromatography. Left 
panel: an SDS-PAGE analysis of myosin 9a extraction by Sarkosyl showed an increase in 
the amount of GFP-9a-S1 in the soluble fraction. SF9 cells expressing GFP-9a-S1 were 
resuspended in a buffer with or without Sarkosyl. Proteins from insoluble (P) and soluble 
(S) fractions were separated on an SDS-PAGE gel followed by Commassie staining. Note 
the improvement in the amount of GFP-9a-S1 in the soluble fraction after the Sarkosyl 
extraction (S1) as compared to a buffer without Sarosyl (S1), as indicated by an arrow. 
Right panel: a His-tag affinity purification of GFP-9a-S1 after Sarkosyl extraction. Cell 
pellets were processed as described and the soluble protein fraction was loaded on a His-
trap column. The column was washed and the protein was eluted with an increasing 
imidazole concentration, yielding highly pure GFP-9a-S1 sample. MW: molecular weight, 
S: Supernatant, P: Pellet, E: Eluate, TEA: Triethanolamine.  
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Taken together, the recombinant myosin 9a showed low solubility when expressed 
in the baculovirus/insect cell system under conditions described. The solubility was 
significantly improved by Sarkosyl extraction. The amount of soluble protein obtained with 
Sarkosyl improved the yield of pure GFP-9a-S1 protein fractions. Nevertheless, the protein 
did not hydrolyze ATP in an ATPase assay and did not translocate actin filaments in the in 
vitro motility assay. Thus, an alternative purification method had to be established.   
 
3.4. Cloning of FLAG-tagged myosin 9a constructs. Optimization of 
expression and purification of myosin 9a.  
A FLAG-tag was linked to the C-terminal end of myosin 9a motor constructs 
(Figure 3.8A), providing means of a highly specific capture of the protein from the 
supernatant (Lichty et al., 2005). GFP-9a-Head and GFP-9a-S1 constructs were used as 
templates for the addition of the C-terminal FLAG-tag. Reverse primers were designed that 
bypass the stop codon of myosin 9a-Head and -S1, hybridizing to 21 nucleotides upstream 
of the stop codon. Additionally, the primers contained a genetic sequence encoding the 
FLAG-tag (aa sequence: DYKDDDDK) in frame with an N-terminal His-tag, GFP and 
myosin 9a. A stop codon and an XbaI restriction site were added after the FLAG-tag 
sequence. GFP-9a-Head and GFP-9a-S1 with the C-terminal FLAG tag were generated by 
PCR with the GFPfwd primer and described myo9a reverse primers. Amplified fragments 
were treated as previously and introduced into a pFastBac vector. Bacmid was created and 
analyzed as before. A schematic drawing of the constructs developed at this stage is 
presented in Figure 3.8, along with appropriate DNA gels. From this point on, those 
constructs are simply referred to as GFP-9a-Head and GFP-9a-S1 within the text. 
Non-fluorescent versions of those constructs in pFastBac were also developed 
(Figure 3.9) but have not been used in this study. 
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Figure 3.8. Cloning and bacmid generation of C-terminally FLAG-tagged GFP-9a-
Head and GFP-9a-S1. A: a schematic picture of a pFastBac vector containing GFP-9a-
Head/GFP-9a-S1 fused to a C-terminal FLAG tag. The expression cassette elements are the 
same as before. B: amplification of GFP-myo9a fragments with reverse primers adding a C-
terminal FLAG-tag upstream of the stop codon yielded products of expected sizes 
(~3100bp for GFP-9a-Head and ~3500 for GFP-9a-S1). Cloning into the pFastBac vector 
was performed as previously described. C: recombinant plasmid DNA was isolated and 
subjected to the restriction analysis. Samples were digested with NotI and XbaI enzymes 
and analyzed by DNA electrophoresis revealing the presence of two fragments as expected: 
a pFastBac vector backbone with GFP (expected size ~5.5kb) and 9a-S1-FLAG (3510bp) or 
9a-Head-FLAG (3081bp). Those samples were sequenced and used to produce recombinant 
bacmids. D: a PCR analysis of purified recombinant bacmids confirmed a successful 
transposition of the genes of interest from the donor pFastBac vector into the bacmid. The 
size of expected products were ~6.1kb and ~6.5kb (including the size of the donor vector 
and the insert) for GFP-9a-Head-FLAG and GFP-9a-S1-FLAG, respectively. Localization 
of the expected products on the gel is indicated with an asterisk.  
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  Figure 3.9. Cloning of non-fluorescent 9a-Head and 9a-S1 with a C-terminal FLAG 
tag. A: a scheme of the expression cassette for 9a-Head and 9a-S1 linked to the C-terminal 
FLAG-tag. B: a PCR amplification of 9a-S1-FLAG and 9a-Head-FLAG yielded products 
of expected sizes. A forward primer for myosin 9a and reverse primers described above 
were used to amplify the desired fragments. C: amplified myosin 9a fragments and the 
pFastBac vector were digested with NotI and XbaI and ligated. Plasmids were amplified in 
E.coli cells and correct recombinants were confirmed by the restriction analysis; plasmids 
were digested with NotI and XbaI and analyzed by DNA electrophoresis, revealing two 
products with sizes corresponding to the pFastBac vector backbone and myosin 9a inserts 
as indicated.  
 
Time-dependent protein expression was assessed for GFP-9a-S1 in a 6-well format 
by seeding the cells at 6x105 cells/well and infecting with a recombinant myosin 9a virus. 
Cells were harvested at 24, 48, 60 and 72h post-infection and whole-cell lysates were 
analyzed by SDS-PAGE (Figure 3.10A). Simultaneously, the solubility of GFP-9a-S1 was 
assessed in the following way: 25 ml cultures of 1x106 cells/ml were coinfected with 5ml of 
the myosin 9a and calmodulin virus and shaken 140rpm, 270C for 60h. Cells were collected 
and sonicated in the Myosin Extraction Buffer in the presence of ATP to facilitate the 
dissociation of myosin from the host actin cytoskeleton. Following 30min nutation at 40C, 
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soluble and insoluble fractions were separated by SDS-PAGE, transferred to a 
nitrocellulose membrane and analyzed by a western blot with an anti-FLAG antibody to 
confirm the presence of myosin 9a in the soluble fraction (Figure 3.10B). Still, a lot of 
protein was found in the insoluble fraction. One possibility might be insufficient cell 
disruption during sonication, hindering the release of the protein to the supernatant. 
However, as assessed by fluorescence microscopy (Figure 3.10C), cells were fully lysed, 
indicating that poor recovery of myosin 9a in the soluble fraction might be due to improper 
folding or aggregation during expression. 
 
Figure 3.10. Time-dependent expression and solubility of myosin 9a, with GFP-9a-
S1 as an example. A: SDS-PAGE analysis of whole cell lysates taken 24, 48, 60 and 72h 
post-infection with GFP-9a-S1 virus. The cell lysate of non-infected cells (-) was included 
as a negative control. The asterisk indicates the position of the protein band corresponding 
to the molecular weight of the GFP-9a-S1 heavy chain. Note the protein was expressed at 
48h post-infection with no further increase in the protein yield afterwards. B: solubility of 
myosin 9a was confirmed by a western blot with an HRP-conjugated anti-FLAG antibody. 
Fractions of Total (T), Supernatant (S) and Pellet (P) were separated on an SDS-PAGE gel, 
transferred to a nitrocellulose membrane and blotted with the anti-FLAG antibody. The 
asterisk indicates the position of the GFP-9a-S1 protein band. C: fluorescent images of 
GFP-9a-S1-expressing SF21 cells before (left) and after (right) sonication. Note that before 
sonication cells are clearly visible in the image field whereas after sonication only the cell 
debris is present in the sample confirming effective cell disruption. Scale bar: 40µm.  
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The amount of coexpressed calmodulin can affect expression levels and solubility of 
myosin (Zhu et al., 1996). The best myosin:calmodulin ratio for the expression and 
preparation of active myosin 9a was assessed for GFP-9a-S1 as this construct contains 7 
putative calmodulin binding sites (as opposed to a single putative CaM binding site in 9a-
Head). Small-scale cell cultures (250ml) were coinfected with GFP-9a-S1 virus and varying 
amounts of CaM virus. As assessed previously, the protein was expressed after 48h and 
there was no further increase in protein yield after that time. Thus, after 48h expression, 
GFP-9a-S1 was purified by means of FLAG-tag affinity chromatography with ~0.3ml 
affinity resin. The molecular composition of the eluate fractions was assessed by SDS-
PAGE, confirming the presence of bands corresponding to the GFP-9a-S1 heavy chain and 
CaM light chains in all conditions tested (Figure 3.11). The best yields were obtained for 
cultures coinfected with the equal volumes of myosin 9a and calmodulin viruses. Apart 
from the protein of interest, an additional band of ~100kDa was present in all samples. That 
co-product is very often present in the FLAG resin eluates and is suspected to be a host 
chaperone (personal communication with Dr Jr Sellers, NIH). However, since that 
contaminant contributed to more than 50% of the protein content of my samples, an 
additional purification step had to be employed to further improve the purity.  
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Figure 3.11. Small-scale expression and purification of GFP-9a-S1 co-expressed 
with varying amounts of calmodulin. 250ml insect cell cultures were coinfected with 
constant amount of GFP-9a-S1 virus and varying amounts of CaM virus and expressed for 
48h at 270C, 140rpm followed by FLAG affinity chromatography as described in Materials 
and Methods. Eluate fractions from cultures with different myosin:CaM ratios were 
analyzed by SDS-PAGE. GFP-9a-S1 copurified with calmodulin from all culture conditions 
tested. However, cultures infected with the equal amounts of myosin and CaM viruses 
provided the highest yield of myosin 9a in the sample. A major contaminant at ~100kDa 
was present in all samples (indicated by a grey arrowhead). Protein bands corresponding to 
GFP-9a-S1 and calmodulin (CaM) are indicated. 
 
Large-scale expression and purification of myosin 9a motor constructs using FLAG 
affinity chromatography yielded identical results, in that two main co-products were present 
in the sample (Figure 3.12). An attempt to rebind the protein to His-affinity resin proved 
unsuccessful. Thus, following FLAG purification, the eluted protein (in a buffer containing 
100mM NaCl) was applied to ion exchange resin and eluted with an increasing ionic 
strength in a step-wise manner. This led to the separation of myosin 9a from major 
contaminants present in the sample, resulting in preparations reaching ~95% purity as 
estimated by a gel densitometry analysis. Furthermore, ion exchange chromatography has 
proven a successful means of concentrating the protein. The implementation of that two-
step purification protocol (1st step: FLAG affinity; 2nd step: ion exchange chromatography) 
resulted in homogenous preparations of myosin 9a proteins (Figure 3.12 and see below). 
Eluate fraction of GFP-9a-Head from FLAG affinity resin did not contain any contaminants 
but subsequent application of the sample to ion exchange resin resulted in the concentration 
of the protein and separation of two fractions: with and without bound calmodulin. The 
latter one did not exhibit any activity in enzymatic assays and thus was omitted from 
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experiments. GFP-9a-S1 eluted from the ion exchange resin at 500mM NaCl and GFP-9a-
Head at 250mM NaCl. Usually, from ~1 x 109 cells, up to 0.6mg of protein was obtained. 
GFP-9a-S1 and GFP-9a-Head exhibited enzymatic activity, as assessed by the steady-state 
ATPase and in vitro motility assays (see next chapters).  
 
Figure 3.12. Implementation of ion exchange chromatography as the second step of 
the myosin 9a purification resulted in homogenous preparations of the protein. 
Representative SDS-PAGE gels showing individual purification steps of GFP-9a-S1 (A) 
and GFP-9a-Head (B). Myosin 9a constructs were purified by means of FLAG affinity 
chromatography as described above. Protein present in FLAG eluates was bound to ion 
exchange chromatography resin and eluted in fractions with 250mM and 500mM NaCl, as 
indicated. Full binding of FLAG eluate specimen to the ion exchange resin was confirmed 
by the lack of the protein in the ‘Unbound’ fraction, referring to an ion exchange flow 
through. The majority of GFP-9a-S1 eluted at 500mM NaCl, whereas GFP-9a-Head was 
present in two fractions: with bound calmodulin (eluting at 250mM NaCl) and without 
bound calmodulin (eluting at 500mM NaCl). Positions of the myosin heavy chain and 
calmodulin are indicated by black and grey arrowheads, respectively.   
 
3.5. Expression of full length myosin 9a needs further optimization 
Encouraged by the successful expression and purification of myosin 9a motor 
truncations described above, I attempted to express full length myosin 9a (9aFL-FLAG). 
Full myosin 9a sequence containing 2548aa was amplified by PCR and introduced into a 
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customized pFBNA vector containing a C-terminal FLAG-tag, followed by the production 
of recombinant bacmid (Figure 3.13).  
 
Figure 3.13. Cloning and recombinant bacmid production of 9aFL-FLAG. A: a 
schematic drawing of the structure of the pFBNA plasmid encoding 9aFL-FLAG. 9aFL was 
introduced between BamHI and NotI sites in frame with the C-terminal FLAG-tag under 
control of the polyhedrin promoter. An asterisk indicates a stop codon upstream of the 
FLAG-tag. B: Full length myosin 9a was amplified by PCR and analyzed by gel 
electrophoresis to confirm the correct size of the product (7641bp) and ligated into the 
pFBNA vector following previously described procedures. C: the restriction analysis of 
pFBNA after introduction of the 9aFL gene confirmed the presence of the insert, as 
analyzed by gel electrophoresis; following restriction with BamHI and NotI, two bands 
corresponding to the vector backbone (~4.8kbp) and the 9aFL fragment (~7.6kbp) appeared 
on the gel. D: gel electrophoresis of PCR products of bacmid amplification revealed a band 
of the size corresponding to ~10kbp (indicated by asterisk) as expected after successful 
transposition into the bacmid.  
 
The recombinant baculovirus was developed and scaled to the P3 stock as before. 
Small scale SF9 culture was co-infected with equal volumes of 9aFL-FLAG and CaM 
baculoviruses. Cells were collected and the expression of the protein was analyzed by SDS-
PAGE and a western blot. As shown in Figure 3.14, no protein band corresponding to full 
length myosin 9a (expected MW: ~293kDa) was resolved on an SDS-PAGE gel and there 
was no signal on the western blot. As a positive control for the western blot, GFP-9a-Head 
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with a FLAG-tag was ran on SDS-PAGE and transferred to a nitrocellulose membrane, 
alongside samples from myo9a FL expression. GFP-9a-Head gave a positive signal on the 
western blot, as opposed to samples infected with 9aFL virus. This suggests that the 
expression of full length myosin 9a needs further optimization.  
 
Figure 3.14. 9aFL-FLAG is not expressed in the baculovirus/insect cell system 
under conditions used. Small-scale SF9 cell cultures were coinfected with equal amounts of 
9aFL and CaM viruses and protein was expressed for 48h at 270C, 140rpm. Samples of 
non-infected cells (-), FLAG-tagged GFP-9a-Head (+) and samples infected with 9aFL 
virus (9aFL expression) were separated on an SDS-PAGE gel (A) and transferred to a 
nitrocellulose membrane, followed by blotting with an anti-FLAG Antibody (B). No band 
corresponding to the 9aFL protein was resolved on SDS-PAGE and no signal was observed 
on a western blot in samples infected with the virus. A positive control for the western blot 
gave the positive signal, confirming that the lack of the signal in 9aFL samples is related to 
the lack of protein expression, instead of a faulty western blot.  
 
3.6. Cloning and purification of Minimal Motor Domain constructs; 
confirmation of protein identity and stability 
The N-terminal extension of myosin 9a has an unknown function. It was proposed 
that it adopts a Ras-binding fold (Bähler, 2000). However, close inspection of the sequence 
revealed it lacks conserved residues essential for binding of Ras (Kalhammer et al., 1997). 
Currently, there is no information on a possible function of protein domains that adopt the 
Ras-binding fold but are unable to bind Ras. It is therefore difficult to speculate on an 
impact of that domain on myosin 9a activity. Still, it is plausible that the N-terminal 
extension: i) does not affect the acitivity of myosin 9a, ii) is essential for an enzymatic 
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activity of myosin 9a, or iii) inhibits the activity of myosin 9a. In order to rule out or 
confirm any one of those scenarios, I designed and developed recombinant baculoviruses 
expressing myosin 9a constructs containing a minimal motor domain (a minimal part of the 
sequence essential for the biochemical performance), lacking the N-terminal extension.  
I created Minimal Motor Domain constructs with (9aMMD-S1) and without 
(9aMMD) the lever arm, introduced them into the pFBNA vector with a C-terminal FLAG-
tag, created recombinant bacmids and baculoviruses, expressed and purified those proteins 
as before. A schematic drawing of the expression cassette including those constructs and 
individual steps of the recombinant bacmid production as well as SDS-PAGE analysis of 
protein expression are shown in Figure 3.15.  
 
Figure 3.15. Cloning, production of recombinant bacmids and expression of 
9aMMD and 9aMMD-S1. A: a schematic drawing of the expression cassette of the pFBNA 
vector with MMD constructs introduced between BamHI and NotI sites, in frame with the 
C-terminal FLAG-tag. An asterisk indicates a stop codon. B: gel electrophoresis of PCR 
products of MMD and MMD-S1 revealed the presence of expected products (2613bp for 
MMD and 3042bp for MMD-S1). C: the recombinant pFBNA plasmid was subjected to the 
restriction analysis with BamHI and NotI enzymes, revealing the presence of two bands on 
DNA gel corresponding to the vector backbone (~4.8kbp) and MMD-S1 and MMD 
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fragments, respectively. D: a PCR analysis of isolated recombinant bacmids confirmed 
successful transposition. E: protein expression was assessed from P3 virus pellets by the 
separation of whole-cell lysates on SDS-PAGE. As compared to non-infected cells (-), cells 
infected with MMD-S1 or MMD viruses expressed proteins with corresponding molecular 
weights (118.5kDa and 100kDa, respectively). 
 
A purification protocol described for GFP-9a-Head and GFP-9a-S1 was 
successfully applied to the purification of 9aMMD constructs. A representative SDS-PAGE 
gel of 9aMMD and 9aMMD-S1 is shown in Figure 3.16A. As for previously described 
constructs, 9aMMD-S1 eluted at 500mM NaCl and 9aMMD at 250mM NaCl from IEX. 
Identity of the heavy chain was confirmed by an anti-FLAG western blot of final myosin 
preparations (Figure 3.16B). Based on previous reports the head of myosin 9 binds 
calmodulin and the binding site has been mapped to the N-terminus of the unique myosin 9 
loop 2 insert (Liao et al., 2010). Sequence comparisons revealed the presence of that 
putative CaM-binding site in the loop 2 insert of human myosin 9a, too. Thus, both 
9aMMD and 9aMMD-S1 were co-expressed with calmodulin. As shown in Figure 3.16A, 
9aMMD copurified with ~17kDa protein that underwent a calcium-dependent shift in 
electrophoretic mobility (Figure 3.16C), as expected for an authentic calmodulin (Liao et 
al., 2010). Furthermore, similar to GFP-9a-Head, 9aMMD eluted from ion exchange both at 
250mM and 500mM NaCl. As opposed to the 500mM NaCl fraction, the 250mM NaCl 
fraction coeluted with calmodulin. This has raised an intriguing possibility that myosin 9a 
exists in two states in the cell – with and without bound calmodulin. However, activity 
assays revealed that myosin 9a lacking calmodulin bound to the motor domain is rendered 
inactive.  
Taken together, the minimal motor domain constructs can be readily expressed in 
the baculovirus/insect system and purified by means of FLAG-tag affinity chromatography 
followed by ion exchange. The latter step provides efficient means of separating two 
fractions of 9aMMD (with and without bound calmodulin) present in cells. Since only the 
fraction that contained bound calmodulin exhibited enzymatic activity, the developed 
purification protocol results in an efficient separation of active and inactive motors. These 
results suggest that calmodulin binding to myosin 9a head is essential for protein activity in 
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vitro. However, a possible regulation of myosin 9a activity in cells by means of calmodulin 
binding and dissociation from the head cannot be ruled out. 
Various storage conditions of myosin 9a constructs were examined, including snap-
freezing of myosin 9a in the presence of 20% sucrose or 50% glycerol and storage at -800C 
or in liquid N2. However, this led to a loss of activity within few days. Thus, purified 
proteins were used fresh within two days following the purification.  
 
Figure 3.16. Purification of 9aMMD and 9aMMD-S1 by FLAG-tag affinity 
chromatography and IEX. Confirmation of protein identity. A: a representative SDS-PAGE 
gel of 9aMMD and 9aMMD-S1 purified with a previously described protocol, separated on 
a 4-20% Tris-Glycine gel. An arrowhead indicates myosin heavy chains of 9aMMD and 
9aMMD-S1 and asterisk indicates calmodulin light chains copurified with each construct. 
Note the difference in the amount of calmodulin copurified with 9aMMD and 9aMMD-S1. 
B: an anti-FLAG western blot of 9aMMD and 9aMMD-S1. Myosin samples were separated 
on a 10% SDS-PAGE gel, transferred to a nitrocellulose membrane and blotted with an 
HRP-conjugated anti-FLAG antibody. Signal was developed with the ECL Western 
Blotting Substrate kit. C: a calmodulin mobility shift assay. 9aMMD and 9aMMD-S1 were 
incubated with 1mM EGTA or 5mM CaCl2 for 15 min at RT and separated on a 15% SDS-
PAGE gel. Arrowheads indicate myosin heavy chains and asterisk indicates calmodulin. 
Shift in the mobility of the light chain protein band in the presence of calcium confirmed its 
identity as calmodulin. 
 
When analyzed by electron microscopy, both 9aMMD and 9aMMD-S1 existed as 
single molecules. No molecules with two heads or protein aggregates were observed, 
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suggesting that both 9aMMD and 9aMMD-S1 exist as monomers in a homogenous 
solution. There was no electron density corresponding to an extended neck domain 
observed in electron micrographs of 9aMMD-S1, suggesting it might be wrapped around 
the motor domain in a nucleotide-free state (Figure 3.17). 
                
Figure 3.17. Negatively stained EM images of 9aMMD (left) and 9aMMD-S1 
(right). Images show individual myosin molecules in solution. Neither 9aMMD, nor 
9aMMD-S1 form higher-order structures and both constructs exist as monomers in solution. 
In case of 9aMMD-S1, no evident electron density corresponding to an extended neck 
region is visible, suggesting the light chain-binding domain might be wrapped on the motor 
domain.  Scale bar 40nm. 
 
Stability of 9aMMD and 9aMMD-S1 preparations over time was assessed by DLS 
(Dynamic Light Scattering; Shiba et al., 2010). Calmodulin binding to each construct made 
it challenging to assess the stability by the temperature-dependent unfolding since the 
dissociation of calmodulin from the heavy chain and calmodulin unfolding would 
contribute to the overall signal, making it impossible to determine the melting temperature 
of the myosin heavy chain. Assuming that drop in the myosin activity would be related to 
the protein degradation and/or aggregation, the intensity of molecular species present in the 
sample was measured at different time points over 48h (Figure 3.18). A high-speed 
centrifugation of protein eluates was used to remove nonspecific aggregates, ensuring 
homogeneity of the sample. Protein was diluted to 0.1mg/ml in a filtered elution buffer and 
the intensity of molecular species present in the sample was measured. Both 9aMMD and 
9aMMD-S1 samples contained mainly a single component. The intensity of the peak in 
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each case was constant over the course of 48h (Figure 3.18), suggesting the protein sample 
did not change its composition over 2 days. 
 
Figure 3.18. Stability of 9aMMD and 9aMMD-S1 over time measured by DLS. 
Intensity of 0.1 mg/ml protein sample was measured at different time points during 48 h. 
The intensity of the molecular species in the sample was traced over time revealing no 
change in the molecular composition of the sample. All measurements were performed in 3 
repeats on each myosin preparation, with 3 independent preparations used for the data set. 
A and B: examples of DLS measurements of 9aMMD and 9aMMD-S1, respectively (note 
the shift in the size of the molecule from 8.1±0.2 nm for 9aMMD to 11±0.1 nm for 
9aMMD-S1). C: an average intensity from each measurement over 48h from 3 independent 
preparations was plotted against time ( 9aMMD-S1, 9aMMD). Data points represent 
mean±S.D. (n=3).  
 
3.7. Calmodulin stoichiometry 
Human myosin 9a contains 7 putative CaM-binding sites. The actual number of 
bound light chain molecules per heavy chain was assessed by protein band densitometry 
(Figure 3.19). Bacterially-expressed calmodulin was used as a standard for the generation 
of the calibration curve. Increasing concentrations of CaM and known myosin 
concentrations (calculated based on their extinction coefficients and A280) were separated 
on SDS-PAGE gels and calibration curve was obtained from the band intensity of CaM 
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standards after staining of the gels. The intensity of the CaM band in the well with known 
myosin concentration was interpolated to the trend line and the molar ratio of light 
chain:heavy chain (LC:HC) was calculated. 9aMMD-S1 (7 IQ motifs) bound 5.8 ± 1.4 CaM 
molecules per heavy chain and 9aMMD (1 IQ motif) - 1.1 ± 0.7 CaM molecule per heavy 
chain based on 3 independent measurements. That suggests that out of the 7 available CaM-
target sites in 9aMMD-S1 only 6 IQ motifs were occupied by CaM light chains. The 
remaining IQ motif might bind a different light chain, not bind any light chain at all or had 
lost its light chain during purification. Given that 9aMMD copurified with a single CaM 
light chain per heavy chain, it is safe to assume that the previously mentioned IQ motif at 
the N-terminus of the loop 2 insert of myosin 9 is the binding site for that CaM. Therefore, 
only 5 IQ motifs within the neck region might be occupied by CaM light chains under 
conditions used.  
 
Figure 3.19. Stoichiometry of calmodulin binding to myosin 9a constructs. A: 
known cncentrations of free CaM and 9aMMD and 9aMMD-S1 samples were separated on 
SDS-PAGE gels and either silver-stained (MMD-S1) or Commassie-stained (MMD). 
Arrowheads indicate myosin 9a heavy chain positions and asterisk indicates CaM. B: band 
intensities at each CaM concentration were plotted against CaM concentration and the 
calibration curve was produced for interpolation of the CaM amount present in myosin 
samples. C: a molar ratio of the light chain to the heavy chain [LC]/[HC] was calculated 
revealing 5.8±1.4 CaM molecules bound to 9aMMD-S1 and 1.1±0.7 CaM molecules per 
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9aMMD heavy chain. Values given are mean ± S.D. from 3 independent myosin 
preparations. 
 
3.8. Dimerization of myosin 9a 
Paircoil2 analysis of human myosin 9a suggested that myosin 9a contains two 
putative coiled-coil domains in the tail domain (Figure 3.20). Coiled-coil domains are α-
helical domains that form primary oligomerization units in proteins. They are characterized 
by the presence of heptad repeats of mainly apolar and hydrophobic residues (Burkhard et 
al., 2001). In order to test the propensity of the putative coiled-coil domains of myosin 9a 
for oligomerization, I cloned myosin 9a tail regions encompassing those fragments into a 
pET vector. Expression cassettes contained an N-terminal His-tag and a C-terminal CFP to 
facilitate purification. Proteins were expressed in E.coli BL21 cells and purified by His-tag 
affinity chromatography (Figure 3.21).  
 
Figure 3.20. Paircoil2 analysis of human myosin 9a sequence reveals the presence 
of two putative coiled-coil domains in the tail. A: Paircoil2 analysis of the full length 
human myosin 9a sequence revealed the presence of two regions in the tail domain with 
high probability of dimer formation (0.025 probability cutoff – dashed line). B: sequences 
of the putative coiled-coil fragments are presented with individual residues assigned to 
particular positions within the heptad repeat of a coiled-coil with hydrophobic residues 
corresponding to a and d positions indicated.  
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  Figure 3.21. Cloning and purification of putative coiled-coil myo9a regions. A: a 
schematic drawing of an expression cassette of the pET28a+ vector with introduced myo9a 
tail fragment encompassing the putative coiled-coil domain (CC) upstream of CFP. An 
asterisk indicates a stop codon. B: amplification of tail fragments of myo9a encompassing 
the putative CC domains by PCR generated fragments of expected sizes (~900bp for CC1 
and ~250bp for CC2). C: recombinant pET28 plasmids with the myo9a tail fragments were 
isolated and subjected to the restriction analysis with BamHI and SalI enzymes. Separation 
of the fragments on DNA gels revealed the presence of two bands in each case, 
corresponding to the vector backbone and tail fragments of myo9a encompassing CC1 and 
CC2. D: putative coiled-coil fragments were expressed in E.coli BL21 cells by means of an 
IPTG induction and purified by His-tag affinity chromatography.  
 
The native molecular weight (MW) of a protein can be properly determined by Size 
Exclusion Chromatography (SEC) only for globular proteins. To correct for molecular 
shapes deviating from globular, the behavior of the molecule of interest in the gel filtration 
media is better related to its hydrodynamic radius (Stokes radius – Rs), rather than the MW. 
A sedimentation coefficient (s20,ω) is another hydrodynamic parameter that is a function of 
mass and shape of a protein. Combination of SEC and rate zonal centrifugation in linear 
sucrose gradients was used to determine the native molecular weight of myosin 9a 
constructs as described in Materials and Methods (Lister et al., 2004 and references 
therein). Calibration of the gel filtration column and sucrose gradient media was performed 
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with globular protein markers (GE Healthcare). Stokes radii and sedimentation coefficients 
of the protein markers were related to the separation of proteins in gel filtration and sucrose 
gradients, respectively (Figure 3.22). 
The oligomerization state of the putative coiled-coil sequences from myo9a was 
studied by the combination of SEC and sucrose density gradients (Figure 3.23). Given that 
isolated protein domains might not represent the behavior of those domains in the context 
of the whole protein, different buffer conditions were tested. In case of isolated coiled-coil 
fragments, an increased salt concentration might lead to the stabilization of the helical 
structure, which in turn could facilitate coiled-coil formation in vitro (Mateja et al., 2006).  
Indeed, when performed in lower and higher ionic strength buffers, CC1 exhibited 
shift into higher molecular weights both in SEC and the sucrose gradient (Figure 3.23A and 
B). In contrast, the molecular weight of CC2 did not change with an increase in the ionic 
strength of the buffer (Figure 3.23C and D). A native molecular weight of CC1 at lower 
ionic strength was slightly lower than that calculated from the aa sequence. That difference 
might be attributed to an experimental error. Nevertheless, at higher ionic strength that MW 
increased ~ 2-fold. Those results indicate that when appropriate conditions are maintained, 
or in the context of the whole protein, the putative coiled-coil 1 (CC-1) could form dimers 
(Figure 3.23F). In contrast, the calculated MW of CC2 corresponded well with what is 
expected for a monomer, regardless of the ionic strength of the buffer. This suggests CC2 
might form a stable α-helical structure that does not dimerize in solution.  
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Figure 3.22. Calibration of SEC and sucrose density gradients. Globular protein 
markers with known hydrodynamic properties and molecular weights were separated on a 
Superdex gel filtration column and in 6-20% sucrose gradients. 100 µl of ~4mg/ml of 
aldolase, BSA, ovalbumin and Rnase A was used for calibration. A: a representative gel 
filtration trace of marker proteins separated on the Superdex 200 10/300 GL with individual 
peaks corresponding to the void volume (V0), aldolase, BSA, ovalbumin and RNase A as 
indicated. B: a standard calibration curve was produced by plotting the natural logarithm of 
Stokes radii (lnRs) of protein markers versus their partition coefficients (Kav). Data was 
collected from 3 independent runs of marker proteins and is presented as means±S.D. of 
Kav. C: a representative SDS-PAGE gel of protein markers separated in a linear 6-20% 
sucrose gradient. Note that aldolase is a homotetramer, composed of 36kDa subunits. D: a 
standard calibration curve of known sedimentation coefficients (s) of protein standards 
versus the elution fraction number. E: a table summarizing known and calculated 
parameters of protein markers.  
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Figure 3.23. Analysis of the oligomerization state of putative coiled-coil fragments 
of human myosin 9a. A: 100µl of 1mg/ml 9aCC1-CFP was separated on the Superdex 200 
10/300 GL column in a buffer containing either 150mM (yellow) or 500mM (green) NaCl. 
B: 1mg/ml 9aCC1-CFP was separated in a linear 6-20% sucrose gradient prepared in a 
buffer containing either 150mM or 500mM NaCl. Eluate fractions were separated on SDS-
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PAGE gels and are indicated. Note the shift of 9aCC1-CFP into a higher molecular weight 
at higher ionic strength. C: 100µl of 1mg/ml 9aCC2-CFP was separated on the Superdex 
200 10/300 GL column in a buffer containing either 150mM (red) or 500mM (pink) NaCl. 
D: 1mg/ml 9aCC2-CFP was separated in a linear 6-20% sucrose gradient prepared in a 
buffer containing either 150mM or 500mM NaCl. Eluate fractions were separated on SDS-
PAGE gels and are indicated. There was no shift in the molecular weight of 9aCC2-CFP 
between two buffers. E: an interpolation of CC1 and CC2 parameters obtained by SEC and 
sucrose gradients to the standard calibration curves. Numbers assigned to each arrow 
correspond to CC1 and CC2 at different ionic strengths, as described in (F). F: a table 
summarizing CC1 and CC2 hydrodynamic properties. Calculated native molecular weights 
of both fragments are highlighted. Note that for CC1 there was a ~2-fold increase in the 
molecular weight at higher ionic strength indicating that this putative coiled-coil sequence 
might dimerize. Furthermore, the calculated native molecular weight of CC1 at 150mM 
NaCl was somewhat lower than that expected from the aa sequence. That difference can be 
assigned to an experimental error and might suggest the protein shape deviates strongly 
from globular in solution. In contrast, the calculated native molecular weight of CC2 was 
not affected by the ionic strength of the buffer and was in a very good agreement with the 
expected MW obtained from aa sequence, indicating the protein adopts globular shape in 
solution and does not form dimers at conditions tested.   
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CHAPTER 4: INTERACTION OF MYOSIN 9A MINIMAL 
MOTOR DOMAIN WITH ACTIN AND STEADY-STATE 
ATPASE ACTIVITY OF HUMAN MYOSIN 9A 
 
 
 
 
4.1.  Human myosin 9a bundles actin 
Previous reports suggest that the extended loop 2 insert of myosin class 9 members 
might act as an additional actin-binding site. This implies myosin 9 could crosslink actin 
filaments (Struchholz et al., 2009).  
To test the possibility of actin crosslinking by myosin 9a, mixtures containing 
increasing 9aMMD:F-actin ratios were subjected to a low-speed centrifugation (15000 x g). 
At such low speed, single polymerized actin filaments remain in solution. On the other 
hand, the total native molecular weight of bundled actin filaments would be high enough to 
cause their sedimentation. Following the centrifugation, the equal amounts of supernatant 
and pellet were separated on SDS-PAGE gels (Figure 4.1). As expected, in the absence of 
9aMMD in the solution most actin remained in the supernatant. However, the amount of 
actin in the pellet increased in the presence of increasing 9aMMD concentrations.  Finally, 
at a critical 9aMMD concentration, essentially all actin was pelleted in the presence of high 
molar ratios of myosin 9a, as compared to a control sample that did not contain myosin 9a. 
An increase in the amount of pelleted actin at such low centrifugation speed is consistent 
with an increase in the molecular weight, which could be achieved via the crosslinking of 
actin filaments. These results suggest that myosin 9a bundles actin filaments, causing 
sedimentation of F-actin under conditions when most actin would remain in the solution. 
The minimal motor domain if enough to cause crosslinking of actin filaments.  
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In order to directly visualize bundling of actin filaments by myosin 9a, mixtures of 
actin and 9aMMD were applied to carbon grids, negatively stained and visualized by 
electron microscopy (in collaboration with Dr. Neil Billington, NHLBI, NIH and Dario 
Saczko-Brack, LMU). In the absence of ATP, 9aMMD crosslinked actin filaments, forming 
clearly visible ladder-like patterns (Figure 4.2A). Individual crosslinks were separated by 
36nm, corresponding to the helical repeat of an actin filament (Walker et al., 2000; 
Egelman, 2010). Those actin structures were visible as soon as 5 minutes after an 
incubation of myosin with actin. Even at excess myosin in the sample and extended 
incubation times, no decoration of individual actin filaments by myosin 9a was observed. 
Also at shorter incubation times (up to 1min), no binding of myosin to actin was seen. Upon 
introduction of ATP to the sample, all myosin dissociated from filaments (Figure 4.2B). 
This is a direct evidence that human myosin 9a binds actin in an ATP-sensitive manner. 
This is also the first direct visualization of actin bundling by a myosin class 9 member. 
 
Figure 4.1. 9aMMD bundles F-actin. A: 2µM phalloidin-stabilized F-actin was 
incubated with increasing 9aMMD concentrations (0 - 1 µM) for 20min, RT, and 
centrifuged at 15000 x g. Equal amounts of supernatant and pellet were separated on an 
SDS-PAGE gel and band intensities were measured. B: quantification of the amount of 
actin present in the pellet at increasing 9aMMD concentrations. In the absence of 9aMMD, 
around 20% of all actin present in the sample was found in the pellet following the low 
speed centrifugation. With the increasing amount of 9aMMD, the amount of actin in the 
pellet increased, until a critical 9aMMD concentration was reached at which nearly all actin 
was found in the pellet. Experiments were performed with three independent myosin 
preparations (n = 3) and bars represent mean values ± S.D.  
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Results presented in this section indicate that human myosin 9a might act as a 
molecular motor that cross-links actin filaments in an ATP-dependent manner. An 
additional actin-binding site resulting in the formation of cross-links is localized within the 
minimal motor domain of human myosin 9a.  
 
Figure 4.2. Negatively stained images of 9aMMD interacting with actin. A: 
9aMMD crosslinked actin filaments in the absence of a nucleotide. Even at high 
myosin:actin ratios no decoration of single filaments was observed. 9aMMD molecules 
bound actin filaments in a very regular manner, with distances between individual 
crosslinks corresponding to the length of the helical actin repeat (36nm; white arrows). B: 
upon addition of ATP all myosin dissociated from actin filaments. Scale bars: 40nm.  
 
4.2. Steady-state kinetics of human myosin 9a in the absence of calcium 
The actomyosin ATPase cycle is conserved within the myosin superfamily in that 
ATP binding to myosin causes the dissociation of myosin from actin, followed by ATP 
hydrolysis by myosin, rebinding of myosin to actin and the release of hydrolysis products 
associated with strengthening of the actomyosin interaction (De La Cruz and Ostap, 2004). 
The basal rate of ATP hydrolysis by myosin is stimulated by actin, following the Michaelis-
Menten steady-state kinetics. The ATPase rate at increasing [actin] can be measured by 
means of an NADH enzyme-linked assay (Figure 4.3).  
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Figure 4.3. A schematic drawing of an NADH enzyme-linked assay reaction. 
NADH is oxidized to NAD+ in a series of reactions coupled to ATP hydrolysis such that 
one molecule of oxidized NADH is equal to one molecule of ATP hydrolyzed by myosin. 
The assay is performed in the presence of an ATP regenerating system; pyruvate kinase 
(PK) converts phosphoenolpyruvate (PEP) to pyruvate in a reaction that uses ADP from the 
myosin ATPase cycle and regenerates it to ATP; subsequently, pyruvate is converted into 
lactate in a reaction catalyzed by lactate dehydrogenase (LDH) coupled to oxidation of 
NADH. NADH, but not NAD+, absrobs light at 340nm and thus the ATPase rate of myosin 
can be obtained from the rate of the decrease in NADH absorbance (De La Cruz and Ostap, 
2009). The myosin ATPase rate at increasing actin concentration follows the Michaelis-
Menten kinetics. By fitting the data to the equation 4 (Materials and Methods), the maximal 
activation rate of myosin (Vmax) at saturating [actin] and an actin concentration necessary 
for the half maximal myosin activation (Km) can be determined. V0 is the basal myosin 
ATPase rate in the absence of actin.  
 
To ensure that none of the buffer components used for the assay interfered with 
myosin activity, I first performed control experiments with rabbit skeletal muscle myosin 
HMM in the ATPase buffer used for myosin 9a, containing 10mM MOPS pH 7.3, 50mM 
KCl, 0.1mM EGTA, 1mM MgCl2 and 1mM DTT. It is well established that this protein 
behaves as a bona fide myosin with its basal ATPase rate stimulated ~100 times by actin 
and with Km = 18μM (Millar and Geeves, 1983). In conditions used here and at 220C, the 
basal ATPase rate of rabbit skeletal HMM was stimulated ~100-fold from V0=0.06 s-1 to 
Vmax=7.5 s-1 and Km = 15μM (Figure 4.4 and Table 4.1). This is in good agreement with 
previously reported values of Km (Millar and Geeves, 1983) and Vmax of 7.8 s-1 (Webb and 
Corrie, 2001). Thus, the buffer chosen for the assay was compatible with myosin activity.  
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Figure 4.4. An actin-activated ATPase activity of rabbit skeletal muscle myosin 
HMM. The ATPase rate of 50nM myosin in the ATPase buffer supplemented with 2mM 
ATP, 0.2mM NADH and an ATP-regenerating system (1mM PEP, 18U/ml LDH, 12U/ml 
PK) was measured in the absence and presence of an increasing actin concentration (0 - 
40μM F-actin, phalloidin-stabilized) by following the decrease in the NADH absorbance at 
340nm over at least 10min time period at 220C. V0 = 0.06 ± 0.05 s-1, Vmax = 7.5 ± 0.4 s-1 
and Km = 15 ± 3.2μM at 220C were obtained by fitting the data points to Michaelis-Menten 
kinetics. Data points represent an average from three independent measurements ± S.D. (n 
= 3).  
 
Having confirmed the correct buffer composition, I measured the ATPase rates of 
GFP-9a-Head and GFP-9a-S1 at increasing [actin]. Previous reports on the actin-activated 
ATPase activity of myosin 9 orthologs state that low actin concentrations (up to 20μM) are 
enough to reach the maximum ATPase activation (Liao et al., 2010). Previously, C. elegans 
myo9 head revealed a10-fold activation by actin, whereas the head-neck construct showed 
only minor activation by actin in the absence of calcium. The head domain exhibited high 
basal ATPase rate (~0.5 s-1) that decreased to 0.13 s-1 in the head-neck construct (Liao et 
al., 2010). Minor actin-activation (from 1.18 s-1 to 1.58 s-1) was also reported for rat myo9b 
truncation encompassing the head and neck domains, whereas full length rat myo9b was 
activated 10-fold by actin. The basal ATPase rate of full length rat myo9b was also 10-fold 
lower than that of the head-neck construct, suggesting the tail domain of myosin 9 might 
stimulate the actin-activation of the ATPase rate (Struchholz et al., 2009). Based on the 
available reports, it is difficult to see any prominent pattern of an enzymatic activity within 
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the myosin class 9. Several features of the ATPase activity of human myosin 9a could be 
expected based on previous reports on other myosin 9 isoforms: i) a high basal ATPase rate, 
ii) an activation of the basal ATPase rate of the head domain by actin, iii) an inhibition of 
the actin-activation by the neck region, iv) the lack of activation of the ATPase rate by actin 
in the absence of the tail domain.  
100 - 200nM GFP-9a-Head or GFP-9a-S1 was used to measure ATPase rates at 
increasing actin concentrations (0 - 20μM) as described above. The actin-dependence of the 
ATPase rate of GFP-9a-Head and GFP-9a-S1 is presented in Figure 4.5 (A and B, 
respectively). Both constructs showed similar, low basal ATPase rates (0.17 ± 0.014 s-1 for 
GFP-9a-Head and 0.18 ± 0.016 s-1 for GFP-9a-S1) indicating that the neck region does not 
affect the catalytic activity of human myosin 9a. Furthermore, the basal ATPase rate of 
neither GFP-9a-Head nor GFP-9a-S1 was stimulated by actin. This is surprising given that 
all catalytically active myosins characterized so far display actin-activated ATPase 
activities. Nevertheless, this result shows that human myosin 9a is enzymatically active and 
able to hydrolyze ATP. 
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Figure 4.5. An actin-dependent ATPase rate of GFP-9a-Head (A) and GFP-9a-S1 
(B). 100 - 200nM myosin was used to measure the rate of ATP hydrolysis in the buffer 
supplemented with 2mM highly pure ATP and an ATP-regenerating system in the absence 
and presence of phalloidin-stabilized F-actin (0 - 20μM). Basal ATPase rates (V0) were 
0.17 ± 0.014 s-1 for GFP-9a-Head and 0.18 ± 0.016 s-1 for GFP-9a-S1 and no actin-
activation was observed for either construct. Measurements were performed at 220C and 
NADH absorbance was followed at 340nm for at least 10min. Each data point represents an 
average from 3 independent measurements from separate myosin preparations ± S.D. (n = 
3).  
 
Even though not reported previously for other myosin 9 isoforms, it is interesting to 
speculate that the N-terminal extension of myosin 9 head could regulate the actin-activated 
ATPase activity of human myosin 9a. Therefore, I investigated the actin-dependent ATPase 
activity of minimal motor domain constructs, truncated after the ~150aa long N-terminal 
extension (Figure 4.6). 9aMMD and 9aMMD-S1 contain the minimal sequence of a myosin 
head domain required for its enzymatic and mechanical activity; 9aMMD-S1 additionally 
encompasses the neck region of the native myosin 9a sequence. Both constructs exhibited 
the same basal ATPase rate (V0 = 0.12 ± 0.01 s-1 for 9aMMD and V0 = 0.13 ± 0.02s-1 for 
9aMMD-S1) that did not differ significantly from those obtained for constructs containing 
the N-terminal extension. Actin did not further stimulate the basal ATPase rate of minimal 
motor domain constructs. Therefore, the N-terminal extension of human myosin 9a does not 
influence its enzymatic properties. Since there was no difference in the actin-dependent 
  109 
ATPase activity of all human myo9a constructs developed, following experiments focused 
on 9aMMD. 
 
Figure 4.6. An actin-dependent ATPase rate of 9aMMD (A) and 9aMMD-S1 (B). 
100 - 200nM myosin was used to measure the rate of ATP hydrolysis in the buffer 
supplemented with 2mM highly pure ATP and an ATP-regenerating system in the absence 
and presence of phalloidin-stabilized F-actin (0 - 30μM). Basal ATPase rates (V0) were 
0.12 ± 0.01 s-1 for 9aMMD and 0.13 ± 0.02 s-1 for 9aMMD-S1 and no actin-activation was 
observed for either protein. Measurements were performed at 220C and NADH absorbance 
was followed at 340nm for at least 10min. Each data point represents an average of 3 
independent measurements from separate myosin preparations ± S.D. (n = 3).  
 
 
Previously, the actin-activated ATPase activity of Acanthamoeba myo1, a motor 
which also crosslinks actin filaments, was shown to be dependent on the myosin:actin ratio. 
It was proposed that the enzymatic activity of myo1 could only be observed at myosin 
concentrations that enabled cooperative actin binding (Albanesi et al., 1985). Therefore, I 
investigated the function of an actin-activated ATPase activity of 9aMMD on the myosin 
concentration (Figure 4.7). 235 - 70nM 9aMMD was used to measure the ATP hydrolysis 
rates in the absence and presence of F-actin stabilized with phalloidin (0 - 20μM). There 
was no effect of the 9aMMD concentration on the Vmax and the rates at 20μM [actin] did 
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not differ from the basal rates at all myosin concentrations tested. Thus, the enzymatic 
activity of human myosin 9a does not depend on the myosin:actin ratio. 
Figure 4.7. The dependence of the actin-activated ATPase rate of 9aMMD on 
myosin concentration. The rate of ATP hydrolysis of 235nM (black circles), 165nM (open 
circles), 110nM (black triangles) and 70nM (open traingles) 9aMMD was measured in the 
buffer supplemented with 2mM highly pure ATP and an ATP-regenerating system in the 
absence and presence of phalloidin-stabilized F-actin (0 - 20μM). Measurements were 
performed at 220C and NADH absorbance was followed at 340nm for at least 10min. No 
difference in the rate of ATP hydrolysis within the range of actin concentrations used was 
observed at any 9aMMD concentration.  
 
It was shown previously that phalloidin affects protein-protein interactions between 
the phalloidin-stabilized actin and non-muscle myosin 2A and non-muscle myosin 2C. In 
both cases, the Vmax of the actin-activated steady-state ATPase activity in the presence of 
phalloidin-stabilized F-actin was decreased 3-4-fold as compared to phalloidin-free F-actin 
(Diensthuber et al., 2011). The effect of phalloidin-decorated versus phalloidin-free F-actin 
on an actin-dependent ATPase activity of 9aMMD is shown in Figure 4.8. Phalloidin does 
not influence maximal ATPase activity of human myosin 9a.  
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Figure 4.8. The effect of phalloidin stabilization of F-actin on the maximal ATPase 
activity of 9aMMD. The ATPase rate of 150nM 9aMMD was measured in the buffer 
supplemented with highly pure ATP and an ATP-regenerating system in the presence of 0 - 
20μM phalloidin-stabilized F-actin (open circles) or phalloidin-free F-actin (black circles). 
Measurements were performed at 220C and NADH absorbance was followed at 340nm for 
at least 10min. There was no difference in the maximum steady-state ATPase activity 
(Vmax) of 9aMMD in either sample. Therefore, phalloidin does not influence the ATPase 
activity of human myosin 9a.  
 
It was shown before that ionic strength has a profound effect on the Vmax of mouse 
brain myosin 5 S1 and HMM constructs (Wang et al., 2000). I tested the effect of the ionic 
strength of the buffer on the actin-dependent steady-state ATPase activity of human myosin 
9a (Figure 4.9). Here as well, no change in the Vmax was observed. Therefore, the lack of 
the stimulation of the basal ATPase rate of human myo9a by actin does not depend on the 
ionic strength. 
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Figure 4.9. The dependence of the maximal ATPase activity of 9aMMD on the 
ionic strength of the buffer. The ATPase rate of 150nM 9aMMD was measured in a buffer 
supplemented with highly pure ATP and an ATP-regenerating system in the presence of 0 - 
20μM phalloidin-stabilized F-actin. Buffers contained 50mM (black circles) or 150mM 
(open circles) KCl. Measurements were performed at 220C and NADH absorbance was 
followed at 340nm for at least 10min. There was no difference in the maximum steady-state 
ATPase activity (Vmax) of 9aMMD in either sample. Therefore, the ionic strength of the 
buffer does not influence the maximum steady-state ATPase activity of human myo9a.  
 
Finally, the maximal actin-activated steady-state ATPase activity of mouse brain 
myosin 5 S1 was increased in the presence of exogenous calmodulin supplemented in the 
buffer, probably reflecting extra calmodulin molecules saturating IQ motifs in the neck 
region of the myosin (Wang et al., 2000). On the other hand, the length and net charge of 
loop 2 (the primary actin interaction site of myosins) was shown to influence the ATPase 
rate of myosins, probably by regulating their interactions with actin (Bobkov et al., 1996). 
The loop 2 of myosin 9 is extended and was proposed to bind calmodulin (Liao et al., 
2010). It is plausible the binding affinity of calmodulin to loop 2 of myosin 9 could affect 
its interaction with actin. Since an isomerization of the weak actin binding state after ATP 
hydrolysis to the strong actin binding state was proposed to be essential for the acceleration 
of the release of hydrolysis products (Holmes et al., 2003), it is plausible that a specific 
binding mode of calmodulin to myosin 9a loop 2 is necessary for the actin stimulation of 
ADP release.   
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First, I added extra calmodulin to ATPase reactions of 9aMMD at saturating [actin]. 
No change in the ATPase rate was observed even in the presence of 1mM exogenous CaM 
(Figure 4.10). Therefore, the lack of the actin stimulation of the basal ATPase rate of 
9aMMD caused by the weak association of calmodulin in the absence of calcium with the 
motor domain can be excluded. 
 
Figure 4.10. The dependence of the maximal actin-activated ATPase activity of 
9aMMD on exogenous calmodulin. The ATPase rate of 300nM 9aMMD was measured in 
the buffer containing 2mM ATP, an ATP-regenerating system and 30μM phalloidin-
stabilized F-actin. The buffer was supplemented with exogenous calmodulin (1μM - 1mM) 
and absorbance of NADH was followed at 340nm for at least 10min. Data was plotted as a 
function of the maximal ATPase rate (s-1) on calmodulin concentration presented as 
logCaM in the presence of a saturating actin concentration. Supplementing the buffer with 
as much as 1mM exogenous calmodulin does not influence the Vmax of human myosin 9a.  
 
In summary, the minimal motor domain of human myosin 9a is enzymatically 
active, but its basal ATPase rate is not stimulated by actin. Neither the N-terminal extension 
nor the neck domain of human myo9a regulate an actin-dependent ATPase activity of 
human myosin 9a. It was shown previously that the basal ATPase activity of full length rat 
myo9b was activated 10-fold by actin (Nalavadi et al., 2005). Therefore, it would be 
interesting to examine the steady-state ATPase activity of the full length human myo9a to 
address the possible role of the tail domain in regulating the ATPase activity of the myosin 
in the presence of actin. 
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4.3. Steady-state kinetics of human myosin 9a in the presence of calcium 
Binding of Ca2+ ions to calmodulin can regulate the affinity and association of CaM 
with its target binding site (Manceva et al., 2007; Bayley et al., 1996). It is interesting to 
speculate that Ca2+ binding to the CaM light chain in the head domain of human myosin 9a 
could affect its interactions with actin in the presence of a nucleotide and regulate its actin-
activated ATPase activity. I assessed the effect of Ca2+ on the actin-activated ATPase 
activity of 9aMMD. 9aMMD was not actin-activated in the absence of Ca2+; however, in 
the presence of 100μM free Ca2+ (pCa 4), the basal ATP hydrolysis rate was stimulated ~3-
fold by actin (Figure 4.11) from V0 = 0.13 ± 0.02 s-1 to Vmax = 0.49 ± 0.03 s-1.  Data was 
collected from 3 independent 9aMMD preparations and 100 - 200nM 9aMMD was used for 
measurements. F-actin concentration necessary to reach the half maximal activation was Km 
= 2 ± 1.3μM which indicates high actin affinity of 9aMMD in a weak actin binding state (in 
the presence of ATP or ADP.Pi). That data indicates that in the presence of Ca2+, the actin- 
and nucleotide-binding sites of 9aMMD become coupled (they regulate each other in a 
reciprocal way).  
 
Figure 4.11. Ca2+ induces actin-activation of the steady-state ATPase activity of 
9aMMD. The rate of ATP hydrolysis of human myosin 9a was measured in the presence of 
100 - 200nM 9aMMD in a buffer supplemented with 2mM highly pure ATP, an ATP-
regenerating system, 0 - 30μM phalloidin-stabilized F-actin and 0.1mM free Ca2+ (open 
circles). NADH absorbance was measured at 340nm for at least 10min at 220C and three 
independent 9aMMD preparations were used to collect the data. Data points were fitted to 
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Michaelis-Menten kinetics, with V0 = 0.13 ± 0.02 s-1, Vmax = 0.49 ± 0.03 s-1 and Km = 2 ± 
1.3μM. Data points represent the mean value from three independent measurements ± S.D. 
(n = 3). Data obtained in the absence of Ca2+ (closed circles) was explained earlier in the 
text and is shown on the plot as a reference.  
 
The ATPase activity of human myosin 9a at 220C in the absence and presence of 
phalloidin-stabilized F-actin is summarized in Table 4.1. For comparison, experimental data 
obtained for rabbit skeletal muscle myosin HMM is also included. 
Table 4.1. The steady-state ATPase activity of human myosin 9a. 
Parameter rabbit skeletal HMM GFP-9a-Head/EGTA GFP-9a-S1/EGTA 
V0 (s-1) 0.06 ± 0.05 0.17 ± 0.014 0.18 ± 0.016 
Vmax (s-1) 7.5 ± 0.4 ND ND 
Km (μM) 15 ± 3.2 ND ND 
Parameter 9aMMD/EGTA 9aMMD/0.1mM Ca2+ 9aMMD-S1/EGTA 
V0 (s-1) 0.12 ± 0.008 0.13 ± 0.02 0.13 ± 0.02 
Vmax (s-1) ND 0.49 ± 0.03 ND 
Km (μM) ND 2 ± 1.3 ND 
 
Ca2+ could induce the actin-activation of the steady-state ATPase of 9aMMD by 
causing the dissociation of CaM from the motor domain. Such mechanism of the regulation 
of the ATPase activity of myosin has been proposed for several different myosin isoforms, 
whereby Ca2+-induced dissociation of CaM from the neck domain activated the actin 
stimulation of the ATPase rate (Krementsov et al., 2004). I investigated the association of 
CaM with 9aMMD at increasing [Ca2+] by incubating 0.8μM 9aMMD with 20μM 
phalloidin-stabilized F-actin for 20min at RT, followed by a high-speed centrifugation. 
Equal volumes of supernatant and pellet were separated on a 15% SDS-PAGE gel to assess 
the presence of CaM in either the supernatant or pellet (Figure 4.12). Variations in the 
amount of CaCl2 present in the buffer included the lack of Ca2+ (EGTA) and presence of 10  
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- 1000μM free Ca2+. Simultaneously, in order to exclude the possibility of CaM pelleting by 
itself or binding to actin on its own, a control containing 1μM exogenous CaM was mixed 
with 20μM actin and treated the same way. As indicated in Figure 4.12, CaM was present in 
pellet fractions containing 9aMMD at all CaCl2 concentrations, even as high as 1mM. In a 
control that did not contain any myosin, CaM was found in the supernatant fraction, 
confirming that CaM did not pellet on its own and did not bind actin (right gel). Therefore, 
CaM present in pellet fractions (left gel) represents a myosin-bound CaM fraction. That 
data suggests that the actin-activation of the steady-state ATPase activity of 9aMMD in the 
presence of Ca2+ cannot be attributed to a simple dissociation event of CaM from myo9a 
head upon addition of CaCl2. 
 
Figure 4.12. The effect of Ca2+ on binding of CaM to the head domain of human 
myosin 9a. 0.8μM 9aMMD was mixed with 20μM phalloidin-stabilized F-actin in the 
absence (EGTA) and presence of 10, 100 and 1000μM free Ca2+ (pCa 4 - 5) in the buffer 
containing 0.1mM EGTA and 100mM KCl. In a separate sample, 1μM exogenous CaM 
was mixed with 20μM phalloidin-stabilized F-actin in the same buffer in the absence of 
CaCl2. Samples were incubated for 20min at RT, followed by 20min, 100000rpm, 40C 
centrifugation. Supernatant was collected and pellets were resuspended in the same volume 
of PBS. Equal volumes of supernatant and pellet were separated on a 15% SDS-PAGE gel 
and stained with Commassie-Blue to confirm the presence of CaM in either supernatant or 
pellet at increasing [Ca2+]. The experiment was performed with three independent 9aMMD 
preparations and a representative SDS-PAGE gel is shown. As depicted on the left gel, 
CaM (indicated by asterisk) was always found in the pellet fractions with myosin, even at 
1mM Ca2+ (pCa 3). A negative control containing only CaM and actin (right gel) was 
treated the same way and free CaM (asterisk) was found in the supernatant, confirming 
CaM did not pellet on its own or bind to actin. Therefore, all CaM found in samples 
containing myosin was 9aMMD-associated and Ca2+ did not induce dissociation of CaM 
from 9aMMD. M - myosin, A - actin, s - supernatant, p - pellet.  
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4.4. Interaction of human myosin 9a with actin in different nucleotide states 
9aMMD is enzymatically active (it hydrolyzes ATP), but its basal ATPase rate was 
stimulated by actin only in the presence of Ca2+. It raised a possibility that in the absence of 
Ca2+ 9aMMD would not bind actin in the presence of ATP, which would explain the lack of 
the actin-activated steady-state ATPase. Upon addition of Ca2+, the head-bound CaM did 
not dissociate from loop 2, but instead Ca2+ could induce a conformational change in CaM 
molecule which in turn could regulate binding of myosin to actin in the presence of ATP by 
inducing a structural rearrangement of loop 2 of myo9a that would facilitate actin binding.  
Binding of myosin 9a to actin in different nucleotide states was addressed by an 
actin spindown assay in the absence and presence of 2mM MgATP or 2mM MgADP 
(Figure 4.13A-C). 0.8 - 1μM 9aMMD was incubated with increasing amounts of phalloidin-
stabilized F-actin (0 - 15μM) in the presence or absence of nucleotides. To investigate the 
rigor binding state, apyrase was used to fully deplete the solution from any nucleotides 
present. Samples were incubated in the buffer containing 100mM KCl and 0.1mM EGTA 
(unless otherwise stated; see below) for 30min on ice, followed by a high-speed 
centrifugation (20min, 100000rpm, 40C). Supernatant was collected and pellet was 
resuspended in an equal volume of PBS. Equal amounts of supernatant and pellet were 
separated on SDS-PAGE gels. Band density was measured and the amount of 9aMMD 
present in the pellet was plotted against F-actin concentration (Figure 4.13D). In the 
presence of the nucleotide some 9aMMD always pelleted on its own (in the absence of F-
actin). In those cases the amount pelleted in the presence of actin was corrected by the 
amount that pelleted on its own. Data points were fitted to a quadratic equation and 
dissociation constants (Kd) in each nucleotide state were determined to be 425 ± 21.1nM in 
rigor (in the absence of the nucleotide), 810 ± 93nM in the presence of ATP and 590  ± 
89nM in the presence of ADP. Taken together, 9aMMD binds actin with high affinity 
(nanomolar range) in all nucleotide states. The highest affinity exhibited in the absence of 
the nucleotide decreased 2-fold in the presence of ATP. The binding affinity in the ADP 
state was between the rigor and the ATP-state affinity. The binding of 9aMMD to actin in 
the absence of the nucleotide reached full saturation at higher actin concentrations (Fmax = 
100%), but only Fmax = 62 ± 3.2% and Fmax = 71 ± 2% of 9aMMD bound at saturating [F-
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actin] in the presence of ATP and ADP, respectively. Therefore, human myosin 9a binds 
actin in a nucleotide-sensitive manner. Binding parameters are summarized in Table 4.2.  
 
Figure 4.13. Binding of 9aMMD to actin in different nucleotide states. 0.8 - 1μM 
9aMMD was incubated with increasing amounts of phalloidin-stabilized F-actin (0 - 15μM) 
in the absence  (A) or presence of 2mM MgATP (B) or 2mM MgADP (C). Samples were 
incubated for 20min on ice in the buffer containing 10mM MOPS, 0.1mM KCl, 1mM DTT, 
0.1mM EGTA and 4mM MgCl2. Following centrifugation 20min, 100000rpm, 40C, 
supernatants were collected and pellets were resuspended in an equal volume of PBS. The 
equal volumes of supernatant and pellet were separated on 10% SDS-PAGE gels and 
stained with Commassie-Blue. Band densities of 9aMMD in the supernatant (s) and pellet 
(p) were measured at each actin concentration and the fraction of 9aMMD bound was 
plotted against [F-actin] (D). In the presence of nucleotides a fraction of 9aMMD pelleted 
by itself and the fraction bound to actin was corrected by the amount of 9aMMD pelleted 
on its own. Dissociation constants (Kd) were obtained by fitting the data to a hyperbola and 
obtained values were: Kd = 425 ± 21.1nM in rigor (open circles), Kd = 810 ± 93nM in the 
presence of ATP (black circles) and Kd = 590  ± 89nM in the presence of ADP (gray 
circles). 9aMMD binding saturated at 100% in the absence of a nucleotide (rigor) but in the 
presence of a nucleotide, binding of 9aMMD to actin plateaued at 62 ± 3.2% with ATP and 
71 ± 2% with ADP. Data points were collected from three independent 9aMMD 
preparations and are represented as mean values ± S.D. (n = 3).  
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The apparent substoichiometric binding of 9aMMD in the presence (but not in the 
absence) of nucleotides could indicate that a fraction of 9aMMD in the sample is incapable 
of binding actin, for example because of protein aggregation or degradation. Alternatively, 
two states of 9aMMD could exist in a dynamic equilibrium: a binding-incompatible and 
binding-compatible state. To distinguish between those two possibilities 9aMMD was 
sedimented with 10μM F-actin following 20min incubation on ice in the presence of 2mM 
MgATP as described above. The unbound fraction of 9aMMD present in the supernatant 
after the 1st spin was re-mixed with 10 μM F-actin, incubated as before and re-sedimented 
in a high-speed spin. The equal volumes of supernatant and pellet from the 1st and 2nd spin 
were analyzed by SDS-PAGE to determine the amount of myosin that rebound to actin. In 
parallel, myosin from the 1st spin was subjected to the resedimentation in the absence of 
actin to compare the amount of 9aMMD pelleting by itself to that pelleted with actin in the 
2nd spin (Figure 4.14). If the presence of a nucleotide renders the myosin permanently 
incompetent of binding actin there should be no difference in the amount of 9aMMD 
pelleted in the 2nd spin in samples with and without actin. In an alternative scenario, if 
myo9a exists in a dynamic equilibrium between a state that binds actin and a state that does 
not bind actin, a higher amount of myosin should bind to actin in the 2nd spin as compared 
to a sample resedimented without actin. Indeed, when 9aMMD present in the supernatant 
from the 1st spin (58% of the total 9aMMD amount) was resedimented in the absence of 
actin only 11% of 9aMMD pelleted by itself, but the amount of 9aMMD present in the 
pellet of the 2nd spin in the presence of actin was 58% (Figure 4.14B, blue bars). Therefore, 
actin binding by myosin 9a is not hindered in the presence of a nucleotide; instead, two 
states of myo9a exist in an equilibrium when the nucleotide is present - actin binding-
competent and -incompetent. The rate of this equlibrium could regulate binding of human 
myo9a to actin in a weak actin-binding state.  
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Figure 4.14. 9aMMD exists in two actin-binding states (binding-compatible and 
binding-incompatible) in the presence of ATP. 1.5μM 9aMMD was incubated with 10μM 
F-actin in the absence (rigor) and presence of 2mM MgATP for 20min on ice and 
centrifuged 20min, 100000rpm, 40C. A sample depleted of the nucleotide (rigor) was 
sedimented and separated on the gel to confirm full binding of 9aMMD to actin in the rigor 
state. In the presence of 2mM MgATP, a large fraction of 9aMMD was found in the 
supernatant. That fraction from two parallel spins, containing unbound 9aMMD fraction, 
was used in the 2nd spin without and with ‘freshly’ added 10μM F-actin, following 20min 
incubation on ice as before. A: a representative SDS-PAGE gel of 9aMMD rebinding to 
actin in the presence of ATP.  Supernatant (s) and pellet (p) fractions show the amount of 
9aMMD in each fraction in rigor and with ATP, from the 1st and 2nd spin. The presence or 
absence of ATP and actin are indicated below the gel. B: band densities were used to 
quantitate the amount of 9aMMD rebinding to actin as compared to the amount of 9aMMD 
pelleting by itself after recentrifugation. In rigor, all 9aMMD bound to actin. In the 
presence of ATP, only 42 ± 10% of total myosin amount bound to actin. From 58% of 
unbound 9aMMD fraction from the 1st spin, 11 ± 3.5% pelleted itself and 58 ± 14% was 
found in the pellet with actin following resedimentation (2nd spin). Therefore, 46% more of 
9aMMD was found in the pellet in the presence than in the absence of actin, confirming 
that binding of 9aMMD to actin is not hindered in the presence of a nucleotide and that 
9aMMD exists in a dynamic equilibrium between a binding-compatible and binding-
incompatible state. M - myosin, A - actin. Data were collected from three independent 
myosin preparations and are presented as mean ± S.D. (n = 3). 
 
Considering the profound effect of Ca2+ on the stimulation of the basal ATP 
hydrolysis rate of 9aMMD by actin, I investigated the effect of Ca2+ on binding of 9aMMD 
to F-actin in the presence of ATP. 9aMMD was cosedimented with 0 - 8μM F-actin as 
described previously in the presence or absence of 0.1mM Ca2+. Samples were treated as 
previously and band density measurements were used to quantitate fractions of 9aMMD 
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bound to actin in the presence and absence of calcium (Figure 4.15). Calcium did not affect 
the dissociation constant or the maximal fraction of 9aMMD binding to high actin 
concentrations in the presence of ATP.  
 
Figure 4.15. The effect of Ca2+ on actin binding by 9aMMD in the presence of 
2mM MgATP. 0.8μM 9aMMD was mixed with increasing [F-actin] (0 - 8μM) in the 
presence (black circles) and absence (white circles) of 0.1mM free Ca2+. Following 20min 
incubation on ice, samples were centrifuged 20min, 100000rpm, 40C and equal volumes of 
supernatant and pellet were analyzed by SDS-PAGE. Band density of 9aMMD fractions 
present in supernatant and pellet fractions were used to calculate the amount of 9aMMD 
bound, corrected for the amount of 9aMMD pelleting itself in the absence of actin. The 
amount of 9aMMD pelleted was plotted against [F-actin] and data was fitted to a hyperbolic 
equation, providing dissociation constants (Kd) and maximal fraction bound (Fmax). Values 
are: Kd = 829 ± 67nM in the absence and Kd = 817 ± 74nM in the presence of 0.1mM Ca2+ 
with Fmax = 59 ± 4 and Fmax = 63 ± 2.1, respectively. Data points represent mean value from 
three independent 9aMMD preparations ± S.D. (n = 3).  
 
Table 4.2. Actin-binding affinity of 9aMMD in different nucleotide states. 
Parameter Rigor ATP/EGTA ATP/Ca2+ ADP 
Kd (nM) 425 ± 21.1 810 ± 93 817 ± 74 590 ± 89 
Fmax (%) 101 ± 0.8 62 ± 3.2 63 ± 2.1 71 ± 2 
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CHAPTER 5: MECHANICAL PROPERTIES OF HUMAN 
MYOSIN 9 
 
 
 
 
5.1. The in vitro gliding filament assay  
The in vitro gliding filament assay (or motility assay) allows direct visualization of 
the mechanical activity of myosin. Using purified components, a system resembling that of 
the muscle sarcomere is reconstituted. The flow chamber is composed of a microscope 
glass slide, two parallel pieces of a double-sided tape and a coverslip, so that the total 
volume of the chamber is ~10μl. In the simplest version of the assay, the coverslip is coated 
with nitrocellulose; upon introduction of myosin to the chamber, the motor adheres 
nonspecifically to the surface. Unbound protein is washed out from the flow cell and free 
binding sites on the coverslip surface are blocked with BSA. Actin filaments stabilized with 
fluorecent-phalloidin (TRITC-actin) are introduced to the assay chamber and allowed to 
attach to the lawn of myosin motors on the surface. Introduction of ATP to the flow cell 
initiates enzymatic cycle of surface-attached myosins that interact with fluorescent actin 
filaments, resulting in translocation of actin filaments across the field of myosins on the 
surface. The assay was developed by Kron and Spudich, 1986. A schematic representation 
of the assay is presented in Figure 5.1. 
A nonspecific attachment of myosin to nitrocellulose results in different geometries 
of molecules on the surface. This might render myosin motors incapable of undergoing a 
series of conformational changes necessary to propel a filament and thus hinder the 
motility. In order to attach myosins to the surface in a specific conformation, one can use an 
antibody raised against a C-terminal tag (i.e. GFP) or a C-terminal part of a myosin (i.e. 
tail). Such site-specific immobilization orients the myosin heads towards the volume of the 
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flow cell, enabling unrestrained progression through the mechanochemical cycle and 
effective power strokes resulting in translocation of actin filaments. 
 
Figure 5.1. A schematic depiction of the in vitro motility assay. Flow chamber is 
constructed from a microscope glass slide, two pieces of a double-sided tape and a 
nitrocellulose-covered coverslip. Myosin is introduced into the chamber and adheres 
nonspecifically to the surface. Unbound protein is washed out and BSA is introduced to 
block free binding sites on the coverslip. Fluorescent actin filaments are introduced into the 
chamber and allowed to bind to the lawn of myosins. ATP is introduced to induce 
translocation of actin filaments. Image adapted from Batters et al., 2014. 
 
Fast skeletal muscle myosin is a well established control of myosin function. I used 
a rabbit skeletal HMM fragment to assess the buffer compatibility with the assay. I applied 
0.2mg/ml rabbit skeletal HMM to a flow cell constructed of a nitrocellulose-covered 
coverslip. Following blocking of free binding sites, TRITC-actin was introduced and 
motility was initiated by adding 2mM MgATP. Fluorophores on actin were excited in epi-
fluorescence. Rabbit skeletal HMM robustly propelled actin filaments in the presence of 
ATP. GMimPro algorithm for the detection of single molecules (Mashanov and Molloy, 
2007) was used to track individual filaments over time and a velocity distribution plot was 
obtained (Figure 5.2). Rabbit skeletal HMM actively translocated fluorescent actin 
filaments with a mean velocity of ~5.5μm/s at 220C, which corresponds well with 
previously reported values (Homsher et al., 2003, Sheetz et al., 1984).  
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Figure 5.2. The in vitro gliding filament assay of rabbit fast skeletal muscle myosin 
HMM. A: 0.2mg/ml rabbit skeletal HMM was applied to a flow chamber and adhered to a 
nitrocellulose-covered coverslip. Actin was stabilized with TRITC-phalloidin and excited in 
epi-fluorescence using the Nikon Eclipse Ti microscope. An image represents fluorescent 
actin filaments (black) bound to myosin molecules on the surface of a coverslip. Scale bar: 
10μm. B: motility was initiated by introducing 2mM MgATP and individual frames were 
acquired every 0.2s. A leading end of each filament gliding over a field of myosins was 
tracked using the GMimPro algorithm. An image represents tracks of individual filaments 
over time confirming active translocation of filaments by rabbit skeletal HMM. Scale bar: 
10μm. C: a velocity distribution plot of rabbit skeletal HMM. 189 filaments were tracked 
over the time course of recorded videos. Mean velocity was ~5.5μm/s at 220C. Three 
separate flow cells were used to collect the data for this analysis.  
 
5.2. Human myosin 9a nonspecifically attached to the surface binds actin in 
an ATP-sensitive manner but does not translocate filaments 
Initial motility assays were performed with GFP-9a-S1 and GFP-9a-Head 
immobilized nonspecifically on nitrocellulose-covered coverslips. The interaction of rabbit 
skeletal HMM (as a control) and GFP-9a-S1 and GFP-9a-Head with actin at indicated 
motor concentrations in the presence of ATP is presented in figure 5.3 (lower panel). The 
collective pixel intensity from the first 50 (rabbit skeletal HMM) or 150 (myo9a) frames is 
presented as the Maximal Intensity Projection (Figure 5.3, lower panel). Both myo9a 
constructs bound actin in the absence of the nucleotide (Figure 5.3, 1st frame). Upon 
introduction of ATP and at 0.2mg/ml motor concentration, no change in the position of 
actin filaments was observed (0.2mg/ml GFP-9a-Head). At 0.05mg/ml motor and in the 
presence of ATP (0.05mg/ml GFP-9a-Head and 0.05mg/ml GFP-9a-S1) actin filaments 
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started jittering and single dissociation and rebinding events of actin filaments were 
observed. However, no translocation of filaments occured. Supplementing the motility 
buffer with 2x molar excess of exogenous calmodulin or increasing the ionic strength of the 
buffer and warming the glass slide to ~300C did not improve the quality of the assay. This 
result suggests that at least a fraction of the motor on the surface is enzymatically active (as 
it released and rebound filaments). The coupling between the actin- and nucleotide-binding 
sites in GFP-9a-Head and GFP-9a-S1 is very poor, as showed by the lack of the actin-
activated ATPase activity of those proteins. This might explain why those proteins were not 
able to translocate actin filaments, despite progressing through catalytic cycles on the 
surface of the coverslip. It is also plausible that a fraction of the motor on the surface is 
catalytically inactive or that a surface geometry of myosin enables binding of actin 
filaments but prohibits the mechanochemical cycle. By lowering the motor surface density, 
the number and spatial distribution of the active and inactive heads will change enabling 
active motors to undergo their catalytic cycles. This is consistent with the fact that at higher 
motor densities of GFP-9a-Head the filaments were rigidly attached to the surface and did 
not change their position, whereas lowering the motor density on the surface allowed 
dissociation and rebinding of the filaments. 
In order to test whether the N-terminal extension regulates the mechanical activity 
of human myosin 9a, I repeated the motility assays with the minimal motor domain 
constructs – 9aMMD and 9aMMD-S1. Both constucts encompass the minimal sequence of 
the head domain of myosins essential for the enzymatic activity; 9aMMD-S1 additionally 
contains the full neck region with 6 IQ motifs.  
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Figure 5.3. GFP-9a-Head and GFP-9a-S1 nonspecifically attached to the coverslip 
surface are enzymatically active but do not translocate actin filaments. 0.2mg/ml rabbit 
skeletal HMM, 0.2mg/ml GFP-9a-Head, 0.05mg/ml GFP-9a-Head and 0.05mg/ml GFP-9a-
S1 were attached nonspecifically to a nitrocellulose-covered coverslip. TRITC-actin was 
bound to myosin on the surface and imaged in epi-fluorescence on the Nikon Eclipse Ti 
fluorescent microscope using 60x 4.2 NA oil objective (Nikon). ‘1st frame’ shows actin 
filaments (black) attached to myosins on the surface of a flow chamber in the absence of 
ATP. 2mM MgATP was added to initiate the motility and frames were collected every 
200ms in case of skeletal HMM and every 3min in case of myo9a. ‘Max. Int. Projection’ of 
the first 50 (skeletal HMM) or 150 (myo9a) frames represents the collective pixel intensity 
across indicated frames. Robust translocation of actin filaments is evident for rabbit skeletal 
HMM. At 0.2mg/ml myo9a no activity upon introduction of ATP was seen and filaments 
did not change their positions over time. When myo9a surface density was lowered to 
0.05mg/ml, jittering of actin filaments over an attachment point and single dissociation 
/rebinding events were observed but no directional translocation of actin filaments took 
place. Data was collected from three independent myosin preparations and a representative 
image plane is shown. Scale bar: 10μm. 
 
Based on previous results, whereby lower motor densities of GFP-9a-Head and 
GFP-9a-S1 supported mechanical activity, 0.05mg/ml of 9aMMD and 9aMMD-S1 were 
applied to flow cells constructed with nitrocellulose-covered coverslips (Figure 5.4). Both 
proteins bound actin (1st frame) and addition of ATP initiated actin filament jittering and 
rebinding (Max. Int. Projection). Still, no directional translocation of actin filaments was 
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observed. This suggests that the N-terminal extension of human myo9a is not necessary for 
motility and that minimal motor domain constructs are mechanically active but attached 
nonspecifically to the surface do not support the translocation of actin filaments. This might 
be due to specific motor geometries on the surface of the coverslip that do not support the 
mechanochemical activity. Alternatively, the lack of actin translocation can be explained by 
poor coupling between the actin- and nucleotide-binding sites in 9aMMD and 9aMMD-S1, 
as became evident in the ATPase assays.  
 
Figure 5.4. Mechanical properties of 9aMMD and 9aMMD-S1 nonspecifically 
attached to the coverslip surface in the absence of calcium. 0.05mg/ml 9aMMD or 
9aMMD-S1 was applied to a flow cell constructed with a nitrocellulose-coated coverslip. 
TRITC-actin was introduced to the flow cell and imaged as before. Both constructs bound 
actin (1st frame; black). 2mM MgATP was introduced to initiate cycling of surface-attached 
myosins and frames were collected every 3min. The first 150 frames were used to obtain 
Max. Int. Projection representing the collective pixel intensity within indicated time period 
in a single field of view. No translocation of actin filaments was observed. Jittering of actin 
around an anchor point and single dissociation/rebinding events were observed. Data was 
collected from three independent myosin preparations and a representative image plane is 
shown. Scale bar: 10μm. 
 
A possibility that human myosin 9a is motile only on a specific actin structure (i.e. 
bundled actin-filaments in filopodia or stress fibers or branched filaments in lamellipodia) 
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cannot be excluded. It has been previously proposed that myosin 10 preferentially moves on 
fascin-actin bundles, parallel actin filaments cross-linked by fascin into rigid bundles that 
filopodia are composed of (Ricca and Rock, 2010). Electron micrographs revealed that 
9aMMD cross-links actin filaments, which might indicate it requires two parallel filaments 
for motility. In line with that, rat myo9a transiently expressed in 16HBE cells was found to 
co-localize with actin bundles at the cell periphery (Omelchenko, 2014). Stable fascin-actin 
bundles were generated by an overnight incubation of fascin with actin and were applied to 
flow cells to examine their translocation by 9aMMD (Figure 5.5). Fascin-actin bundles bind 
directly to a glass surface of a coverslip that was not blocked with BSA. Surprisingly, no 
fascin-actin bundles bound to 9aMMD immobilized on the surface. Even though a 
preference towards other specific actin architectures cannot be excluded, human myosin 9a 
does not bind fascin-actin bundles. It is possible that mechanical properties of filaments 
within the bundle (i.e. rigidity) disable tethering by myo9a. Alternatively, myo9a binding 
sites on actin are buried within the bundle causing the observed effect. 
 
Figure 5.5. Human myosin 9a does not bind fascin-actin bundles. Facin-actin 
bundles were prepared by an overnight incubation of 3:8 molar ratio of fascin to phalloidin-
stabilized F-actin at 40C. Bundles are lean, rigid rods (black) and bind directly to the glass 
surface of a coverslip (No myosin 9a). When 0.2mg/ml biotinylated 9aMMD was 
immobilized on the coverslip, no binding of bundles to the surface was observed (Myosin 
9a on the surface).  
 
 
As stated above, the lack of actin translocation might be a result of poor coupling 
between the actin- and nucleotide-binding sites in the absence of Ca2+. However, adding 
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Ca2+ to the ATPase assays switch on that coupling in 9aMMD. Therefore, it is plausible that 
9aMMD requires Ca2+ for the mechanical activity. I assessed the effect of Ca2+ on the 
motility of nonspecifically-immobilized 9aMMD by supplementing the motility buffer with 
0.1mM Ca2+. In agreement with the steady-state ATPase data, individual filaments were 
propelled in a smooth, directional fashion by myosin (Figure 5.6). The mean velocity of 
9aMMD in the presence of 0.1mM Ca2+ was 9.6nm/s at 220C. That result suggests that 
calcium binding to CaM light chain associated with the head of 9aMMD might be 
necessary to induce coupling of the mechanochemical cycle of human myosin 9a.  
 
Figure. 5.6. Mechanical properties of 9aMMD nonspecifically attached to the 
coverslip surface in the presence of calcium. 0.05mg/ml 9aMMD was deposited in the flow 
cell. TRITC-actin was added and imaged in epi-fluorescence as before. 9aMMD bound 
actin (A) and propelled single filaments when 2mM MgATP was added in the presence of 
0.1mM Ca2+. Moving filaments were tracked in GMimPro (B) and the velocity distribution 
was obtained (C). 162 actin filaments from three independent myosin preparations were 
used to measure the velocity and the mean velocity of 9aMMD in the presence of 0.1mM 
Ca2+ was 9.6nm/s at 220C. Scale bar: 10μm. 
 
 
 
5.3. Cloning, purification and biotinylation of an Avi-tagged myosin 9a  
Despite the fact that supplementing the motility buffer with 0.1mM Ca2+ initiated 
motility, actin transport was very poor with only a few filaments moving within the field of 
view for very short distances (Figure 5.7B). This suggests that multiple different 
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orientations of myosin on the surface might still contribute to an inefficient translocation of 
actin filaments by myosin 9a.  
To immobilize myosin 9a in a specific conformation on the nitrocellulose surface, 
two additional constructs were developed: 9aMMD-Avi and 9aMMD-S1-Avi with the C-
terminal Avi-tag. An Avi-tag (GLNDIFEAQKIEWHE) serves as a biotin-binding site, 
enabling biotinylation of myosin 9a constructs on the C-terminus. Oligos encoding an Avi-
tag were chemically-synthesized and contained sticky ends with phosphate groups on the 5’ 
end for ligation into an appropriate plasmid. pFBNA plasmids with 9aMMD and 9aMMD-
S1 were digested with NotI and the Avi-tag was introduced in frame with the C-terminal 
FLAG-tag for the affinity chromatography (Figure 5.7A). The presence of 9aMMD and 
9aMMD-S1 inserts in pFBNA after introduction of an Avi-tag was confirmed by restriction 
analysis (Figure 5.7B). Given the small size of the Avi-tag, its correct introduction into the 
plasmid was confirmed by sequencing. Recombinant bacmids were obtained as described 
previously and successful transposition was confirmed by PCR (Figure 5.7C).  
Recombinant baculoviruses expressing 9aMMD-Avi and 9aMMD-S1-Avi were 
produced as before and protein was expressed and purified as before except that after the 
sonication of cells, BirA ligase, D-biotin (Sigma Aldrich) and additional ATP were added 
the the sample and the cell slurry was rotated for 1h at 40C. Soluble fraction was collected 
by centrifugation and purification followed as previously described. Protein biotinylation 
was confirmed by a western blot with an HRP-conjugated streptavidin (Figure 5.8). 
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Figure 5.7. Cloning and bacmid generation of 9aMMD-Avi and 9aMMD-S1-Avi. 
A: a schematic drawing of the expression cassette of 9aMMD-Avi and 9aMMD-S1-Avi. 
Previously developed 9aMMD and 9aMMD-S1 constructs in the pFBNA vector were used 
as templates for fusion of the Avi-tag. Two antiparallel strands carrying DNA sequence 
encoding an Avi-tag (GLNDIFEAQKIEWHE) and containing sticky ends compatible with 
the NotI restriction site as well as a phosphate group attached to the 5’ end of each strand 
were chemically synthesized (Sigma Aldrich). Equal amounts of each strand were mixed, 
incubated at 950C for 5min followed by slow cooling to allow hybridization of two strands. 
Myo9a plasmids were digested with NotI following general protocols and mixed with a 3-
molar excess of Avi-tag oligos. DNA pieces were ligated by T4 DNA ligase following the 
manufacturer’s protocol (Thermo Scientific) and transformed into E.coli DH5ɑ cells using 
a heat-shock protocol. Plasmid DNA was isolated. The Avi-tag was introduced in frame 
with the N-terminal myo9a fragments and the C-terminal FLAG-tag. B: the presence of 
9aMMD and 9aMMD-S1 regions was confirmed by restriction analysis with BamHI and 
NotI enzymes. Digestion products were analyzed on an 0.6-0.8% agarose gel revealing two 
bands in each sample: one corresponding to the vector backbone (expected size: ~4.8kbp) 
and one corresponding to either 9aMMD-S1 (expected size:  ~3kbp) or 9aMMD (expected 
size: ~2.6kbp), as indicated on the gel presented. Correct introduction of the Avi-tag for 
each construct was confirmed by sequencing. C: E.coli DH10Bac cells were transformed 
with appropriate plasmids and recombinant bacmids were obtained as previously described. 
Successful transposition was confirmed by PCR. Products were analyzed by gel 
electrophoresis, revealing bands of expected sizes (~5.5kbp and ~6kbp for 9aMMD-Avi 
and 9aMMD-S1-Avi, respectively).  
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Figure 5.8. Purification and biotinylation of 9aMMD-Avi and 9aMMD-S1-Avi. A: 
a representative SDS-PAGE gel of purified 9aMMD-Avi and 9aMMD-S1-Avi. The 
purification protocol described before was used. Purified proteins correspond well with the 
expected molecular weights (~120kDa for 9aMMD and ~135kDa for 9aMMD-S1). B: 
samples presented in A were transferred to a nitrocellulose membrane and assayed for the 
presence of biotin by incubation with an HRP-conjugated streptavidin. The negative control 
(-) indicates 9aMMD-Avi preparation in the absence of BirA ligase. Adjacent lanes 
contained 9aMMD-Avi and 9aMMD-S1-Avi biotinylated in the presence of BirA ligase. 
Signal was developed with a commonly accessible ECL kit and confirmed successful 
biotinylation of 9aMMD-Avi and 9aMMD-S1-Avi. 
 
5.4.  Site-specifically immobilized 9aMMD actively transports actin 
Biotinylated 9aMMD-Avi was used in the in vitro motility assay. Biotin-BSA was 
applied to the flow chamber, followed by an addition of streptavidin, 0.2mg/ml biotinylated 
9aMMD and TRITC-actin. Actin filaments were excited in epi-fluorescence and frames 
were acquired every 3min for 10min at 60x optical zoom with 4.2NA Nikon objective and 
Nikon Eclipse Ti microscope. Motility buffer was supplemented with 2mM MgATP, 
100mM KCl and 0.5% methylcellulose. 9aMMD specifically immobilized on the flow cell 
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surface actively translocated actin filaments (Figure 5.9) with all filaments within the image 
plane moving. The mean velocity obtained from 576 filaments was 34.7nm/s. This is the 
first direct evidence that human myosin 9a translocates actin filaments and therefore could 
function as a mechanically active molecular motor in a cell. The velocity is ~160 times 
lower than that of skeletal muscle myosin reported here (5.5μm/s). 
 
Figure 5.9. 9aMMD-Avi specifically attached to the coverslip surface actively 
translocates actin filaments. A: 0.2mg/ml 9aMMD-Avi was immobilized on the coverslip 
surface via a streptavidin-biotin linkage and TRITC-actin was introduced into the flow cell. 
Actin filaments (black) were excited in epi-fluorescence on the Nikon Eclipse Ti 
microscope revealing binding to surface-attached myosin motors (1st frame). Motility was 
initiated with 2mM MgATP in a motility buffer supplemented with 100mM KCl and 0.5% 
methylcellulose at 220C. Subsequent frames were acquired every 3min for 10min and the 
Maximum Intensity Projection (representing the collective pixel intensity from all frames) 
from a representative image plane is shown revealing active translocation of actin 
filaments. B: a velocity distribution plot of 9aMMD-Avi. 576 individual filaments from at 
least three independent myosin preparations were tracked and mean velocity was 34.7nm/s. 
 
Methylcellulose is a viscosity agent that has the ability to compensate for the lack of 
weak actin binding by myosins (Joel et al., 2001). Previous reports on other myosin 9 
isoforms all state that methylcellulose was necessary to maintain actin filaments close 
enough to the surface for the motility to occur (Liao et al., 2010, Elfrink et al., 2014). 
Therefore, initial in vitro motility assays with 9aMMD-Avi were supplemented with 0.5% 
methylcellulose. However, when assayed in the absence of methylcellulose, the motility 
was not affected (Figure 5.10); the average velocity in the absence of methylcellulose (no 
MetCel) was 34.6 ± 4.5nm/s and 37.4 ± 5.9nm/s in the presence of 0.5% methylcellulose 
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(0.5% MetCel) in the motility buffer supplemented with 2mM MgATP and 100mM KCl.  
Therefore, human myosin 9a interacts with actin in a weka actin-binding state and 
methylcellulose is not required for actin translocation by human myosin 9a. All following 
in vitro motility assays of myo9a were performed in the absence of methylcellulose in the 
motility buffer. 
 
Figure 5.10. Methylcellulose is not required for actin translocation by 9aMMD-Avi. 
0.2mg/ml biotinylated 9aMMD-Avi was immobilized on a coverslip via the streptavidin-
biotin linkage. Following binding of TRITC-actin, motility was initiated by flashing in a 
motility buffer supplemented with 2mM MgATP and 100mM KCl at 220C. Translocation 
of filaments was observed in the absence (no MetCel) or presence (0.5% MetCel) of 0.5% 
methylcellulose in the motility buffer. Frames were acquired every 3min for 10min total 
time using 60x zoom, 4.2NA objective (Nikon) and a CCD camera under the Nikon Ti 
Eclipse fluorescent microscope. Three independent flow cells were prepared for each 
condition and bars in (A) represent average velocity ± S.D. The table summarizing the 
average velocities at each condition is shown in (B). The average velocity in the absence of 
methylcellulose was 34.6 ± 4.5nm/s and 37.4 ± 5.9nm/s in the presence of 0.5% 
methylcellulose. Average values were obtained from velocities of 234 and 576 filaments in 
the absence and presence of 0.5% methylcellulose, respectively.  
 
The actin-activated ATPase activity of full length myosin 5 increased in the 
presence of Ca2+ (Wang et al., 2004; Lu et al., 2006), similarly to 9aMMD. Conversly, Ca2+ 
inhibited the motility of myosin 5. Motility was partially restored in the presence of CaM 
(Krementsov et al., 2004). Ca2+ caused dissociation of CaM from the neck domain of 
myosin 5, associated with a conformational change from a folded to an unfolded state 
compatible with binding actin, resulting in an increase in the maximal ATPase. However, 
the lever arm lost its rigidity upon CaM dissociation, causing inhibition of motility (Wang 
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et al., 2004; Krementsov et al., 2004). The putative CaM-binding site of 9aMMD is in the 
loop 2 region and its interactions with CaM could influence the dynamics of the actomyosin 
complex of myosin 9a. I tested the effect of Ca2+ and exogenous CaM on the maximal 
velocity of actin translocation by 9aMMD-Avi in the in vitro motility assay (Figure 5.11). 
Supplementing the motility buffer with 0.1mM Ca2+ or 10μM exogenous CaM (~5-fold 
molar excess of calmodulin to myosin) did not affect the speed of 9aMMD. Therefore, the 
interactions between CaM and loop 2 of hyman myosin 9a do not affect the dynamics of the 
actomyosin complex.  
 
Figure 5.11. The effect of CaCl2 and exogenous calmodulin on the velocity of 
9aMMD-Avi. 0.2mg/ml biotinylated 9aMMD-Avi was immobilized on a coverslip surface 
via the streptavidin-biotin linkage. TRITC-actin was bound and motility was initiated by 
introducing a motility buffer supplemented with 2mM MgATP in the absence (control) and 
presence of 0.1mM Ca2+ or 10μM exogenous CaM at 220C. Motility buffer contained 
50mM KCl. Subsequent frames were collected as before. Three independent flow cells 
were used to collect data for each condition.  Bars in (A) represent average velocities ± S.D 
at each condition. As summarized in (B), average values were 29.4 ± 5.6 in the absence of 
additives (control), 26.9 ± 3.3 in the presence of 0.1mM Ca2+ and 29.1 ± 5.2 in the presence 
of ~5-fold molar excess of CaM from 210, 132 and 300 filaments, respectively.  
 
The dependence of the motility of myosin on ionic strength is related to the affinity 
of myosin to actin in the presence of ATP (Wang et al., 2000). The effect of ionic strength 
on 9aMMD motility was addressed (Figure 5.12). At a constant motor density (0.2mg/ml), 
site-specifically immobilized 9aMMD-Avi bound and supported movement of fluorescent 
actin filaments over a great range of ionic strengths (25 - 500mM KCl) in the absence of 
methylcellulose. An average velocity increased nearly 4-fold in the range from 25 to 
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200mM KCl with the maximum sliding velocity of 65.6 ± 9.8nm/s, followed by the 
decrease in average velocities at higher [KCl] (Figure 5.12A). A decrease in the sliding 
velocity of 9aMMD was associated with the dissociation of filaments from the coverslip 
surface (Figure 5.12B). It was difficult to track filaments above 500mM KCl because of 
strong filament jittering over a relative anchor point and low sliding velocities. Figure 
5.12C presents a table summarizing sliding velocities and fraction of filaments that 
remained bound as a function of [KCl] in a buffer supplemented with 2mM MgATP at 
constant 9aMMD surface densities (0.2mg/ml). 9aMMD bound and propelled actin 
filaments even at 500mM KCl in the absence of methylcellulose. This reflects high affinity 
of human myo9a for binding actin in the presence of ATP and at high ionic strength.  
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  Figure 5.12. The effect of increasing ionic strength on the sliding velocity and 
filament attachment to 9aMMD. 0.2mg/ml biotinylated 9aMMD-Avi was immobilized on a 
coverslip surface via the streptavidin-biotin linkage. TRITC-actin was bound and motility 
was initiated by introducing a motility buffer supplemented with 2mM MgATP and 
indicated [KCl]. Subsequent frames were collected as before. A: the dependence of the 
sliding velocity of actin by 9aMMD on the ionic strength. The average velocity increased 
nearly 4-fold in the range of [KCl] between 25 and 200mM, followed by a sharp decrease. 
B: the dependence of an actin filament binding by 9aMMD on the surface as a function of 
[KCl]. No dissociation of filaments from the myosin-coated surface took place up to 
200mM KCl; at higher [KCl] filaments jittered and started dissociating, resulting in a linear 
decrease of the fraction of filaments bound at increasing [KCl]. Data points represent 
average values ± S.D. from at least three separate flow cells. C: a table summarizing mean 
sliding velocities of actin over the constant surface density of 9aMMD and fractions of 
filaments bound to the myosin-coated surface at increasing [KCl]. 
 
The steady-state ATP affinity of 9aMMD was also assayed in the in vitro motility 
assay by calculating the average sliding velocities of 9aMMD over a range of an increasing 
ATP concentration (Figure 5.13). The sliding velocity increased with an increasing [ATP] 
and data points were fitted to a quadratic equation. The half-maximal velocity was reached 
at KATP = 0.37 ± 0.085mM. The velocity was constant above 0.6mM ATP.   
 
Figure 5.13. The dependence of 9aMMD velocity on ATP concentration. 0.2mg/ml 
biotinylated 9aMMD-Avi was immobilized on a coverslip surface via the streptavidin-
biotin linkage. TRITC-actin was bound and motility was initiated by introducing a motility 
buffer supplemented with 100mM KCl and indicated Mg[ATP]. Subsequent frames were 
collected as before. Data points represent average values ± S.D. from at least three 
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independent flow cells for each [ATP]. Data was fitted to a quadratic equation and the half 
maximal velocity was reached at KATP = 0.37 ± 0.085mM. 
 
5.5.  The neck region of human myosin 9a acts as a lever arm 
It was previously reported that the sliding velocity of the head and head-neck 
constructs of C. elegans myosin 9 was the same, suggesting that the neck domain of myosin 
9 does not act as a lever arm (Liao et al., 2010).  
I investigated the role of the neck domain in the regulation of the sliding velocity of 
human myosin 9a in the in vitro motility assay. Assays with the biotinylated 9aMMD-S1-
Avi (encompassing the minimal motor domain and the neck domain of human myo9a) were 
set up as described above. Initial attempts did not result in translocation of actin filaments 
in the presence of ATP (Figure 5.14). Filaments jittered around an anchor point and 
individual dissociation/rebinding events were observed, but no active transportation of 
filaments took place. 
 
Figure 5.14. Sie-specifically immobilized 9aMMD-S1-Avi does not support actin 
sliding in the absence of exogenous calmodulin. 0.2mg/ml biotinylated 9aMMD-S1-Avi 
was immobilized specifically in the flow cell through attachment to a streptavidin-covered 
coverslip. Unbound motor was removed and free binding sites on the coverslip were 
blocked with BSA. Fluorescent actin filaments (black) were added to the chamber and 
imaged in epifluorescence as before. Motility buffer containing 2mM MgATP and 100mM 
KCl was introduced and frames were acquired every 3min for 10min. 9aMMD-S1-Avi 
bound actin filaments (1st frame; black). Upon addition of ATP no directional translocation 
of actin filaments was observed; instead, filament ends jittered and individual 
dissociation/rebinding events were observed (Max. Int. Projection). Scale bar: 10μm. 
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Given that 9aMMD actively translocated actin filaments, lack of actin transport by 
9aMMD-S1 was surprising. 9aMMD-S1 contains six additional CaM-binding sites, as 
compared to 9aMMD. It is possible that one or more IQ motifs within the neck region of 
9aMMD-S1 are not saturated with CaM. This could lead to a decrease in the rigidity of the 
lever arm and inhibition of power strokes. I attempted to optimize the assay by adding a 5-
fold molar excess of exogenous calmodulin to the motility buffer. Indeed, supplementing 
the motility buffer with 10μM exogenous CaM was required for active translocation of 
actin filaments by site-specifically immobilized 9aMMD-S1-Avi (Figure 5.15). The mean 
sliding velocity of 9aMMD-S1 was 204.4nm/s (n = 232) - almost 6 times greater than that 
of 9aMMD (34.7nm/s). Therefore, the neck domain of human myosin 9a functions as a 
lever arm to increase the step size and sliding velocity of the myosin. Note that the filament 
traces in the Maximum Intensity Projection for 9aMMD-S1 appear longer than for 
9aMMD. Since these were obtained from the same amount of frames for both constructs, it 
is apparent that 9aMMD-S1 slides actin filaments faster than 9aMMD.  
 
Figure 5.15. 9aMMD-S1 site-specifically immobilized on the coverslip surface 
actively translocates fluorescent actin filaments in the presence of the 5-fold molar excess 
of exogenous calmodulin. A: 0.2mg/ml biotinylated 9aMMD-S1-Avi was immobilized 
specifically in the flow cell through attachment to a streptavidin-covered coverslip. 
Unbound motor was removed and free binding sites were blocked with BSA. Fluorescent 
actin filaments (black) were added to the chamber and imaged in epifluorescence as before. 
Motility buffer containing 10μM exogenous calmodulin, 2mM MgATP and 100mM KCl 
was introduced and frames were acquired every 3min for 10min. 9aMMD-S1-Avi bound 
actin filaments (1st frame; black). Upon introduction of the motility buffer, directional 
translocation of actin filaments was observed and is presented as the Maximum Intensity 
Projection of the collective pixel intensity from all frames. Scale bar: 10μm. B: a velocity 
distribution plot of 9aMMD-S1-Avi. Mean velocity was 204.4nm/s. At least three separate 
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flow cells were prepared with 9aMMD-S1-Avi from each of the two independent 
purifications and mean velocity was obtained by tracking 232 filaments.  
 
Given that the neck region of human myo9a binds calmodulin light chains, I 
addressed the effect of Ca2+ on the sliding velocity of 9aMMD-S1 in the presence of 10μM 
exogenous CaM in the motility buffer. Surprisingly, as little as 1μM Ca2+ fully inhibited the 
mechanical activity of 9aMMD-S1. Together with the fact that supplementing the motility 
buffer with the 5-fold molar excess of CaM was required for the translocation of actin by 
9aMMD-S1 in the absence of Ca2+, and that very low [Ca2+] inhibited the motility, at least 
two possibilities could be considered. Firstly, the requirement for an exogenous calmodulin 
in the buffer might indicate that at least a single light chain molecule binds to the neck 
region with low affinity, causing compliance in the molecule and hindering actin 
translocation. In the presence of excess calmodulin, there would be enough light chain in 
the solution to compensate for a weak binding to an IQ motif, providing enough rigidity for 
the neck region for effective power strokes and robust translocation of actin. Secondly, 
Ca2+-loaded CaM could bind an IQ motif (at least one) with a lower affinity, causing the 
dissociation of calmodulin from the IQ motif, once again introducing compliance in the 
neck region. In this situation, maintaining the rigid lever arm could be challenged even in 
the presence of exogenous CaM in the solution.  
To assess the effect of Ca2+ on the association of CaM with 9aMMD-S1, an actin 
spin-down assay was used. ~1μM 9aMMD-S1 was mixed with 10μM phalloidin-stabilized 
F-actin in the absence and presence of an increasing Ca2+ concentration. Since as little as 
1μM Ca2+ inhibited the motility of 9aMMD-S1, I used 1-10μM Ca2+ in the assay. Following 
20min incubation in RT, samples were ultracentrifuged and equal volumes of supernatant 
and pellet were separated on a 4-20% SDS-PAGE gel (Figure 5.16). CaM present in the 
supernatant would represent the light chain fraction that dissociated from 9aMMD-S1, 
whereas that found in the pellet would represent the myosin-associated CaM fraction. 
Unexpectedly, a fraction of calmodulin dissociated from myosin in the absence of Ca2+ 
(EGTA); Ca2+ did not cause any further dissociation of CaM as there was no visible 
difference between the amount of CaM in the supernatant and pellet fractions at increasing 
[Ca2+]. This means either that CaM binds to the neck region of human myosin 9a with such 
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very low affinity that shear forces acting on the sample during a high-speed centrifugation 
are enough to separate the light chain from the heavy chain or that the association of CaM 
with myosin in that particular construct is unstable. Such instability could result from the 
lack of myosin domains stabilizing the interaction between CaM and the heavy chain (for 
example, the N-terminal extension of myosin 9). Alternatively, the neck region of human 
myosin 9a might preferentially bind other types of light chains in a native intracellular 
environment. Currently, the effect of Ca2+ on the motility of 9aMMD-S1 cannot be 
investigated.  
Nevertheless, the requirement for exogenous CaM in the motility buffer suggests 
weak association of calmodulin light chain with at least one IQ motif within the neck of 
human myosin 9a. Furthermore, addition of Ca2+ to the motility buffer weakens the 
association of CaM with the neck region to the point where it cannot be compensated for by 
the addition of extra light chain. 
 
 Figure 5.16. The effect of Ca2+ on the association of CaM with 9aMMD-S1. ~1μM 
9aMMD-S1 was mixed with 10μM phalloidin-stabilized F-actin in the absence (EGTA) and 
presence of 1-10μM Ca2+. Myosin was allowed to bind to actin for 20min at RT and 
supernatant and pellet were obtained at 100000rpm, 20min, 40C. Supernatant was collected 
and pellet was dissolved in equal volume of PBS. Equal volumes of supernatant and pellet 
were mixed with a loading dye and separated on a 4-20% Tris-glycine gel (Bio-Rad) to 
assess the association of CaM with 9aMMD-S1 heavy chain in the absence and presence of 
increasing [Ca2+]. CaM fraction present in the supernatant represent light chain molecules 
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that dissociated from the heavy chain whereas CaM present in pellets remains associated 
with 9aMMD-S1 heavy chain. A representative SDS-PAGE gel from three independent 
runs is shown. [Ca2+] is depicted in the form of pCa below the gel. Positions of 9aMMD-S1, 
actin and CaM on the gel are indicated. In the absence of Ca2+ (EGTA), a fraction of CaM 
was found in the supernatant suggesting that the binding of CaM to the neck region of 
human myosin 9a is so weak that shear forces acting in the tube during an 
ultracentrifugation are enough to separate it from the heavy chain. Alternatively, CaM 
binding might me stabilized by intramolecular interactions provided by the tail domain or 
the N-terminal extension. Further dissociation of CaM upon addition of low micromolar 
[Ca2+] was not observed.  
 
5.6. Processivity of human myosin 9a 
Previously it was shown that rat myo9b and C. elegans myo9 are single-headed 
processive molecular motors. The processivity (the ability to undergo multiple steps on an 
actin filament before dissociation) of a monomeric motor is puzzling; it was suggested that 
the class 9-specific loop 2 insert is the determinant of processivity (Nishikawa et al., 2006, 
Liu et al., 2010, Elfrink et al., 2014).  
As 9aMMD appeared more stable in the motility assays, I used this construct for the 
following experiments. In order to investigate the processivity of human myo9a, I first 
assayed the oligomerization state of 9aMMD in the solution. Hydrodynamic properties of 
9aMMD (Stokes radius and sedimentation coefficient) were determined by the gel filtration 
and a centrifugation in a linear sucrose gradient (Figure 5.17). 9aMMD exists as a single 
conformer in the solution, as indicated by elution in a single peak from a gel filtration 
column and a single fraction from the sucrose density gradient (Figure 5.17A). The 
expected molecular weight of a monomeric 9aMMD is ~120kDa. The behavior of 9aMMD 
in the gel filtration media and the linear sucrose gradient suggests it has similar biophysical 
properties to that of aldolase, indicating it is a globular protein in solution (Figure 5.17B). 
The native molecular weight of 9aMMD calculated from the parameters obtained was 121.8 
± 0.4kDa from three independent experiments, which is in a very good agreement with the 
molecular weight expected for a monomeric 9aMMD with a single calmodulin bound. 
Therefore, 9aMMD is a globular protein and a monomer in solution.  
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To determine if 9aMMD is a single-headed processive molecular motor, the in vitro 
motility assay was performed at decreasing motor surface densities and the velocity of actin 
translocation was measured (Figure 5.18). For a processive myosin, as little as a single 
molecule is enough to propel actin; if 9aMMD is processive, no decrease in the velocity as 
a function of a decreasing motor density should take place (Howard et al., 1989). Flow 
chambers were prepared as before with varying motor concentrations. Knowing the molar 
concentration of 9aMMD-Avi applied to the flow cell and given that the total flow cell 
volume is ~10μl with the surface area of ~72μm2, motor surface densities were calculated. 
All surface densities of 9aMMD assume that all molecules entered the flow cell, none was 
denatured and half adsorbed to each surface of the chamber. 9aMMD supported actin 
translocation even at very low surface densities (~102/μm2). Actin translocation velocities 
did not change over the range of surface densities tested. At lower surface densities 
filaments exhibited nodal pivoting and finally free filament ends swiveled around a single 
attachment point. Filaments moved over a single contact point and when filament end 
reached the tethering point, it diffused away. These are characteristics of processive 
motility. Therefore, a single-headed 9aMMD moves processively on actin.   
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Figure 5.17. 9aMMD is a monomer in solution. A: hydrodynamic properties of 
9aMMD were assessed by gel filtration and sucrose gradient centrifugation. 100μl of 
0.2mg/ml purified 9aMMD was separated on the Superdex 200 10/300 GL column (GE 
Healthcare) calibrated with protein markers as indicated in Figure 3.21. A representative 
UV trace is shown. 9aMMD eluted in a single peak at 11.95ml. The void volume of the 
column V0 = 8ml. The identity of the peak was confirmed by SDS-PAGE. The partition 
coefficient (Kav) of 9aMMD was calculated from the elution and void volume as described 
in Materials and Methods. 100μl of 0.2mg/ml purified 9aMMD was layered on top of a 6-
20% sucrose gradient and centrifuged 37000rpm, 18h, 40C. Fractions were collected and 
analyzed by SDS-PAGE. 9aMMD eluted as a single species in the 10th fraction. B: lnRs and 
sedimentation coefficient of 9aMMD were determined by an intrapolation of 9aMMD Kav 
and elution fraction obtained from gel filtration and sucrose gradients to standard curves. In 
both cases, 9aMMD elutes slightly faster than aldolase (158kDa), suggesting it is a 
monomer in solution. C: calculation of the native molecular weight of 9aMMD in solution 
gives 121.8 ± 0.4kDa (n = 3) which is in a very good agreement with the expected 
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molecular weight of 119.1kDa for a single heavy chain with one CaM molecule bound. 
Therefore, 9aMMD is a monomer in solution.  
 
     
  
Figure 5.18. 9aMMD exhibits properties of a processive molecular motor. A plot 
shows 9aMMD velocity (nm/s) as a function of the surface motor density (μm-2). The table 
summarizes velocities at decreasing motor densities. Indicated motor densities of 
biotinylated 9aMMD-Avi were deposited on a streptavidin-covered coverslip and motility 
was initiated and traced as before. Sliding velocities of actin filaments were quantified and 
data points represent average velocities ± S.D. Three independent flow cells were prepared 
for each myosin density. The number of filaments tracked for each motor density is 
indicated in the table.  
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CHAPTER 6: DISCUSSION 
 
 
 
Based on the primary protein sequence similarity of the motor domains, the myosin 
superfamily is composed of 35 classes and 149 sequences that cannot be assigned to any of 
the classes (Odronitz and Kollmar, 2007). Myosins exhibit the same structural organization, 
in that they are composed of a globular N-terminal head that can progress through the 
mechanochemical cycle, a regulatory neck domain that serves to amplify the step size, and 
a C-terminal tail domain with highly divergent functional domains. However, considerable 
differences in rate constants of the enzymatic cycle steps, actin affinity and rates of motility 
exist even when one considers myosins assigned to a single class. Additionally, some 
myosins are processive, high duty ratio motors, whereas others undergo only one step on 
actin before dissociating. For example, human myosin 5c was suggested to spend most of 
its ATPase cycle in a weak actin-binding form and did not exhibit processive movement on 
actin (Watanabe et al., 2008), as opposed to highly processive myosin 5a which exhibits 
high duty ratio properties (De La Cruz, 1999; Moore et al., 2001). Taken together, myosin 
motors have their enzymatic properties tailored to suit their cellular tasks, specified by the 
versatile tail domains (De La Cruz and Ostap, 2004; Sellers, 1999). 
Due to the presence of a RhoGAP domain in the tail, the physiological role of 
myosin 9 is highly unique within the superfamily. It was proposed before that myosin 9 
regulates the architecture of actin filaments it moves along (Bähler, 2000). This poses an 
intriguing possibility that myosin 9 is a motorized signaling molecule. However, how 
myosin 9’s mechanochemical performance is coupled to its signaling role is unknown. In 
order to tackle that problem, one first needs to characterize its in vitro biochemical 
properties. Here, I showed that a previously uncharacterized protein, human myosin 9a, 
exhibits features of a myosin: i) it binds actin, ii) it hydrolyzes ATP, iii) it undergos ATP-
dependent motility.  
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6.1.  Cloning, expression and purification of enzymatically active human 
myosin 9a 
Previous attempts to obtain recombinant myosin 9a have not been successful, with 
many of them fruitless at the level of gene amplification (personal communication with Dr. 
N Billington, NIH and Dr. C Batters, LMU). Here, I cloned strategic protein fragments and 
produced recombinant baculoviruses for protein expression in the baculovirus/insect cell 
system. The main advantage of that expression system over a bacterial system is that it 
provides eukaryotic capabilities of the protein translation and post-translational 
modifications machinery (Busconi and Michel, 1995). It therefore is a system of choice for 
expression of myosin motors.  
I successfully cloned human myosin 9a truncations and created recombinant 
bacmids with the Bac-to-Bac system (Invitrogen). Bacmids were generated in genetically 
engineered E.coli cells that support an efficient site-specific transposition of a gene of 
interest from the donor pFastBac plasmid into a shuttle bacmid vector. All bacmids 
generated with that system contained the appropriate myosin 9a fragments. SF9 cells 
transfected with bacmid DNA showed signs of virus production – increased cell diameter, 
inhibited cell growth and eventually cell lysis.  
The sequence borders of the strategic regions of human myosin 9a were assigned 
based on sequence alignments with Dictyostelium myosin 2 (Figure 3.3). It is known that 
the minimal sequence requirement for an enzymatically active motor of Dictyostelium 
myosin 2 contains amino acid residues E89-I759 (personal communication with Dr. J 
Sellers, NHLBI, NIH; Kuhlman and Bagshaw, 1998; Woodward et al., 1995). Therefore, 
the minimal motor domain of human myosin 9a is expected to be composed of D149-
H1016. Amino acid residues upstream of D149 were assigned to be the class-specific N-
terminal extension. The neck region in Dictyostelium myosin 2 contains only 2 IQ motifs, 
and finishes at W808. Additional 3 putative light chain-binding sites, as compared to 
Dictyostelium myosin 2, extend the neck domain of human myosin 9a. Based on the 
localization of the IQ motifs following the motor domain of human myosin 9a, its neck 
domain finishes with F1152. The remaining sequence was assumed to form a C-terminal 
tail. Thus, individual human myosin 9a fragments were designed to encompass the strategic 
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residues; the first 1019 and 1162aa encompass the full head or head-neck regions of 9a-
Head and 9a-S1, respectively. The minimal motor domain constructs start with D149 and 
finish with V1019 and E1162 for proteins without and with the neck domain. It has been 
established that the light chain-binding region of myosin is not required for the normal 
ATPase activity, but amplifies the motility rate (Kurzawa et al., 1997; Woodward et al., 
1995; Kuhlman and Bagshaw, 1998; Waller et al., 1995). Therefore, it was expected that 
human myosin 9a constructs truncated at V1019 should exhibit normal ATPase properties 
of the intact molecule. The goal of adding the light chain-binding domain (constructs 
truncated at E1162) was to investigate its effect on the motility rate of myosin 9a.  
Protein expression was assessed based on the presence of a protein band on SDS-
PAGE gels corresponding to an appropriate molecular weight in cell lysates after virus 
amplification. This was followed by initial purification trails of GFP-9a-Head and GFP-9a-
S1 by means of a His-tag affinity chromatography. The fluorescent tag provided means for 
quick analysis of protein solubility and binding to the resin. Protein yields obtained by the 
His-tag affinity purification were low, and many by-products were present in the eluates. 
Based on the visual inspection, lots of protein was in an insoluble form. In order to improve 
the solubility, 1% Sarkosyl was used to disrupt protein aggregates. Indeed, when purified 
on the HisTrap affinity chromatography after Sarkosyl extraction, I obtained highly pure 
fractions of human myosin 9a motor constructs. Unfortunately, the protein did not show 
any activity in the in vitro motility assay and did not hydrolyze ATP as assessed by the 
NADH-linked ATPase assay. Supposedly, the use of Sarkosyl resulted in the loss of the 
enzymatic activity by myosin 9a. Therefore, means of obtaining highly pure proteins under 
native conditions had to be established. 
In order to achieve more specific capture of the protein on the resin, I added a C-
terminal FLAG tag to non-fluorescent or GFP-tagged 9a-Head and 9a-S1 constructs. I 
chose to continue with the fluorescent variants at this stage to be able to quickly assess 
protein amount in the soluble fraction. Additionally, a GFP-tag served as a marker for 
assessing cell disruption by sonication. Beforehand, cells expressing GFP were clearly 
distinguished in the fluorescent microscope. Following the sonication, no intact cells were 
seen in the field of view. Simultaneously, the time-dependence of the total amount of 
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expressed protein was assessed by SDS-PAGE analysis of whole cell lysates 24, 48, 60 and 
72h post-infection with myosin 9a virus. The maximum amount of protein expressed was 
achieved at the 48h time point, and no further increase in the yield was observed with time. 
Therefore, 48h expression time was chosen as the most optimal. The presence of the protein 
in the soluble fraction was directly proved by an anti-FLAG western blot. GFP-9a-S1 
contains 7 putative CaM-binding sites (one in the class-specific loop 2 insert and 6 in the 
neck domain) and therefore its level of expression was suspected to be dependent on the 
amount of CaM present in cells. Indeed, when expressed with varying amounts of CaM 
virus, the yield of GFP-9a-S1 in the eluate varied greatly. Taken together, performing the 
analysis of time-dependent protein expression and CaM coexpression on the protein yield 
turned ut essential for establishing a successful expression protocol for obtaining highest 
yields of myosin 9a possible. Simultaneously, capture of the protein on the FLAG resin 
resulted in much more pure protein preps and yields compared to the His column. It is 
worth mentioning that the amount of the FLAG resin (1ml) used was 5 times lower than the 
volume of the His column (5ml) and could contribute to the purification results. 
Nevertheless, protein samples obtained from the FLAG-tag affinity purification contained 3 
proteins as characterized by SDS-PAGE: ~160 kDa which matched the molecular weight 
expected for the heavy chain of GFP-9a-S1, ~18 kDa which matched the expected CaM 
MW and ~100 kDa which corresponded to an uncharacterized by-product of the FLAG 
affinity. Given the relative amounts of the proteins present in the FLAG eluate, it was 
necessary to remove the ~100 kDa purification by-product. Since the sample was stable in 
100mM NaCl buffer (no visual precipitation occurred), it was applied to an ion exchange 
resin. Elution with an increasing ionic strength resulted in the separation of myosin 9a from 
the nonspecific by-product. The same purification protocol was successfully employed for 
the purification of GFP-9a-Head and the Minimal Motor Domain constructs. Therefore, a 
two-step purification procedure involving the FLAG-tag affinity chromatography followed 
by ion exchange was established as a general method for obtaining homogenous human 
myosin 9a preps. The established protocol resulted in ~0.6mg pure myosin 9a fractions 
from 1 x 109 cells. The yields obtained were enough to investigate the mechanical, actin-
binding and enzymatic properties of the human myosin 9a motor.  
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Human myosin 9a constructs containing the full head domain hydrolyzed ATP but 
the basal ATPase rate was not stimulated by actin (discussed in the following section). I 
considered the possibility that the N-terminal extension of human myosin 9a might affect 
its intrinsic ATPase properties. In order to investigate it, constructs containing the minimal 
motor domain (9aMMD and 9aMMD-S1) were developed. Given that the expression 
procedure developed for GFP-9a-S1 was successful, I no longer needed a fluorescent 
marker on the minimal motor domain constructs. Furthermore, an expression of GFP alone 
might happen with fluorescently tagged proteins, unnecessarily engaging the host 
translational machinery in translation of an off-target protein. Nonetheless, the yields of the 
minimal motor domain constructs were comparable to those containing the full head region 
of myosin 9a.  
Since there was no significant difference between the ATPase properties of the full 
head and the minimal motor domain constructs, most of the following experiments focused 
on the minimal motor domain proteins.  
There are 7 putative light chain-binding sites in the S1 region of human myosin 9a – 
one in the loop 2 insert and 6 in the neck domain. All of them belong to the family of IQ 
motifs, which are most often occupied by calmodulin light chains (Atcheson et al., 2011). 
In order to establish if all putative CaM-binding sites in 9a-S1 bind CaM, I quantified the 
number of CaM molecules bound to 9aMMD and 9aMMD-S1. 9aMMD bound a single 
CaM light chain, whereas 9aMMD-S1 bound 6. Therefore one IQ motif in 9a-S1 is 
expected to be unoccupied by CaM. It is possible that one of the IQ motifs in the neck 
region does not bind CaM. This could be caused by: i) the transient nature of the interaction 
between CaM and an unoccupied IQ motif in the neck, ii) a complete lack of binding of 
CaM to an IQ motifs, iii) a requirement for a different light chain. It has been shown before 
that C.elegans myosin 9, which contains 5 putative CaM-binding sites, binds only 4 CaM 
molecules. One of the IQ motifs in the neck region had a conserved glycine in a consensus 
sequence IQXXXRGXXXR substituted for lysine (Liao et al., 2010). Substitution at this 
position could hinder binding of CaM in a compact conformation, leading to a complete 
loss of CaM binding (Terrak et al., 2005). Indeed, the 5th IQ motif in the neck domain of 
  151 
human myosin 9a also has glycine substituted for lysine. Therefore it is possible that this 
particular IQ motif is unoccupied by CaM in human myosin 9a S1.  
Proteins were used fresh within two days after the purification and thus the stability 
of the preps within that time period was established for the minimal motor domain 
constructs. Assuming that protein degradation within 48h could lead to loss of the 
enzymatic and mechanical activity, Dynamic Light Scattering was used to assess time-
dependent changes in the molecular composition of the samples. In principle, the system 
measures the diameter of the protein species present in the sample, assuming that the 
diameter of each molecule corresponds to a minimal sphere that could be drawn around the 
molecule. Diameters measured for 9aMMD and 9aMMD-S1 were ~8 and 11nm, 
respectively. 8nm diameter for 9aMMD is in good agreement with what is expected for a 
single globular myosin head (Morel et al., 1992). If one assumes the the neck domain of a 
myosin forms a rigid α-helical rod extending from the head domain, the measured diameter 
of 9aMMD-S1 seems a bit small as compared to 9aMMD. It was suggested previously that 
each CaM-occupied IQ motif in the neck region of an unconventional myosin has ~3.6nm 
in length (Tominaga et al., 2012). Assuming that only 5 IQ motifs in the neck region of 
9aMMD-S1 are occupied by CaM, this would result in ~18nm long neck. If the neck of 
9aMMD-S1 is rigid and extended, the diameter measured by DLS should be much higher 
than 11nm. It is possible, however, that the neck of 9aMMD-S1 is wrapped around the head 
domain. Such structural orientation of the neck domain of 9aMMD-S1 is in great agreement 
with the fact that there was no electron density corresponding to an extended α-helix in the 
electron micrographs of 9aMMD-S1. Why the neck domain remained wrapped around the 
head domain in 9aMMD-S1 is not known, but it is possible that the neck domain was not 
saturated with CaM light chain molecules, as suggested above. This could result in the loss 
of the rigidity of the neck region of the myosin (Lin et al., 2005; East and Mulvihill, 2011). 
IQ motifs are hydrophobic in nature and if unoccupied by a light chain could form 
interactions with other areas of the protein.  
Initial attemps at expressing the full length human myosin 9a protein proved 
fruitless. Despite the successful bacmid and baculovirus generation, there was no protein 
present in whole cell lysates, as assessed by SDS-PAGE and a western blot. It is possible 
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that the expression of that protein is too challenging for the host insect cells. It could be 
tackled by varying the amount of the baculovirus used for cell infection or by codon-
optimization of the template DNA.  
 
6.2. Oligomerization state of human myosin 9a 
Based on the sequence analysis of full length human myosin 9a, there are two 
putative coiled-coil regions in its tail domain. This is in great contrast to human myosin 9b 
and its orthologs, which do not contain any putative coiled-coil regions. It was proposed 
before that myosin 9 functions as a single-headed processive motor on actin (Inoue et al., 
2002; Nishikawa et al., 2006; Liao et al., 2010). The presence of putative coiled-coils in the 
tail domain of human myosin 9a was suprising, and could suggest that this motor forms 
dimers under appropriate conditions in the cellular environment.  
The tail fragments encompassing the putative coiled-coil regions of human myosin 
9a were expressed in a bacterial host and purified to homogeneity by means of the His-tag 
affinity chromatography. The propensity to dimerize was tested under varying ionic 
strength conditions by a combination of gel filtration and sucrose density gradient 
centrifugation. Higher ionic strength can lead to higher helicity of isolated protein 
fragments and therefore increase the propensity to dimerize (Mateja et al., 2006). Indeed, 
the tail fragment encompassing the first putative coiled coil region of human myosin 9a 
dimerized at higher ionic strength, as evident in two times higher native molecular weight 
than at lower ionic strength (Figure 3.23).  
The Paircoil2 analysis of protein sequences automatically assigns individual 
residues within a putative coiled-coil sequence to their positions within the heptad repeat 
(McDonnell et al., 2006). Residues at positions ‘a’ and ‘d’ of the heptad repeat are 
predicted to be apolar and in a native molecule face the hydrophobic core of the coiled-coil 
(Burkhard et al., 2001). The sequence of the putative coiled coil of myosin 9a with the 
assignment to the position within the heptad repeat is shown in Figure 3.20. Closer 
examination of the primary sequence of that putative coiled-coil reveals the majority of the 
amino acids within it are polar and charged, with only four hydrophobic residues present at 
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the strategic ‘a’ and ‘d’ positions out of the total of 9 assigned strategic hydrophobic 
positions. The remaining 5 ‘a’ and ‘d’ positions are occupied by charged or polar amino 
acids, such as K, E, R (charged), Q and T (polar). The occupancy of ‘a’ and ‘d’ positions by 
hydrophobic residues is the main factor contributing to the stability of coiled-coil 
(Wagschal et al., 1999; Tripet et al., 2000), suggesting that in a native protein no coiled-
coils would be formed by that sequence. On the other hand, the majority of ‘e’ and ‘g’ 
residues within the myosin 9a putative coiled-coil are charged, able to form interchain salt 
bridges and electrostatic interactions that could increase the stability of the coiled-coil. 
Similarly, mainly charged and polar residues occupy the ‘b’, ‘c’, and ‘f’ positions in the 
myosin 9a sequence. Residues at those positions are surface-exposed in native coiled-coils 
(Burkhard et al., 2001). Based on the data presented in this work, the helicity of the putative 
myosin 9a coiled-coil sequence, and therefore the propensity to form a coiled-coil, is 
affected by the buffer composition. A potential mechanism regulating the helicity of that 
region in a native molecule could also contribute to the stability of the coiled-coil.  
Many myosin motors contain putative coiled-coil sequences but not all of them are 
involved in the dimerization of heavy chains. For example, a proximal (N-terminal) part of 
the myosin 10 tail was predicted to form a coiled-coil based on the primary sequence. Yet, 
closer investigation revealed that this region forms a single α-helix that served to extend the 
step size of the myosin (Knight et al., 2005). On the other hand, the putative coiled-coil 
sequence of myosin 6 is composed of ~150aa, yet the protein does not dimerize on its own 
and requires binding partners to regulate its dimerization (Park et al., 2006; Phichith et al., 
2009). In comparison, both myosin 2 and myosin 5 form stable dimers (Syamaladevi et al., 
2012). 
In order to investigate the propensity of the native human myosin 9a to dimerize, 
longer myosin 9a fragments, containing the putative coiled-coil region need to be expressed 
and purified. It would be interesting to investigate the effect of dimer formation on the 
mechanochemical activity and the cellular function of human myosin 9a.  
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6.3. Steady-state ATPase activity of human myosin 9a 
The reported maximum ATPase rates of myosin 2 S1 can vary by an order of 10, 
from 7.8 s-1 (Webb and Corrie, 2001) to 29 s-1 (Trentham et al., 1976). Such differences 
might arise from different buffer agents used, different temperature at which experiments 
were performed or the type of muscle used for the preparation of muscle myosin S1. 
Nevertheless, the ATPase rate of muscle myosin S1 was stimulated ~100 times (from 0.06 
to 7.5 s-1) with half maximal activation at 15μM F-actin, which is in good agreement with 
reported values. Thus, the buffer composition and actin preparation are compatible with an 
intrinsic ATPase activity of a myosin.  
The basal ATPase rates of myosin 9 isoforms differ significantly between ~0.1-2.5 
s-1 (Liao et al., 2010; Struchholz et al., 2008). Similarly, some authors report actin-activated 
ATPase activities of myosin 9 (Nalavadi et al., 2005), whereas others show that the 
enzymatic activity of myosin 9 is very poorly (~2 times) activated by actin (Kambara and 
Ikebe, 2005; Struchholz et al., 2008; Liao et al., 2010). 
Human myosin 9a truncations, involving the full head or the minimal motor, either 
with or without the neck domain, all hydrolyzed ATP in the absence of actin at similar rates 
0.12-0.18 s-1. Such relatively high basal rate of ATP hydrolysis is unique among the myosin 
superfamily members. However, the basal ATPase rates of human myosin 9a truncations 
are in good agreement with the values reported for full length rat myosin 9b with and 
without the N-terminal extension (Nalavadi et al., 2005). This suggests that neither the tail 
nor the N-terminal extension participate in the regulation of the basal ATPase activity of 
myosin 9.  
Liao et al., reported that in the absence of Ca2+, the catalytic activity of the head 
domain of C.elegans myosin 9 was stimulated ~5 times by actin, whereas the actin 
activation of the head-neck construct was negligible (Liao et al., 2010). This would suggest 
that the neck domain negatively regulates the ATPase activity of myosin 9. However, this is 
in great contrast to the previously established lack of the ATPase regulation by the neck 
region (Kurzawa et al., 1997; Woodward et al., 1995; Kuhlman and Bagshaw, 1998; Waller 
et al., 1995) and to my results on human myosin 9a. It is possible that the neck domain of 
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the construct used by Liao et al. folds back onto the head domain, as observed in EM 
images of human myosin 9a S1. The conformation of the molecule in such state could 
hinder binding of myosin to actin, which would explain the discrepancy between the 
observed actin-activated ATPase activity of two C. elegans myosin 9 constructs. 
Nevertheless, the activity of human myosin 9a truncations with or without the neck domain 
was stimulated by actin, which suggests that the neck of human myosin 9a does not regulate 
the actin-activated ATPase activity of human myosin 9a, in agreement with previously 
reported data (Kurzawa et al., 1997; Woodward et al., 1995; Kuhlman and Bagshaw, 1998; 
Waller et al., 1995).  
Actin did not stimulate the basal ATPase rate of human myosin 9a in the absence of 
Ca2+, in great contrast to full length rat myosin 9b which was stimulated 10-20 times 
(Nalavadi et al., 2005). This might suggest that the tail region participates in the regulation 
of the actin-activated ATPase activity of myosin 9. It is worth mentioning that Nalavadi et 
al. performed their experiments at 370C (as opposed to 220C in this study) in MOPS-
HEPES buffer and the extent of actin activation was dependent on the concentration of 
MOPS and HEPES in their buffers. On the other hand, the head domain of C. elegans 
myosin 9 was stimulated ~5 times in the absence of Ca2+ (Liao et al., 2010), suggesting that 
the motor domain of myosin 9 is enough for an actin-activation of the basal ATPase rate.  
Neither the basal nor the actin-activated ATPase rate of human myosin 9a were 
dependent on ionic strength of the buffer, presence of exogenous calmodulin or phalloidin-
stabilization of F-actin. This suggests that the lack of the increase in the maximal ATPase 
rate as compared to the basal rate lies within the sequence or structural organization of 
human myosin 9a.  
The lack of actin-activation of the basal ATPase rate of human myosin 9a was 
suprising, especially since the protein clearly was enzymatically active. Amino acid 
substitutions in conserved regions of the active site elements could contribute to the lack of 
actin-activation of the ATPase rate of human myosin 9a. Both switch 1 (consensus 
sequence: NXNSSRFGK) and switch 2 (consensus sequence: DIXGFE) are conserved in 
human myosin 9a (switch 1 sequence: NNNSSRFGK, switch 2 sequence: DIFGFE). The P-
loop (conserved sequence: GESGAGKT) is involved in the coordination of ATP in the 
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active site and participates in the cleavage of γ-phosphate. The conserved A is substituted 
for S in human myosin 9a as well as rat myosin 9b and C. elegans myosin 9. However, 
considering structural similarities of those two amino acids, it seems unlikely that this 
amino acid substitution could be responsible for the lack of actin-activation of human 
myosin 9a.  
Other structural elements within the myosin molecule have also been suggested to 
participate in the actin activation of the ATPase rate of myosins. For example, a TEDS site 
within the CM loop contains one of the indicated amino acids at the position corresponding 
to D403 in D. discoideum myosin 2 (Kollmar, 2002). The enzymatic activity of myosin 
motors with T or S at this position is subject to regulation by phosphorylation, whereas E or 
D are present in constitutively active myosin motors. A position corresponding to D. 
discoideum D403 is occupied by E480 in human myosin 9a sequence, suggesting that the 
enzymatic activity of those myosins is not regulated by phosphorylation at this site. Right 
upstream of the CM loop is conserved R397 (in D. discoideum sequence) that is essential 
for actin-activation of the ATPase (Sasaki et al., 1999). Positively charged K474 in human 
myosin 9a occupies that position. Finally, a recently characterized activation loop (Várkuti 
et al., 2012) contains a conserved positively charged residue at position corresponding to 
R520 in D. dictiostelium sequence. That position is occupied by K601 in human myosin 9a. 
Taken together, the analysis of the primary sequence of human myosin 9a predicts it is a 
constitutively active, actin-activated molecular motor, and does not suggest any reason for 
the lack of actin activation.  
The mechanism of the activation of the ATPase rate of myosin by actin involves 
acceleration of the hydrolysis product release rate upon strong binding to actin. This 
ensures that force production occurs in an actin-bound state of myosin and limits futile 
kinetic pathways (Holmes et al., 2003). The rate of the ATPase rate observed in the NADH-
linked assay is directly associated with the rate of ADP release by myosin. The lack of 
increase in the ATPase rate as observed in the assay suggests there is no increase in the rate 
of ADP release by human myosin 9a as compared to its basal rate. This suggests that 
human myosin 9a might not bind actin in the presence of ATP or that it is unable to 
undergo a transition from a weakly-bound to a strongly-bound state. Steady-state actin 
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cosedimentation assays clearly showed that human myosin 9a binds actin in the presence of 
nucleotides, therefore excluding the former possibility. However, it cannot be excluded that 
the latter mechanism contributes to the lack of actin activation of the ATPase rate of human 
myosin 9a in the absence of Ca2+. Fluorescence anisotropy experiments with pyrene-actin 
would need to be performed to investigate strong actin binding of myosin 9a in the presence 
of the nucleotide.  
Finally, the loop 2 of myosin 9 is greatly extended as compared to other myosin 
superfamily members, and was suggested to bind calmodulin (Liao et al., 2010). The N-
terminal part of loop 2 of human myosin 9a also contains a CaM-binding site. The head of 
human myosin 9a copurifies with calmodulin, and based on sequence similarities with other 
myosin 9 members this specific IQ motif in loop 2 is expected to be the CaM-binding site 
in the head. Loop 2 is the primary actin interaction site in myosin and participates both in 
weak and strong interactions (Lorenz and Holmes, 2010; Behrmann et al., 2012). It is 
plausible that the head-bound CaM regulates human myosin 9a interactions with actin in a 
Ca2+-dependent manner. In line with that, supplementing ATPase reactions with Ca2+ led to 
nearly 4-fold activation of the basal ATPase rate of the motor domain by actin. The 
regulation of the actin interaction could occur by one of the two mechanisms: i) Ca2+-
induced CaM dissociation from the head or ii) Ca2+-induced conformational change of CaM 
that would stabilize a specific loop 2 conformation, compatible with the acceleration of the 
ADP release rate. It was shown that as high as 1mM Ca2+ does not lead to the dissociation 
of CaM from the motor domain, thus leaving only the 2nd option as a valid mechanism of 
regulation. Ca2+ did not affect the steady-state binding of the myosin 9a motor to actin in 
the presence of ATP. Fluorescence anisotropy experiments would need to be performed in 
order to investigate the effect of Ca2+ on strong actin binding by human myosin 9a. It would 
also be interesting to analyse the interactions between CaM and the loop 2 insert. Ca2+ 
binding to CaM might regulate the affinity of CaM binding to its target site. This in turn 
could affect the helicity of the target site and result in conformational rearrangements of the 
neighbouring region (Bähler and Rhoads, 2002). A specific conformation of loop 2 has 
been proposed before as a contributing factor to strong actin binding by myosin (Lorenz 
and Holmes, 2010).  
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The Ca2+-mediated actin-activation of the motor domain of human myosin 9a is in 
great contrast to Ca2+-induced inhibition of actin activation of the C. elegans myosin 9 
motor (Liao et al., 2010). The CaM-binding site in the loop 2 insert is conserved within 
myosin class 9 and belongs to the family of 1-8-14 CaM-binding motifs, characterized by 
the presence of hydrophobic residues at positions 1, 8 and 14 of the motif. Both C. elegans 
myosin 9 and human myosin 9a contain W, F and F and corresponding positions. 
Therefore, sequence differences do not underlie the observed differences in the effect of 
Ca2+ on the actin-activated ATPase activity of those myosins. It is plausible that specific 
interaction mechanisms between CaM and the loop 2 insert of those two myosins 
constribute to observed differences in ATPase activities.  
 
6.4. Human myosin 9a interactions with actin 
It was suggested before that the myosin 9 class-specific insert in loop 2 acts as an 
additional actin-binding site, enabling crosslinking of actin filaments by myosin 9 
(Reinhard et al., 1995; Post et al., 2002; Inoue et al., 2002; Struchholz et al., 2009). The 
isolated loop 2 of rat myosin 9b was shown to bind actin with high affinity and was 
proposed to remain bound to actin even in the presence of ATP (Nalavadi et al., 2005; 
Struchholz et al., 2009).  
The ability of human myosin 9a to cross-link F-actin was tested indirectly by low-
speed actin sedimentation assays and directly by electron microscopy. Actin was mixed 
with an increasing amount of myosin and subjected to low-speed centrifugation. Under 
these conditions, individual actin filaments remain in the solution. Increasing amount of 
myosin caused sedimentation of actin filaments, suggesting they are being crosslinked by 
myosin. The native molecular weight of bundled filaments is sufficient to drive their 
sedimentation. Negatively stained images of the minimal motor domain of human myosin 
9a with phalloidin-stabilized F-actin confirmed that myosin 9a crosslinks actin filaments. 
Upon incubation of 9aMMD with F-actin, two or more filaments were crosslinked by 
regularly interspaced molecules. Actin filaments in the bundles appeared stiffer and more 
rigid than individual actin filaments. The molecules dissociated in the presence of ATP, 
leaving undecorated actin filaments. That confirms that catalytically active motor heads 
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caused actin cross-linking. Actin crosslinking by myosin 9a also directly demonstrates that 
myosin isoform is able to interact with actin, and that actin binding by myosin 9a is ATP-
dependent.  
Actin crosslinking by myosin was previously shown for Acanthamoeba myosin 1 
(Fujisaki et al., 1985), brush border myosin 1 (Coluccio and Bretscher, 1987), liver myosin 
1 isoforms (Coluccio and Conaty, 1993; Stafford et al., 2005) and was accounted for by the 
presence of an additional actin-binding site in the tail of those monomeric myosins 
(Hammer et al., 1991). 9aMMD is also monomeric in solution, as confirmed by negatively 
stained EM images and native molecular weight measurements performed by a combination 
of gel filtration and sucrose density gradients. That construct was enough to crosslink F-
actin. Together with the fact that 9aMMD exists as a monomer in solution, it indicates that 
the second actin-binding site of human myosin 9a is localized within 149-1019aa of the 
protein. Based on previous reports, the loop 2 insert is the predicted second actin-binding 
site of human myosin 9a; nevertheless, studies with an isolated human myosin 9a loop 2 
and with myosin 9a mutants lacking the insert would need to be performed to unequovically 
confirm the role of the insert in cross-linking actin filaments. 
Crosslinking of actin filaments increases stiffness of organized actin structures and 
is responsible for tension generation in cells. Spatiotemporal regulation of such structural 
rearrangements is necessary for cell migration, division and morphology (Esue et al., 2009; 
Stafford et al., 2005). In line with that, depletion of myosin 9a caused defects in the 
stabilization of protrusive actin structures essential for maintenance of cell-cell junctions, 
ultimately hindering collective cell migration in human bronchial epithelium (16HBE) cells 
(Omelchenko and Hall, 2012).  
The binding affinity of myosin 9a to actin was measured in actin cosedimentation 
assays. In nucleotide-depleted conditions that enable formation of rigor complexes of actin 
and myosin, all myosin bound to actin with high affinity (Kd = 425nM). Full depletion of a 
nucleotide was achieved by addition of EDTA that sequesters Mg2+, and apyrase that 
cleaves nucleotides. In the presence of ADP and ATP, the amount of myosin that bound to 
actin decreased to ~70 and ~60%, respectively. The binding affinity in the presence of ADP 
was slightly smaller than in rigor, wherease the presence of ATP caused ~2-fold decrease in 
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the affinity as compared to rigor conditions. A fraction of myosin 9a pelleted on its own in 
the presence of a nucleotide, raising a possibility that a decrease in the maximum amount of 
myosin bound to actin under those conditions might result from myosin denaturation or 
aggregation. However, when unbound myosin fraction was remixed with actin, part of it 
associated with filaments. Therefore, human myosin 9a exists in two subpopulations – one 
compatible and one incompatible with binding actin. These two subpopulations exist in 
dynamic equilibrium and interconvert on a timescale of the experiment. The fraction of 
human myosin 9a that binds to actin in a weak binding state exhibits a relatively high 
binding affinity (Kd = 810nM in the presence of ATP).  The extended loop 2, which is 
positively charged, could be responsible for tethering myosin to actin in the presence of 
ATP. Similar behavior was previously described for other myosin 9 isoforms (Nalavadi et 
al., 2005; Struchholz et al., 2009).  
The high affinity actin binding of human myosin 9a in a weakly bound state clearly 
suggests that the lack of an actin-activated ATPase activity does not result from the lack of 
myosin binding to actin in the presence of nucleotides, as discussed above. This further 
supports the idea that the only possibility why myosin 9a is not activated by actin is 
abnormal 50kDa cleft dynamics. The opening and closing of the cleft, related to the 
transition between strongly and weakly bound states, could be affected by a specific spatial 
arrangement of loop 2, a nucleotide present in the active site and/or strain.  
Presence of Ca2+ resulted in actin activation of the ATPase of myosin 9a, therefore 
suggesting normal cleft dynamics are Ca2+-dependent. As proposed before, such 
mechanism could involve binding of Ca2+ to loop 2-bound CaM, ultimately causing it to 
adopt a specific spatial arrangement, compatible with closing of the cleft and formation of a 
strongly bound myosin state. Addition of Ca2+ to cosedimentation assays did not influence 
the affinity of binding in the presence of ATP under steady-state conditions. The exact 
mechanism of the transition between weakly and strongly bound actin states in the presence 
of nucleotides remains to be investigated.  
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6.5.  Mechanical properties of human myosin 9a 
Based on sequence analysis of human myosin 9a and previous reports regarding the 
mechanical activity of other myosin 9 isoforms (Post et al., 2002; Liao et al., 2010; Inoue et 
al., 2002), human myosin 9a was expected to exhibit mechanical activity and translocate 
fluorescent actin filaments in the in vitro motility assay. Assay conditions used in this work 
were compatible with robust translocation of actin filaments by rabbit skeletal muscle 
HMM. The velocities obtained by me were comparable to reported values. Therefore, the 
assay conditions should support motility of myosin 9a, provided it is a mechanically active 
motor.   
When immobilized nonspecifically on a nitrocellulose-covered coverslip, all myosin 
9a constructs released and reattached to actin filaments. Therefore, myosin 9a is able to 
undergo ATPase cycles when deposited on the flow chamber surface. However, none of the 
constructs used translocated actin filaments. This could be due to intrinsic inability of 
myosin 9a to move on actin; alternatively, the conformation of myosin on the nitrocellulose 
surface inhibits mechanical activity of myosin 9a. In order to tackle the problem of the 
surface conformation of myosin that is incompatible with motility, I designed, cloned, 
expressed and purified minimal motor domain constructs with or without the neck region, 
fused to a C-terminal Avi-tag for a site-specific biotinylation of the protein. Expression and 
purification protocols described previously, combined with incubation of cell slurry with 
biotin and BirA ligase in the presence of ATP, were successfully applied to obtaining 
biotinylated fractions of 9aMMD and 9aMMD-S1. Protein biotinylation was confirmed 
with a western blot against biotin and proteins were immobilized via a biotin-avidin linkage 
on the surface of the flow chamber. This ensures specific conformation of myosin on the 
surface, with its motor domain facing the flow chamber, facilitating interactions of myosin 
with actin and progression through the mechanochemical cycle. The site-specific 
immobilization of human myosin 9a constructs on the surface resulted in robust 
translocation of actin filaments. Therefore, human myosin 9a is a mechanochemically 
active motor and could move along actin filaments in cells.  
Previous reports suggest that adding methylcellulose to motility assays is necessary 
to maintain translocation of actin filaments by myosin 9 isoforms (Liao et al., 2010; Elfrink 
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et al., 2014).  Methylcellulose is a viscosity agent that compensates for the lack of weak 
actomyosin interactions and serves to keep actin filaments close to the surface of the flow 
chamber facilitating actin movement by myosin (Bobkov et al., 1996). However, the sliding 
velocity of 9aMMD in the presence and absence of methylcellulose was nearly identical 
and no abrupt dissociation of filaments from the surface was observed. This suggests that, 
in contract to other myosin 9 isoforms, weak actomyosin interactions are not hindered in 
myosin 9a.  
Since addition of Ca2+ to ATPase reactions stimulated the actin-activated ATPase 
activity of 9aMMD and switched on coupling between the actin- and nucleotide-binding 
sites, it was surprising the motor moved actin in the absence of Ca2+. Furthermore, addition 
of 100μM Ca2+ to the motility buffer did not increase the sliding velocity of 9aMMD. If 
Ca2+ is necessary to restore normal actin cleft dynamics of myosin 9a, as proposed above, 
Ca2+ should influence the ability and/or velocity of actin gliding. The lack of the effect of 
Ca2+ on the motility of 9aMMD could only be explained if the site-specific immobilization 
of 9aMMD on the coverslip surface positions it in a conformational state that is compatible 
with normal cleft dynamics, progression through the mechanochemical cycle and 
translocation of actin filaments, regardless of the presence or absence of Ca2+. Addition of 
exogenous CaM also did not affect the velocity or the actin-activated ATPase activity of 
9aMMD, indicating that after purification the motor maintains its stability and can perform 
its mechanochemical activities.  
 9aMMD sliding velocity was ionic strength-dependent, showing peak velocity at 
200mM KCl. Above 200mM KCl, the sliding velocity as well as the number of filaments 
tethered to the surface drastically dropped. Still, a fraction of filaments was observed to 
move at as high as 500mM KCl. This indicates high affinity actomyosin interactions of 
human myosin 9a.  
The affinity of ATP binding by 9aMMD in the presence of actin was assessed by 
measuring sliding velocities of 9aMMD at increasing [ATP]. The obtained KATP value 
(0.37mM) is well below 2mM used for ATPase experiments, therefore confirming the 
amount of ATP in those reactions was not limiting and could not be responsible for the 
observed lack of actin activation in the absence of Ca2+. 
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Furthermore, 9aMMD moved actin with the speed of ~35nm/s. This is not 
exceptionally fast when compared to most myosins (for example, rabbit skeletal HMM 
moved 5.5μm/s in my assays), but it is faster than some other myosins (for example 
Leishmania myosin 21 moved ~16nm/s; Batters et al., 2012). Considering that 9aMMD 
consists of the motor domain alone and lacks the neck domain, which increases the step size 
in other myosins, it was surprising it moved with such relatively high velocity. This 
suggests that the fulcrum point over which the neck domain of myosin 9a would rotate is 
located closer to the core of the motor, upstream of the last amino acid of 9aMMD 
construct.  
Previously it was proposed that the neck domain of myosin 9 does not act as a lever 
arm, i.e. that it does not increase the speed of actin movement (Liao et al., 2010). I 
addressed that issue by investigating motility properties of 9aMMD-S1, site-specifically 
immobilized on the surface of the flow chamber. The motor robustly translocated actin 
filaments at higher rates than 9aMMD, clearly showing that the neck domain of human 
myosin 9a acts as a lever arm. The rate of 9aMMD-S1 movement was nearly 6 times faster 
than that of 9aMMD (Figure 6.1) 
 
 
Figure 6.1. A velocity distribution plot of 9aMMD and 9aMMD-S1 at 100mM KCl. 
Experiments were performed as described in previous chapters. 9aMMD-S1 translocated 
actin filaments at 204.4nm/s, nearly 6 times faster than 9aMMD (34.7nm/s). Therefore, the 
neck domain of human myosin 9a acts as a lever arm to increase the step size.  
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 9aMMD-S1 motility was observed only in the presence of exogenous CaM in the 
motility buffer. This again suggests that at least one IQ motif in the neck domain of human 
myosin 9a might not be saturated with CaM. This could be caused either by weak 
interactions of the IQ motif with CaM or by the preference towards binding a different light 
chain. In the absence of exogenous light chain, the neck domain could not be rigid enough 
to support motility. Supplementing the motility buffer with subsaturating CaM 
concentration could support association of the unoccupied IQ motif with CaM, providing 
enough rigidity of the lever arm to facilitate movement.  
 Adding as little as 2μM Ca2+ to the motility buffer fully inhibited actin translocation 
by 9aMMD-S1, even in the presence of exogenous CaM. This suggests that Ca2+ 
effectiviely prohibits binding and/or causes dissociation of CaM from the neck of 9aMMD-
S1. In order to investigate the effect of Ca2+ on the association of CaM light chains with 
9aMMD-S1, myosin was bound to actin in the absence and presence of increasing [Ca2+] 
and subjected to ultracentrifugation. Equal volumes of supernatant and pellet were 
separated on SDS-PAGE gels. CaM found in the pellet fraction represents myosin-
associated light chain molecules, whereas CaM found in the supernatant represents CaM 
molecules that dissociated from myosin. Surprisingly, even in the absence of Ca2+, a 
fraction of CaM was found in the supernatant. And, based on visual judgement, no 
additional CaM dissociated from myosin upon addition of Ca2+. That might suggest that in 
the absence of Ca2+ CaM associated with one or more IQ motifs within the neck region 
binds with low affinity so that forces acting on the sample during ultracentrifugation are 
enough to separate CaM from the heavy chain of myosin. Low affinity CaM binding could 
also contribute to the lack of motility in the absence of exogenous CaM. Alternatively, the 
integrity and stability of the recombinant protein could be influenced during the purification 
process, ultimately leading to weakening of the interaction between the light chains and the 
heavy chain. However, stability measurements performed on 9aMMD-S1 always resulted in 
a single intensity peak present in the sample, suggesting that 9aMMD-S1 maintains its 
integrity over time. Therefore, a weak interaction between CaM and IQ motif(s), rather than 
protein stability, is the most probable cause for the observed dissociation of CaM from 
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9aMMD-S1 during ultracentrifugation. A possibility that human myosin 9a preferentially 
binds other light chains cannot be excluded. The exact mechanism of the regulation of 
motility of human myosin 9a by Ca2+ remains to be explored.  
 Myosin 9 isoforms were previously suggested to move processively along actin 
filaments despite existing as monomers in solution. Since processive motility of a 
monomeric molecular motor cannot be explained by a hand-over-hand mechanism 
proposed for double-headed processive motors, it was proposed that the extended loop 2 of 
myosin 9 determines processive motility, tethering myosin head to actin as it binds 
subsequent monomers in the filament during processive motion (Post et al., 2002; Liao et 
al., 2010; Elfrink et al., 2014; Inoue et al., 2002; Nishikawa et al., 2006). In order to 
investigate if human myosin 9a acts as a single-headed processive molecular motor, I first 
examined the native molecular weight of 9aMMD. I used the combination of gel filtration 
and sucrose density gradients to obtain hydrodynamic properties of 9aMMD. The 
calculated native molecular weight was in great agreement with the molecular weight 
calculated from the amino acid sequence of single 9aMMD heavy chain with one bound 
CaM. Therefore, 9aMMD exists as a monomer in solution. I addressed its processivity by 
measuring the sliding velocity of actin filaments over a range of myosin surface densities. 
9aMMD translocated actin flaments with no significant changes in the velocity over a wide 
range of surface densities. At lower densities, the probability of more than one molecule 
interacting with the filament is low. Therefore, the data suggests that human myosin 9a 
functions as a single-headed molecular motor. The mechanism of a processive motility of a 
monomeric motor remains to be investigated. 
 
 6.6.  Final conclusions 
 That work presents the first successful approach towards expression and purification 
of recombinant active human myosin 9a fragments. Proteins were obtained in sufficient 
amounts to perform basic biochemical characterization of myosin function.  
  Expressed protein constructs exhibited ATPase activity and mechanical activity. 
Therefore, the properties of human myosin 9a are typical of those of other myosin 
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superfamily members. 
 This work provides a solid basis for further investigation of myosin 9a function and 
enables addressing the role of the tail domain, the N-terminal extension and the loop 2 
insert in mechanochemical properties of that myosin superfamily member.  
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